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SYNOPSIS 
It is known that morphine-6-glucuronide is more potent than morphine, but it is 
difficult and expensive to produce. Our aim was to synthesise an analogue(s) of 
morphine-6-glucuronide which would have similar or enhanced properties, but that 
could be obtained via a simple synthetic route. It is hoped that such a compound could 
be used to treat terminally ill cancer patients. Due to the enhanced potency a smaller 
dose of the drug would be required to effect the same analgesic effect as morphine, and 
this may help to reduce the effect of morphine tolerance. 
Initially the demethylation of codeine to yield morphine was examined. Investigations 
first involved the use of diisobutylaluminium hydride, but success was found using 
boron tribromide in chloroform. 
Hydroxyl group protection was investigated using acetyl, benzyl, t-butyldimethylsilyl 
and methoxymethyl protecting groups. Selective protection of the phenolic function of 
morphine as opposed to the secondary alcohol was achieved in all cases. 
A number of codeine-6-0-ester were synthesised using the reaction of an acid chloride 
or an acid anhydride on the secondary alcohol, or the coupling of a carboxylic acid with 
the secondary alcohol using J,3-dicycIohexyIcarbodiimide and 4-N,N-
dimethylaminopyridine as a catalyst. A parallel series of morphine-6-0-ester 
derivatives was then completed. The phenol function in morphine was protected with 
the t-butyldimethylsiIyl group before esterification, as in the codeine series, and later 
removed by fluoride ions. Tetrabutylammoniurn fluoride was used as the SOurce of 
fluoride ions except in the case of the 6-0-phthalate ester where hydrogen fluoride in 
pyridine was used. The products isolated were essentially aromatic esters 
encompassing a variety of functional groups: acetyl, carboxylate, halogens, hydroxyl, 
methoxy and nitro. 
The preparation of a series of 6-0-benzyl ethers of morphine was attempted, but was 
largely unsuccessful due to quaternisation at the amine function. 
The synthesis of codeine-6-glucuronide and morphine-6-glucuronide was successfully 
completed. The glucuronic acid residue was introduced by use of the 
acetobromoderivative of glucuronic acid, via the Koeings-Knorr reaction. De-
acetylation of the sugar moiety was effected using sodium methoxide and hydrolysis of 
the ester function was performed using pig liver esterase, rather than barium hydroxide 
and oxalic acid as previously reported in the literature. 
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INTRODUCTION 
What is pain? Pain is one of the most fundamental and important human 
experiences, and also one of the most complex. It is a waming signal of physiological 
disorder for which man has evolved a system of producing and sending nonciceptive 
('pain receptor') messages to the central nervous system (CNS) for decoding. Pain is 
always subjective. Each individual learns the application of the word through 
experiences related to injury in early life. Though pain is a familiar experience it only 
becomes a clinical problem if it becomes chronic or reaches a severity that restricts 
normal activity. 
Pain maybe broadly divided into acute and chronic according to duration. Acute pain 
can arise through a number of physical causes such as tissue damage, inflammation or 
muscle spasm, or physiological processes such as labour. Pain arising through 
physical causes can vary in intensity from mild to severe but is nearly always transient 
and self-resolving. It is considered a normal physiological response to guard the 
integrity of the organism and allow healing of damaged tissues. 
Chronic pain generally arises through disease processes which lead to long lasting 
inflammation, or through inappropriate signals originating in the brain or. peripheral 
nerves. In some patients pain can become so severe as to be intolerable without 
medical intervention. 
Severe pain relievers such as the opiates have a strong narcotic action, are centrally 
acting and are termed analgesics. Minor pain relievers such as aspirin are non 
narcotic, act peripherally and are termed analgetic. They all act by diminishing pain 
perception. 
I 
1.1 Morphine 
The power to alleviate severe pain has been one of man's foremost aspirations for 
many centuries. The world's first relief being in the form of opium, the dark sun-
dried latex exuded from the fruit of the poppy, Papaver somniferum. References to 
the use of opiates have been found dating back to about 3000 BC. Opium itself is a 
resinous material that contains at least 40 different alkaloids, but the most important 
active constituent, isolated and identified in 1803 by Derosne,l is morphine (1). It 
was purified for pharmaceutical use a year later by Seguin.2 
(1) 
Many chemists tried to elucidate its structure over the years but it was Robinson and 
Galland's3 proposal in 1925 that gave the correct structure for the alkaloid. However, 
a further 30 years elapsed before a successful total synthesis was determined by Gates 
and Tschudi4 in 1956. 
Since its discovery morphine has been and still remains the foremost analgesic in the 
world. It is readily available, relatively inexpensive, a powerful sedative and its 
analgesic action is rapid in onset, reliable and long lasting. However, it is by no 
means ideal and its clinical use is greatly restricted by a number of unwanted side 
effects. Prolonged use can result in physical dependence on the drug. Ceasing 
administration of the alkaloid at this stage results in dangerous and painful withdrawal 
symptoms which can ortIy be alleviated by recommencing morphine administration, or 
that of certain related compounds. Allied to physical dependence is the phenomenon 
of tolerance whereby a greater and greater dose of morphine is required to achieve the 
2 
desired result. Another severe consequence is that it causes respiratory depression, 
serious at Iow dosage but often fatal at higher doses. In addition to the problems of 
clinical usage, the euphoric effect induced by morphine has led to its large-scale 
world-wide abuse, both in its natural form and, more often, as its easily produced 
diacetyl derivative heroin (2). 
(2) 
Heroin is three times as potent as morphine and its increased solubility in lipids leads 
to faster penetration through the blood brain barrier, producing an intense 'rush' when 
injected intravenously. 
1.2 Synthetic Analgesics 
These side effects have made the development of other analgesics lacking such 
properties a highly desirable objective. Thus for many years there has been intensive 
research into the chemistry of the opium alkaloids and related compounds. This work 
can be categorised into 3 main areas: 
a) the synthesis of similar compounds possessing only part of the morphine 
skeleton. 
b) the construction of molecules more complex than morphine by altering the 
peripheral shape. 
c) modifications of morphine itself, retaining the pentacycIic system. 
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1.2.1 Compounds possessing part of the morphine skeleton 
A large proportion of the early work consisted of the preparation of simple fragments 
of the morphine molecule. In this way it was hoped to separate the features of the 
molecule responsible for its analgesic action from those responsible for the unwanted 
side-effects. 
Several groups of compounds which can be regarded as fragments of the morphine 
skeleton have been synthesised. 
i) Morphinans 
The morphinans contain the complete carbon-nitrogen skeleton of morphine but lack 
the dihydrofuran oxygen. 
(3) (4) 
N -Methyl morphinan (3) has about one fIfth the analgesic activity of morphine, 
though the introduction of a hydroxyl group at the 3-position leads to a substantial rise 
in potency, (-) levorphanol (4) being four times as active as morphine. The 
(+) isomer, dextrorphan, is totally devoid of analgesic activity because its 3-D shape 
prevents it from binding to the receptor. Variations of the JS:-substituent in 
(-) levorphanol produced changes of activity similar to those in the morphine seriess, 
often leading to antagonist properties. 
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ii) Benzomorphans 
May6 further dissected the morphinan skeleton producing the 6,7 -benzomorphans (5). 
In addition to the dihydrofuran oxygen the alicyclic ring is also lost leaving the A, B 
and E rings of morphine. 
(5) (1) 
To indicate ring C, two methyl groups were retained on ring B, leading to the 
metazocine (6) series, which are non addictive analgesics. 
R '" -CH3 (6) 
(7) 
Generally compounds in which the two non cyclic alkyl substituents on ring B are cis 
are powerful analgesics but they cannot relieve withdrawal symptoms in addicted 
animals, meaning they are not addictive. The trans isomers, however, while also 
potent analgesics, will relieve withdrawal. 
Numerous metazocines have been evaluated for pharmaceutical use. The most useful 
so far is probably pentazocine (7), N-(3,3-dimethylallyl)benzomorphan, an analgesic 
of less potency than morphine but showing greatly diminished physical dependence7 
and respiratory depression. When administered to morphine dependent people, it 
usually precipitates a withdrawal syndrome, because it displaces the more potent 
opioids from the receptors. Hence it is known as a mixed agonist-antagonist opioid. 
5 
Further development has lead to bremazocine (8), a powerful kappa agonist of long 
duration which is devoid of addictive properties and respiratory depressant activity. 
On the basis of receptor binding, it is about 200 times more active than morphine. 
(8) 
Hi) Piperidine Derivatives 
The 4-phenylpiperidines constitute the oldest class of synthetic morphine like 
analgesics. The first important member, pethidine (9), I-methyl-4-carbethoxy-4-
phenylpiperidine,9 was discovered in 1939. This class of compounds retains the A 
and E rings of morphine. 
= 
(1) 
Pethidine has 10-12% of the overaJI activity of morphine, though it takes effect more 
quickly and has a shorter duration of action. It has moderate antispasmodic as well as 
sedative properties, but also possesses many similar side-effects to morphine. 
The addition of a 3-0H group results in the bemidone series, while modification of the 
ester group to a ketone gives the ketobemidones (10), which have more than six times 
the activity of pethidine. 
6 
wMe HO~ 
(10) 
G-Me 
11 
o 
Perhaps the most successful modification of the 4-phenylpiperidine derivatives of 
morphine are the 4-anilino compounds, like fentanyl (11). 
(11) 
This drug is 50-lOO times more active than morphine, owing to its accelerated 
transport across the blood brain barrier and into the eNS, as a result of its high 
lipophilicity. Spectacular activities (-5000 times that of morphine) have been achieved 
by introducing ether or keto substituents e.g. sufentanil (12). 
All fentanyl derivatives are very fast acting and of short duration. 
7 
iv) Methadone 
Further reduction in the morphine skeleton leads to methadone (13), 6-dimethylamino-
4,4-diphenyl-3-heptanone. Its phannacological activity is very similar to morphine 
but it has an extended duration of action, is less emetic or constipating and leads to 
little euphoria. It is used clinically to ease the effects of heroin withdrawal, as 
withdrawal symptoms are less severe than other addictive narcotics. The methadone 
molecule has been modified in hundreds of ways leading to a number of effective 
analgesics, such as dextromoramide (14). Though all these compounds can be abused 
with resulting dependence liability. 
(13) 
Me 
~Me 
Me 6 
(14) 
1.2.2 Compounds having structures more complex than morphine 
Bentley 10 postulated that compounds with a more elaborate structure than morphine, 
particularly in regard to peripheral shape and rigidity, may fit the part of the receptor 
concerned with analgesia, but not those concerned with undesirable side effects. He 
thus developed a series of bridged opiates. 
These oripavine derivatives are derived from thebaine (15), a naturally occurring 
alkaloid which is not a narcotic analgesic but a convulsant, via Diels-Alder and 
Grignard reactions. Attack of the dienophile, in particular vinyl ketones and alkyl 
acrylates,1l,12 occurs on the outer face of the conjugated diene, from the same side as 
the nitrogen bridge, and hence the resultant adducts have the etheno bridge located on 
the opposite side of the molecule compared to the nitrogen bridge. This gives rise to 
8 
the 6,14-endo-etheno-6,7,8,14-tetrahydro-thebaine series (16). The dienophile adds 
regiospecificallyat C-7, however stereoisomers can be produced depending on the 
position of the dieneophile relative to the diene. 
MeO 
MeO 
(15~ 
o R R = alkyl 
The presence of the etheno bridge adds greater rigidity to the molecule and the new 
centre at C-19 offers the opportunity for tangible changes to be made in both 
peripheral shape and polarity. A number of carbinol (17) compounds have been 
prepared via Grignard reaction with the methyl ketone derivative, which are all highly 
potent analgesics. Grignard addition occurs stereoselectively via a co·ordination 
complex. 
HO...-'l' I Me 
R 
(17) 
Hydrolysis of the 3·methoxy group to the phenolic hydroxyl results in a large increase 
in analgesic strength. Catalytic reduction of the etheno bridge increases activity 
further still. Etorphine (18) is 2000 times as potent as morphine. It is active in doses 
as small as 0.1 mg for an adult. However, it has only about 30·40 times the affmity 
of morphine for the opiate receptor. Its enormous activity is due to its great 
9 
lipophilicity and thus great ease at penetrating the blood brain barrier. It is used in 
veterinary medicine for the immobilisation of wild game. Buprenorphine (19) is a 
powerful analgesic in man, which interestingly at higher doses begins to antagonise 
itself. 13 
N-Me 
Ho"t'Me 
CH2CH2CH3 
(18) 
HO'\"Me (19) 
C-M M .... , e 
e Me 
1.2.3 Modifications of morphine retaining the pentacyclic system 
Alkylation of the phenolic hydroxyl group on C-3 in morphine decreases analgesic 
activity, illustrated by codeine (20), which shows about one tenth the potency of 
morphine, if given parenterally. Its activity is due to the fact that it is partially 
demethylated in the liver and thus transformed to morphine, the active component. If 
it is given intracerebrally it is totally inactive as an analgesic. It is widely used as an 
antitussive (cough suppressant) drug. 
Weakening of the electron density at the 3-0H position by the introduction of electron 
withdrawing substituents (e.g. N02) is deactivating. Shifting the phenolic group to 
position 2 or 4 results in total loss of activity. 
(20) (21) 
10 
Hydrogenation of the 7,8 double bond to give dihydromorphine (21), results in a 
compound with increased activity but reduced duration of action. 
The N-methyl substituent is not absolutely essential to analgesic activity, it is more 
attributed to lipid solubility. N-Norrnorphine (22), the secondary amine, has only one 
eighth of the central activity of morphine, though in vitro it is equiactive with 
morphine,14 indicating that it can not cross the blood brain barrier, because of its high 
polarity. Higher alkyl substituents at the nitrogen render the molecule less active, 
though if the side chain carries an aromatic ring activity is increased. N-Furylmethyl-
norrnorphine (23) and N-phenylethyl-norrnorphine (24) derivatives and their 
analogues can be up to 50 times more active than morphine, due to the involvement of 
auxiliary binding sites. Substituting N-allyl, nalorphine (25), or 
N-cycJopropylmethyl, naletrexone (26), shows a dramatic change to antagonist 
properties. 
R=-H (22) 
HO 
= -CH 2- CH2-O (23) 
0 
= -CH 2-CH2-0 (24) 
N-R 
= ~ (25) 
= -CH 2-<1 (26) 
14-Hydroxy derivatives, such as oxymorphone (27), show increased potency up to 
five times that of morphine, believed to be the result of additional hydrogen bonding 
to the receptor. 
(27) 
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Many modifications can also be performed at the alcoholic hydroxyl group at C-6. 
Both the 6-keto derivative and the 6-methylene derivative are active analgesics. 
Hetercodeine, which contains no C-6 hydroxyl group, is about five times as active as 
morphine. 
1.3 The Opiate Receptor 
The opiate receptor is generally believed to be composed of protein combined with 
membrane lipids, though its absolute configuration remains a mystery. The drug has 
its effect by binding to the receptor and provoking a signal where none was wanted. 
Opioid receptors are located in specific areas of the brain, spinal cord and 
gastro-intestinal tract. They are not all identical, several distinct types exist, and each 
one has a different affmity for binding with various opioid analgesics. The major 
categories of receptors have been identified and they have been designated as mu, 
kappa, delta and sigma receptors. Additionally sub-types of these receptors have_ also 
been identified e.g. mu-l and mu-2,1s 
As we lack specific agonists and antagonists at each of the opiate receptors, the role of 
each receptor is not entirely clear. 
The mu receptor seems to be the main receptor involved in pain suppression, since all 
the compounds that are the most effective pain killers do have a preference for this 
receptor. 16 Mu receptors are located mostly at supraspinal sites. Activation of 
receptors in these areas seems to underlie the analgesic, respiratory depressant, miotic, 
euphoric and physical dependence properties of opiates. It is thought that the mu-l 
subtype modulates analgesia and euphoria primarily while the mu-2 subtype 
modulates respiratory depression. As yet no specific mu-l or mu-2 analgesics are 
clinically available. Thus, all analgesics that stimulate mu receptors also induce 
euphoria and can cause drug dependence. Some mu receptors are also located in the 
12 
spinal cord, and help modulate part of the spinal analgesia that is induced by 
morphine. 
Kappa receptors are located principally within the dorsal horn of the spinal cord. 
They are responsible for inducing analgesia by depressing the initial relay site of pain 
transmission. Other kappa receptors are located in the brain stern and produce miosis 
and sedation. Euphoria, physical dependence, and respiratory depression are not 
mediated by kappa receptors. 
Delta receptors are poorly delineated as yet, but they may be involved at brain stern 
and spinal levels in the production of certain aspects of analgesia. 
Sigma receptors appear to be located primarily in the limbic system of the brain. 
Activation of these receptors results in psychotomimetic, hallucinogenic, and 
dysphoric responses to certain opioids. 
Any drug which elicits a positive response on binding to a receptor is called an 
agonist. A drug that binds to a receptor but does not elicit a response is called an 
antagonist. A few drugs exhibit modest analgesic activity in isolation, but can have 
antagonistic properties in the presence of morphine, and are known as mixed agonists-
antagonists. 
Snyder17 and his group published a series of papers characterising the receptor and 
proposed that it is an allosteric lipoprotein modulated by sodium ions. In the presence 
of Na+, the receptor preferentially binds an antagonist, whereas in the absence of Na+ 
the agonist binding form of the receptor predominates. Lithium ions can replace 
sodium, but potassium is inactive. The binding of an agonist can be increased by 
Cu2+, Mg2+, Mn2+ and Ni2+, whereas the binding capacity is destroyed by reagents 
which bind to -SH groups, like N-ethylmaleirnide, indicating the presence of an 
essential -SH group near the binding site. 
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1.4 Endogenous Peptides 
It is inconceivable that man has developed receptors to distinguish alkaloids derived 
from plants, thus neuropharmacologists surmised that opiate receptors serve to detect 
endogenous regulators of pain perception rather than respond to a plant product. 
According to this view the opiates exert their pharmacological effects by mimicking 
molecules that are normally present in the bodies of vertebrates. The breakthrough 
came in 1975 when a natural morphine like substance was discovered in the brain of 
pigs. 18 The substance isolated termed 'enkephalin' (Greek for "in the head"), was 
soon found to be a mixture of two pentapeptides methionine-enkephalin and 
leucine-enkephalin, in the ratio of 3:1 respectively. Structurally they are very alike 
differing only in the carboxyl terminus. These peptides interacted selectively with 
opioid receptors in vitro and were shown to be analgesic on intracerebroventricular 
administration, although the effects were brief due to rapid metabolism. 
A year later longer opiate peptides were isolated from the intermediate lobe of the 
pituitary gland and termed endorphins. I 9 Endorphins are about as potent as morphine 
on a molecular basis in relieving pain. It is interesting that Met-enkephalin forms the 
amino terminus of the endorphins, which in turn represents residues 61-91 at the 
carboxyl terminus of the pituitary hormone, ~-lipotrophin, although ~-Iipotrophin 
itself does not possess any opiate properties. 
A further 17 amino acid peptide was isolated in 1977,20 and named dynorphin. 
Dynorphin is leu-enkephaIin with an extension of twelve amino acid residues at the 
carboxyl terminus. 
That these peptides are endogenous Iigands for the opiate receptor was shown early on 
since they closely mimic the action of morphine and could be antagonised by the 
morphine antagonist naloxone.21 
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Peptide 
Met-enkephaJin 
Leu-enkephalin 
a-endorphin 
~-endorphin 
dynorphin 
Amino acid sequence 
Tyr1-Gly2_Gly3-Phe4-Met5 
Tyr-Gly-Gly-Phe-Leu 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-
Pro-Leu-Val-Thr-Leu 
Tyr -Gly-Gl y-Phe-Met -Thr-Ser-Glu-Lys-Ser -Gl yn-
Thr-Pro-Leu-V al-Thr-Leu-Phe-Lys-Asp-Ala-Ile-Ile-
Lys-Asn-Ala-His-Lys-Lys-Gly-Gln 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-
Lys-Trp-Asp-Asn-Gln 
The endogenous ligands are not absolutely specific for the different types of opioid 
receptor. ~-Endorphin appears to bind equally well to mu and kappa receptors but has 
no affinity for delta. Leu-enkephalin, on the other hand binds preferentially to the 
delta receptor but less well to the mu. Morphine itself favours the mu receptor but still 
has measurable affinity at kappa and delta.22 
A large number of peptide analogues have been prepared but only a relatively small 
number have shown any activity, usually of short duration of action. Rapid 
hydrolysis between Tyr-Gly deactivates enkephalins and removing Tyrl or interfering 
with its phenolic hydroxyl or amino group abolishes any activity. Replacement of the 
Gly2 residue with D-Ala renders the peptide resistant to hydrolysis. D-Ala2 analogues 
combined with modifications of Met5 have produced the most potent derivatives e.g. 
[D-Ala2, MePhe4, Met(O)015jenkephalin, which showed 1000 times the activity of 
morphine in the mouse tailflick test. 23 Unfortunately this activity did not extend to 
clinical trials,24 being limited by various pharmacological drawbacks. 
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The intrathecal administration of ~-endorphin directly into the cerebrospinal fluid has 
provided rapid and long lasting (33 h) pain relief in cancer patients with otherwise 
intractable pain.25 Synthetic ~-endorphins have also been prepared and found to give 
prolonged and long lasting analgesia when given intrathecally for pain due to 
disseminated cancer. Unfortunately, all synthetic opioids produce tolerance and 
addiction. 
It may be that individual variations in sensitivity to pain depend on levels of 
endogenous opioids. In addition, it is believed that in acupuncture there is a release of 
these natural substances into cerebrospinal fluid. Direct measurement has shown a 
rise in ~-endorphin but not met-enkephalin levels, after acupuncture for recurrent pain. 
Ectopic ~-endorphin and met-enkephalin have been found in tumour tissue. If this is a 
common finding these substances may automatically subdue pain in certain malignant 
diseases and these or other unknown substances may cause physiological changes in 
the sufferer. 
1.5 Morphine 6.glucuronide 
Morphine is metabolised in man mainly within human liver microsomes, by 
glucuronidation at the 3 or 6-position. The major metabolites are morphine 
3-glucuronide (M-3-G) (28) and morphine 6-glucuronide (M-6-G) (29), occurring in 
the ratio 5: 1. Small amounts of morphine 3,6-diglucuronide, normorphine, and 
normorphine 6-glucuronide are also formed. 
16 
(28) 
HO 
Cl 
eOOH -'. 
~~O\" H~ 
OH 
(29) 
The M-3-G and M-6-G metabolites accumulate in the plasma in higher levels than that 
of the parent compound morphine, after chronic oral dosing,26 and are still present in 
substantial amounts several hours later.27 
Traditionally conjugation was thought to terminate the pharmacological activity of a 
compound and many pharmacologists still believe conjugation means detoxification. 
Indeed morphine is excreted via the urinary tract as its glucuronides, but it has been 
shown that M-6-G is pharmacologically more active than morphine. 
M-3-G shows no significant binding to any receptor subtype and is devoid of 
analgesic activity, although it may antagonise some pharmacological effects of 
morphine.28 In contrast M-6-G shows a similar binding profIle to mu (3H-DAGO), 
delta (3H-DPDPE) and kappa (3H-EKC) receptors, as morphine. 
1Cso Value (nM) 
Mu Delta Kappa 
M-3-G >500 >1000 >250 
M-6-G 7.3 + lA >150 >250 
Morphine 4.3 + 1.1 >150 >250 
These binding studies indicated that M-6-G is a mu selective opioid with a potency 
similar to morphine. However on comparing analgesic properties, when injected into 
rats intracerebroventricularly or into the periaqueductaJ gray, M-6-G elicited a 
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profound analgesia, in tailflick tests. In fact M-6-G appeared to be 20-45 times more 
potent than morphine.29 Increasing the dose of M-6-G increased the peak latency and 
duration of analgesia. 
More importantly, M-6-G was 1-4 times more active than morphine when the two 
compounds were administered subcutaneously, suggesting that it can penetrate into 
the brain despite its 'high polarity'. M-6-G has been shown by reverse phase HPLC 
to be far more lipophilic than predicted, in fact not much less lipophilic than morphine 
itself. Carrupt30 postulated that in aqueous media the structure of M-6-G is extended 
to expose maximally the polar groups for interaction with water. However, that a 
folded form was also possible, in which the polar groups were shielded, enabling 
membrane passage of the conjugate. 
1.6 Morphine 6-0-esters 
A thorough search of the literature has revealed a number of 6-0 substituted esters. 
Here we attempt to outline some of their uses, and properties in comparison to 
morphine. 
Morphine 6-succinate (30) has been prepared to assist in the investigation of the 
structure of the opioid receptor, using affinity chromatography. It exhibited no 
difference in peak effect or duration of analgesia compared to morphine, though the 
lethaJity of morphine was 1.7 times that of morphine 6-succinate. Its magnitude of 
dependence was also very similar to morphine.3 l 
R =H (30) 
=Me (31) 
3,6-Dipropanoyl morphine (DPM) (32), 3,6-dibutanoylmorphine (DBM) (33) and 
3,6-dihexanoylmorphine (DHM) (34) have been prepared as prospective long-acting 
analgesics In aqueous solution the stability of the HCI salts of these compounds 
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decreased with increasing alkyl chain length, so that DHM underwent rapid hydrolysis 
to 6-monohexanoylrnorphine (MHM). Comparison studies using electrically 
stimulated guinea pig ileum revealed similar potencies and efficacies for all 
compounds, but marked differences in the onset of drug action 
Le. morphine>heroin>MHM>DPM>DBM. DBM and MHM however were found to 
be five times longer acting than morphine.32 
RO 0 11 (32) R=R1 = C-Et 
0 
11 (33) C-Pr 
0 
11 (34) C-(CH~4Me 
Further 6-0-alkyl ester and 3,6-0-alkyl diester derivatives have been prepared using 
the fatty acids. These compounds tend to induce changes in thermal sensitivity and 
motor activity less than the parent compound i.e. reduced potency. They also tepded 
to show a higher water and lipid solubility and were much more lipophilic than the 
parent drug in terms of octanol-buffer partition coefficients. 
o 
6 11 
-O-C-(CH2)"Me n = 3, 7, 8,10,12,14, 16,20 
Codeine phosphate has been found to react with citric and tartaric acid, in experimental 
tablet formulations with paracetamol, forming citrate and tartrate esters,33 though no 
morphine analogue is documented. The structures and absolute configurations have 
been elucidated but there is no discussion of pharmacological properties. 
o OH 
6 11 I 
-0- C- CH2yCH2C0:2H 
C02H 
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A number of perfluoracylated compounds have been used to assist in the 
determination of impurities in heroin and to identify morphine, using capillary GC and 
mass spectrometry techniques. The trifluoroacetate derivative is formed by injecting 
the free base with N-methylbistrifluoroacetamide directly onto the GC column. The 
pentafluropropanoate and heptafluorobutanoate derivatives are prepared using 
pentaflurobenzoyl chloride or heptafluorobutyric anhydride in pyridine. Reaction with 
morphine gives the disubstituted fluoro esters and reaction with 3-0-alkyl derivatives 
gives the 3-0-aIkyl 6-0-fluoro esters,34 but selective substitution at position-6 in 
morphine has not been achieved. 
o 
6 11 
-O-C- CF3 
Amino acids have also been attached to the morphine skeleton at position-6, in the 
search for polysaccharidic prodrugs for enzymatically controlled release. Research 
has mainly been carried out on phoIcodine (35),35 being attached to cellulose via an 
amino acid spacer arm. The drug is immobilised by the ester function formed between 
the hydroxyl at position-6 and the carboxylic group of the C-terminal aromatic 
a-amino acid (Phe or Tyr). Significant release of the drug was only observed in the 
presence of a-chymotrypsin. There is no release if the C-terminal amino acid has 
D-configuration. 
(35) 
The spacer arm which gave the maximum duration for controlled release was the 
dipeptide ne and Tyr. 
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I as NHCOCH2NH2 
C=O I Me I I 
yHNHCOCHCHCH2Me Q 
OH 
Qligoethylene glycol esters of codeine have been produced. In this case the ethylene 
glycol forms an ether bridge between two codeine molecules at their six positions. 
1. 7 Research Aims 
The majority of research into the opium alkaloids has been in the search for an 
analgesic with a potency equivalent to that of morphine but without the addictive side 
effects. This project. however. is concerned with the potency and tolerance. The 
hope is to synthesise a drug more potent than morphine though not necessarily non 
addictive. such that smaller doses of the drug would be required to effect the same 
result as morphine. in the hope that the effects of tolerance could be reduced. Also 
that this may pr~lVide more predictable kinetics. 
Due to the high potency ofM-6-G it has been chosen as our model. Unfortunately. it 
is very difficult to produce, the published procedure being via the Koenigs KnOIT 
reaction. a quite lengthy and tedious pathway. giving a relatively low total yield. Our 
hope is to produce compounds with a similar or enhanced activity via a more effective 
route. 
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Initially we hoped to introduce a six membered ring connected through the oxygen at 
position-6 and we have decided to start with a simple aromatic ring. It was further 
proposed to introduce a number of functional groups to assess their effect on potency, 
hoping to incorporate carboxyl and hydroxyl functionalities as are present in M-6-G. 
A limiting factor throughout the course of this research has been the high cost of 
morphine -£250 per g. For this reason much of the work has been directed towards 
codeine, considerably cheaper at -£20 per g, derivatives of codeine being successfully 
synthesised before moving to the morphine series. 
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DEMETHYLATION OF CODEINE 
2.1 Introduction 
Initially synthetic studies were directed towards the removal of the 3-methoxy group 
in codeine (20) to produce morphine (1). The strategy was to synthesise the 
6-derivative of codeine and then to demethylate at the 3-position to give the morphine 
equivalent. A method is required that will successfully cleave the aromatic methyl 
ether but that will also preserve the labile oxygen bridge and the newly synthesised 
6-derivative. The exposure of codeine or morphine to strong acid or alkali conditions 
at higher temperatures is known to promote substantial decomposition of these 
alkaloids. Thus, conventional procedures for ether cleavage have been unsuccessful 
when applied to the conversion of codeine to morphine. 
Treatment of codeine with pyridine hydrochloride at elevated temperature was the first 
successful method employed. It was used by Rapoport36 for the O-demethylati{)n of 
14C-labelled codeine, by Gates4 in his total synthesis of (-)-morphine, and by Got037 
in the preparation of (+ )-morphine. Practical difficulties though were encountered in 
isolation and purification, and yields were Iow (15-34%). Next Takeda utilised 
lithium diphenylphosphide to convert B/C trans-codeine and B/C trans-isocodeine38 to 
the corresponding morphines, in up to 61 % yield. Later DeGraw39 reported a 
comparatively mild method, where codeine was treated with an excess of sodium 
propyImercaptide in dimethylforrnarnide at elevated temperatures to afford morphine in 
80% yield. It was Rice,4o however, who produced the most simple, efficient and 
high yielding conversion of codeine to morphine (91 %), using boron tribrornide. 
More recently Andre41 has replaced this reagent with the methane sulfonic acid -
methionine system, known as hard acid - soft nucleophile, reacting by a push-pull 
mechanism. Me+ has an appreciable affrnity with sulphur because of its softness, 
thus methionine acts as an alkyl acceptor forming methionine S-methyl. Although 
some sulphides other than methionine may accept alkyl groups in this reaction, 
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methionine is preferable because of its biofunctionality, which makes isolation of the 
phenolic product convenient. This method overcomes problems with toxicity at an 
industrial scale, but has sacrificed the high yields (69%). 
2.2 DIBAL·H 
It has been reported that the aromatic steroidal ethers of the estrone series are split by 
alkylalurninium derivatives.42 Demethylation of these ethers could not be conducted 
under acid or Lewis acid catalysed conditions because of side reactions involving 
re arrangements. The only previous acceptable method was a high temperature process 
using a Grignard reagent to prepare the magnesium salts of the corresponding 
phenols. These ethers are, however, smoothly cleaved at 70·80°C with 
diisobutylalurninium hydride or triisobutylalurninium, to generate the corresponding 
phenol in high yield. 
OH 
DffiAH. 95% 
MeO HO 
It was decided to utilise this procedure for the demethylation of the aromatic ether in 
codeine. Unfortunately the treatment of codeine with DffiAH in toluene at 70°C, did 
not lead to the isolation of morphine. Instead an orange powder believed to be an 
aluminium salt, because of its abnormally high melting point (>300°C), was obtained. 
Similar unsuccessful results were obtained using thebaine. This failure meant a 
different approach was required. 
2.3 Boron Tribromide 
Of the methods outlined earlier, that of Rice appeared to be the simplest and gave the 
highest yields. The procedure consists of addition of a chloroform solution of codeine 
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to an excess of boron tribromide in chloroform, at room temperature. Brief stirring is 
followed by quenching the reaction mixture with ice-anunonium hydroxide and simply 
fIltering off the morphine hydrate which results. Initial reactions afforded very Iow 
yields (28%) but a study of reaction times and dilution soon allowed high yields to be 
repeatedly reproduced. The optimum reaction time was found to be 1 h and the 
optimum dilution 80% of that quoted by Rice, this giving yields of 95%. Morphine 
was identified by its NMR spectrum which showed no methoxy singlet when 
compared to that of codeine. 
(20) (1) 
The reaction probably proceeds via a complex formed between the reagent and the 
ethereal oxygen atom.43 
ArOMe+ BBr3 ---l.~ ArOBBr2 + MeBr 
It is important to note that reagent grade chloroform was used in this procedure, as 
stated in the original method.40 Using dry, distilled chloroform gave very Iow yields. 
It is thought that the ethanol impurity acts as a catalyst initiating the reaction, possibly 
by removing bromide from the intermediate complex, thus driving the reaction 
forward. 
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2.4 Application to Codeine Esters 
The first 6-0-ester derivative to be synthesised was codeine 6-0-phthalate (36). This 
was easily prepared by refluxing codeine with phthalic anhydride in pyridine. See 
Chapter 4. 
MeO MeO 
N-Me 
phthalic anhydride 
pyridine .. 
(20) (36) 
To obtain the morphine analogue of this compound it was proposed to demethylate 
using boron tribromide. Unfortunately the product isolated from the demethylation 
was found to lack the phthalate moiety. Initially it was thought that morphin~ had 
been regenerated but the product isolated was soluble in CHCl3, where morphine is 
totally insoluble. A close inspection of NMR data showed significant differences in 
the fine structure, in comparison to morphine. Fig 1. 
In the proton spectrum the 1 and 2-H ABq remained unchanged at Ii 6.60. The 16-H2 
and 15-H2 splitting patterns remain unchanged but shifted slightly upfield. The 1O-H2 
. splitting patterns also remain unchanged with the lO~-H remaining at Ii 3.03, but the 
lOcx-H is shifted downfield. These results suggest that the morphine structure itself 
remains intact. Subtle differences in the rest of the fine structure suggest some type of 
rearrangement. The double bond protons appear shifted downfield, by 0.4 ppm, and 
the further downfield doublet loses much of its resolution, suggesting reduced 
coupling effects. The 5-H doublet suffers a similar fate, losing resolution and being 
shifted 0.2 ppm downfield. The 6-H multiplet at Ii 4.19 is shifted little, but a distinct 
doublet is observed. The 9-H quartet remains but again is shifted downfield, by 
0.2 ppm. The 14-H is also shifted downfield, but now appears as a distinct doublet. 
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Examining the COSY spectra of morphine and this new compound (Fig 2 and 3) 
help to highlight these changes. Both the double bond protons are now coupled to the 
S-H whereas only the further downfield one was in the morphine case. The 14-H also 
shows apparent 105S of coupling to the double bond protons but enhanced coupling to 
the 6-H proton. The S-H shows no coupling to the 6-H proton, suggesting that they 
are no longer neighbouring groups. The 9-H shows the same coupling pattern in both 
cases, as do the lO-H2. 
It is concluded from this information that p-isomorphine (37), the 8-0H isomer of 
morphine, has been isolated. The shifts in fine structure and resolution differences 
being accounted for by this structure. References to this compound do occur in the 
literature, but there is no apparent documented NMR data for comparison. 
(37) 
It is certain that the reaction conditions are too strongly acidic and are removing the 
ester functionality. There are therefore two possible avenues open. Firstly, find a 
new process of demethylation which will leave the ester function intact. This could be 
a difficult task since the conditions required for cleaving a methyl ether are most likely 
to cleave the ester. Secondly introduce a protecting group at the phenolic position on 
morphine to prevent reaction during esterification of the 6-hydroxyl group, and which 
would be able to be removed in the presence of an ester, (e.g. benzyl or TMS). 
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SELECTIVE PROTECTION OF 3-0H 
The use of protective groups is a very important tool in synthetic methodology and has 
been a rapidly expanding field over recent years. The requirements for a good 
protecting group are: 
a) it must react selectively in good yield to give a protected compound. 
b) it must be selectively removed in good yield. 
c) it should preferably be non-toxic. 
d) it forms a crystalline derivative that is easily isolated from unwanted side 
products. 
e) it gives minimum additional functionality to avoid further sites of reaction. 
In the case of morphine, we need to protect a phenol in the presence of a secondary 
alcohol. 
3.1 Acetylation 
One of the earlier protecting groups used selectively at the phenolic function in 
morphine was the acetate function. It is easily introduced by the method of Welsh,44 
treating a basic suspension of morphine in water with acetic anhydride. Unfortunately 
3-0-acetylmorphine (38) has a tendency to be amorphous, existing with occluded 
solvent which is difficult to remove. Welsh chose to isolate his compound as the 
sulfamate. Carrupt30 chose to avoid any isolation procedure and to conduct his 
reactions in situ. We did manage to isolate a relatively clean crude product but found 
the acetate group to be highly labile in nature and decided against its continued use, on 
the basis that this could lead to reduced selectivity. The high stability of the phenoxide 
anion and the acetate carbocation leads to rapid hydrolysis of phenylacetates under 
mild conditions. 
31 
o 
11 
HO Me-CO 
acetic anhydride. 
N- Me hydrogen carboanate 
(1) (38) 
Ethers now tend to be more widely used for protecting phenols and there are a number 
of protecting groups documented in this area that could be utilised in this situation. 
3.2 Benzylation 
The methyl ether, as already seen, requires rather drastic conditions for removal but 
the benzyl group can easily be removed under much milder conditions i.e. 
hydrogenolysis. 
The preparation of 3-0-benzyJmorphine has been described by Merck45 and 
Rodionow.46 Benzylation is performed by refluxing in DMF with potassium 
carbonate and benzyl chloride. Attempting to repeat this reaction proved 
unsuccessful, a multi-benzylated compound being obtained. 
Brands47 et al also found difficulties in trying to prepare 3-0-benzylmorphine. They 
suggest that dibenzylation occurs, at the phenolic position and at the nitrogen, 
producing a quaternary ammonium salt. Scheme 1. They propose that this 
compound then undergoes a Hofmann degradation under alkaline conditions, and on 
rearrangement produces the diene (41). 
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Scheme 1 
BnBr/DMF 
N-Me 
BnO 
N-Me 
Ell Bn 
The IR spectrum of the compound we isolated showed a broad band at 
Umax 3364 cm-I, suggesting the presence of an OH group, and the ferric chloride test 
for a phenol proved negative, so this must be due to the hydroxyl group. The 
I H NMR data showed certain similarities to the diene isolated by Brands, but we have 
isolated a tribenzylated rather than a dibenzylated product. The spectrum shows the 
presence of 3xABq in the region Ii 4.60 - 5.31 which would represent three benzyl 
CH2 groups. It is believed that 3-0-benzylation did occur highlighted by the 
0.15 ppm downfield shift of the 1- and 2-H ABq, compared to morphine. The 
spectrum also shows three olefinic signals at Ii 5.72, 6.16 and 6.45 suggesting 
conjugation, and consistent with Brands' structure. The downfield shift of the N-Me 
to Ii 2.95, however, suggests a quaternary nitrogen. If the D-ring has been broken to 
produce the diene then this must be due to the addition of two benzyl groups. This 
could also explain the location of the ABq relating to the benzyl group attached to the 
nitrogen, which we would expect to find in the region Ii 3.40. Instead both are located 
downfield at a 4.60-5.09. The presence of a quaternary nitrogen could produce a 
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significant electron withdrawing effect compared to the amine, and thus produce this 
downfield shift. From this information we can surmise that the compound we have 
isolated is a Hofmann degradation product, which has been further benzylated before 
isolation, possibly having the structure shown below. 
6) 
14 ,N;-Me 
A 8 Bn Bn 
(42) 
The reaction was repeated using different bases (Le. NaH, NaOH and KOH) and in 
different solvents (Le. EtOH, DMF and DMSO) but where reaction did occur the 
results remained the same. 
Brands overcame this problem in selectivity by using cesium carbonate, and isolated 
3-0-benzyl-morphine in 97% yield. These results were attributed to two properties of 
cesium cations. First that they are poorly solvated in DMF due to their relatively large 
ionic radii, and therefore, caesium salts exist as intimate ion pairs in solution. Second 
that they are capable of forming so-called triple ions due to their high polarisability, 
thus allowing the formation of a transition state as depicted below. 
34 
We proceeded by moving to the more reactive reagent, benzyl bromide. Reacting with 
potassium carbonate in DMF was unsuccessful, even after adding a little KI in an 
attempt to initiate the reaction. Using a different solvent, acetone, gave similar results. 
However, on choosing a more powerful base, potassium hydroxide in a finely divided 
form, 3-0-benzylmorphine (43) was finally obtained, albeit in low yield, 30%. 
K,CO,/BnBr 
acetone .. 
N-Me 
(I) (43) 
The lH NMR spectrum showed a broad multiplet at Ii 7.36-7.44 corresponding to the 
benzyl aromatic protons. The benzylic ABq was observed at Ii 5.05-5.19, with a 
coupling constant of J 12 Hz. The N-Me singlet located at Ii 2.4 showed no 
N-benzylation. The remainder of the fine structure showed the same spin - spin 
coupling as in morphine and signals occurred at similar chemical shifts. 
The main disadvantage in using the benzyl ether protecting group is that when it is 
removed by hydrogenolysis, the morphine double bond in the C-ring is also lost. It is 
known that the double bond does not contribute to the analgesic properties of 
morphine, but we have also investigated a silylation procedure which would allow the 
retention of the double bond. 
3.3 Silylation 
Initial silylation reactions centred on the trimethylsilyl (TMS) group, which is easily 
removed in aqueous conditions. The reaction involves heating to 30-35'C with 
TMSCI in pyridine.48 Unfortunately even though the reaction was seen to progress 
by TLC, isolation of a product proved fruitless, only morphine was recovered. It is 
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thought that the highly labile TMS group is being removed during the work up. We 
cannot, however, conduct the reaction in situ as we do not know at which position the 
TMS group has been incorporated, if indeed at only one position. 
It was decided to use a silyl protecting group that was more stable, and the highly 
popular tert-1;mtyldimethylsilyl (TBDMS) group was chosen. It is easily introduced 
with a variety of reagents, is relatively stable to a variety of organic reactions and is 
readily removed under conditions that do not attack other functional groups. It is 
approximately 104 times more stable to hydrolysis than the TMS group. It has 
excellent stability towards base but is relatively sensitive to acid. 
The most common method for the introduction of the TBDMS group is reacting with 
TBDMSCI and imidazole in DMF at 25'C.49 Utilising this procedure to protect 
morphine we managed to isolate the disilyl derivative (44). 
(I) 
I 
+SiO 
I 
imidazole I DMF ~ 
N- Me TBDMSCl 
(44) 
The IR spectrum lacked any OH stretching bands suggesting silylation at both the 
phenol and secondary alcohol. The IH NMR spectrum showed the N-Me singlet at 
o 2.49 comparable to morphine. Two singlets were observed at 0 0.92 and 0.98 
corresponding to the two t-butyl groups (2xSiCMe3) and four singlets were observed 
in the region 0 0.10 - 0.21 corresponding to the four methyl groups (4xSiMe2). The 
remainder of the fine structure appearing similar to that in morphine. The reaction was 
repeated altering the equivalents of reagents used and reaction times, but a 
monosilylated product could not be obtained. 
36 
The solution to this problem must be to make the phenol more susceptible to 
electrophilic attack than the secondary alcohol, and it was decided, as in the benzyl 
case, to use a strong base to produce the phenoxide anion, and enhance reactivity at 
that position. Thus the reaction of morphine with NaH and TBDMSCl in THF 
allowed isolation of the desired monosilylated product (45). Yields were relatively 
low at 50%, but unreacted morphine was recovered. 
(1) 
I 
+SiO 
I 
NaH I THF 
TBDMSCl .. N-Me 
(45) 
The IR spectrum exhibited a broad OH band at 3552 cm-! and, as the ferric chlo?ride 
test for a phenol proved negative, this must be due to the hydroxyl group. The 
! H NMR spectrum as expected, showed the N-Me singlet at 15 2.54 comparable to 
morphine, a singlet at 15 0.98 and two singlets at 15 0.20 and 0.16 corresponding to one 
t-butyldimethylsilyl group. The remainder of the fine structure was comparable to that 
of morphine. 
This morp!1ine 3-0-TBDMS ether compound has been used extensively in our 
research. 
3.4 Methoxymethyl (MOM) Ether 
Morphine 3-0-MOM ether (46) was prepared in a similar manner to morphine 
3-0-TBDMS ether, using NaH to produce the phenoxide anion and then utilising 
chloromethyl methyl ether (MOM-Cl) to effect a substitution reaction. Unfortunately 
in this case the reaction was found to be less selective. The morphine 3-0-MOM ether 
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was isolated but in very low yield (20%), and the disubstituted product (47) was 
identified as the major product (26%) 
N-Me 
(1) (46) (47) 
The NMR spectrum of morphine 3-0-MOM ether showed the appearance of a 3 H 
singlet at Ii 3.46 and a 2 H doublet at Ii 4.97, signifying the presence of the MOM 
group. The 1- and 2-H ABq was shifted 0.2 ppm downfield compared to morphine, 
suggesting substitution at the 3-position. The 5-, 16- and 15a-H were also shifted 
downfield to Ii 5.56, 3.16 and 2.71 respectively, probably due to their close proximity 
to the MOM group. The remainder of the fine structure was very similar to morphine. 
It was suggested that lack of reactivity at the phenolic function may be caused by 
solubility problems with the morphine anion in non-polar solutions. It was decided to 
use a phase transfer catalyst and a biphasic system. A similar procedure has been 
successfully used to protect phenolic functions in complex chalcones.50 
Chloromethyl methyl ether was added to a mixture of morphine, aqueous sodium 
hydroxide and tetrabutylammonium hydrogen sulphate in DCM, at room temperature. 
Unfortunately no reaction was observed. 
Ral15! also encountered problems in methoxymethylating phenol functions in certain 
chalcones. A solution was found by using 18-Crown-6, probably due to the ability of 
crown ethers to dissolve alkali metal salts in non-polar solvents. Chloromethyl methyl 
ether was added to a mixture of 18-Crown-6 and the potassium salt of morphine in 
dry acetonitrile, at room temperature. Unfortunately no reaction was observed. 
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Thus a high yielding process for the preparation of morphine 3-0-MOM ether has. as 
yet. eluded us. 
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ESTERIFICATION 
The first linkage to be investigated for the introduction of our substituents was the 
ester. Much of the research conducted during the course of this project has been 
towards the production of a number of substituted morphine esters. Initially for 
pharmacological comparison purposes and to assess the viability of each esterification 
reaction, the codeine analogue was first prepared in each case. Aromatic esters were 
chosen as a starting point with the view to incorporate carboxyl and hydroxyl 
functions as in M-6-G. 
4.1 Codeine Esters 
The first ester to be synthesised was codeine 6-0-phthalate (36), prepared in high 
yield by refluxing codeine with phthalic anhydride in pyridine. The IR spectrum 
showed two carbonyl stretches at 1713 and 1608 cm-I, the first signifies the presence 
of an ester group and the second that of a carboxylic acid group_ In the NMR 
spectrum the N-Me singlet of codeine was apparent at /) 2.70 and the O-Me singlet at 
6 3.85. The upfield fine structure was very similar to that of codeine. The 5- and 
6-H protons, however were shifted downfield to 6 5.44 and overlaid the 8-H double 
bond proton, an observation later found to be apparent in all 6-substituted esters. 
Two 1 H triplets were observed at 67.37 and 7.51 and two 1 H doublets at 6 7.67 
and 8.04, corresponding to the four phthalic protons. A mass spectrum obtained by 
FAB showed the molecular ion (M+H:I") at 448.1752 consistent with the formula 
C26H26N06. Data shows that the ester has indeed been prepared but a few 
abnormalities are apparent. The carbonyl stretch relating to a carboxylic acid is 
generally observed at ca 1700 cm-I, in the IR spectrum, here its appearance is much 
lower than expected. This may be explained by the existence of the carboxylate anion 
(COO·) which is generally apparent at ca 1600 cm-I. The NMR data also showed an 
unusually high shift for the N-Me singlet, 0.6 ppm relative to codeine. The addition 
of a phthalic group at position-6 could not influence such a large chemical shift alone. 
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It is known, however, that quaternary nitrogen is shifted downfield compared to its 
tertiary counterpart, suggesting that such a group is present here. This leads us to 
conclude that codeine 6-0-phthalic ester must exist as a zwitterion. 
MeO 
(36) 
Codeine 6-0-succinate (48) was prepared in the same way as the 6-0-phthalate 
derivative using succinic anhydride, though it was isolated in lower yields. Again the 
IR spectrum showed two carbonyl stretches at 1720 and 1632 cm·I , corresponding to 
the ester and carboxylic acid functions respectively. The N-Me and O-Me singlets 
were easily identifiable in the NMR spectrum, appearing at 0 2.62 and ;1.86 
respectively. The 5 and 6-H's were shifted downfield, as in the case of codeine 
6-0-phthalate, and overlaid with the 8-H doublet at 0 5.28, signifying ester formation 
at the 6-position. The mass spectrum showed the molecular ion at 399 consistent 
with the formula CZSHZ6N06. Again the carbonyl stretch for the carboxylic acid 
functionality in the IR spectrum is low, suggesting carboxylate anion formation. The 
N-Me singlet in the NMR spectrum is also shifted downfield, suggesting 
quaternisation. Thus we can conclude that codeine 6-0-succinate must also exist as a 
zwitterion. 
An attempt was made to prepare codeine 6-0-maleate, by refluxing with maleic 
anhydride in pyridine. The reaction, however, was unsuccessful, resulting in a 
brown solid which was insoluble in all common solvents. 
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4.1.1 Codeine Benzoate Esters 
Substituted benzoate esters had been highlighted as the main compounds of interest, 
the aim being to see which substituents would enhance analgesic activity the most, if 
at all. 
The first compound of this series to be synthesised was codeine 6-0-benzoate (49). 
Preparation was first effected by stirring codeine with benzoyl chloride in pyridine, at 
room temperature. The reaction solution was dissolved in ethyl acetate and the 
pyridine solvent was removed by complexation with copper sulphate solution. The 
product was isolated in good yield. 
Codeine 6-0-benzoate (49) was also prepared using a 1,3-dicyclohexylcarbodiimide 
(DCC) coupling reaction.52 This procedure offers a convenient method for the 
esterification of carboxylic acids with alcohols, under mild conditions. Its success 
depends on the high efficiency of 4-diaIkylaminopyridines as nucleophilic catalys_ts in 
group transfer reactions. The esterification proceeds without the need of a preformed, 
activated carboxylic acid derivative, at room temperature, under non acidic, mildly 
basic conditions, in an aprotic solvent. Thus codeine and benzoic acid were stirred 
together in the presence of 4-N,N-dimethylaminopyridine (DMAP), in DCM. The 
addition of DCC followed by prolonged stirring, allowed on work up, the isolation of 
codeine 6-0-benzoate. The product was isolated in a slightly lower yield compared 
with the reaction employing benzoyl chloride. The IR and NMR spectra were 
identical in each case. The IR spectrum exhibited a carbonyl stretch at 1717 cm'\ 
corresponding to the ester functionality. The NMR spectrum contained the 
characteristic codeine N-Me and O-Me singlets at (l 2.48 and 3.72, the fme structure 
was clearly identifiable and comparable to codeine with the 5- and 6-H's being shifted 
downfield to (l 5.20 and 5.47, as expected with ester substitution at the 6-position. 
The benzoate protons were located farthest downfield, a doublet was observed at 
(l 8.09 integrating for two protons, consistent with the two aromatic hydrogens 
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Scheme 2 
MeO 
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~O\" 4 ~OH (36) 
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~ \" 4 (50); X=N02 (52); X=F I 0 (51); X=OMe (53); X=C1 (54); X=Br 
Reagents: i, phthalic anhydride, pyridine, reflux; ii, succinic anhydride, pyridine, reflux; 
iii, benzoyl chloride, pyridine; iv, benzoic acid, DCC, DMAP, DCM; 
v, p-x-benzoyl chloride, pyridine; vi, piperonylic acid, DCC, DMAP, DCM. 
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located next to the ester functionality. Two triplets were observed at 0 7.43 and 
7.45, the upfield triplet integrating for two protons. The upfield triplet represents the 
two identical hydrogens meta to the ester functionality and the downfield triplet the 
single para hydrogen. The accurate mass was found to be 403.1795 consistent with 
the formula C2SH2SN04. 
Codeine 6-0-p-nitrobenzoate (50) was the next ester to be synthesised. Initial 
attempts at preparation centred on a transesterification procedure, using methyl 
p-nitrobenzoate. Refluxing codeine with methyl p-nitrobenzoate and PTSA, in 
benzene, with dry molecular sieves to remove any methanol produced, proved 
unsuccessful. Initial production of the morphine anion with N aH before reaction with 
methyl p-nitrobenzoate in THF did show some limited success with codeine 
6-0-p-nitrobenzoate being produced in 18% yield. Reaction with concentrated 
sulphuric acid in benzene, to promote the loss of methanol as the leaving group, 
however, proved unsuccessful. 
The failure of the transesterification procedure led to the use of the highly reactive acid 
chlorides. Reaction of codeine with p-nitrobenzoyl chloride in pyridine, at room 
temperature, allowed the successful isolation of codeine 6-0-p-nitrobenzoate. The 
ester carbonyl stretch was seen in the IR spectrum at 1722 cm-I. The NMR spectrum 
showed the codeine N-Me and O-Me singlets at 0 2.46 and 3.71 respectively, the 5-
and 6-H's were as usual shifted downfield to 0 5.20 and 5.47, and the four benzoate 
protons were located together at 0.8.27. The accurate mass was found to be 
448.1607 consistent with the formula C25H2~206. 
This successful procedure was applied to the preparation of further codeine esters. 
The p-fluorobenzoate derivative (52) was next prepared, followed by the 
p-chlorobenzoate (53) and p-bromobenzoate (54) derivatives so that the effect of 
increasing size and electronegativity of the substituent could be investigated. The 
p-fluorobenzoate derivative was easily prepared in quantitative yield from codeine and 
p-fluorobenzoyl chloride. The IR spectrum showed a carbonyl stretch at 1717 cm-I. 
44 
The NMR spectrum showed the characteristic codeine N-Me and O-Me singlets at 
Ii 2.52 and 3.72 respectively. The 5- and 6-H's were shifted downfield to Ii 5.19 and 
5.43 as expected for 6-substituted esters. The benzoate protons were seen as two 
doublets at Ii 7.11 and 8.10, each integrating for two protons. The accurate mass was 
found to be 421.1689 consistent with the formula C25H24NF04. 
The p-chlorobenzoate derivative was subsequently prepared in quantitative yield from 
codeine and p-chlorobenzoyl chloride. The IR spectrum showed a carbonyl stretch at 
1719 cm· l . The NMR spectrum showed the characteristic codeine N-Me and Q-Me 
singlets at Ii 2.49 and 3.72 respectively. The 5- and 6-H's were shifted downfield to 
Ii 5.19 and 5.43 as expected for 6-substituted esters. The benzoate protons were seen 
as two doublets at Ii 7.41 and 8.02, each integrating for two protons. Two accurate 
mass ions were apparent in the mass spectrum at 439.1364 and 437.1394, in the ratio 
3: 1 and consistent with the formula C25H2~CI04. 
Unfortunately in repeating the reaction to prepare the p-bromobenzoate deriviltive 
using p-bromobenzoyl chloride, the yield fell drastically to -50%. This was 
attributed to the relative deactivating effect of the bromo substituent on the acid 
chloride, but the problem was overcome by using DMAP to drive the reaction. The 
IR spectrum showed a carbonyl stretch at 1719 cm· l . The NMR spectrum showed 
the characteristic codeine N-Me and Q-Me singlets at Ii 2.48 and 3.72 respectively. 
The 5- and 6-H's were shifted downfield to Ii 5.19 and 5.42 as expected for 
6-substituted esters. The benzoate protons were seen as two doublets at Ii 7.58 and 
7.94, each integrating for two protons. Two accurate mass ions were apparent in the 
mass spectrum at 483.0887 and 481.0716, in the ratio 1:1 and consistent with the 
formula C25H24NBr04. 
Further variations were to include benzoate esters containing oxygen substitution. 
The p-methoxybenzoate derivative (51) was successfully prepared by the reaction of 
codeine with p-methoxybenzoyl chloride in pyridine. The IR spectrum exhibited an 
ester carbonyl stretch at 1711 cm ·1. The NMR contained the characteristic codeine 
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N-Me and O-Me singlets at a 2.48 and 3.74 respectively, with the benzoate O-Me 
singlet observed at a 3.44. The 5- and 6-H's were as usual shifted downfield to 
Ii 5.18 and 5.41, with two doublets being observed for the benzoate protons at a 6.92 
and 8.04. The accurate mass was found to be 433.1915 consistent with the formula 
C26H27N05. 
The 3,4 methylenedioxybenzoate derivative (55) was successfully prepared by the 
reaction of codeine with piperonylic acid and DCC, in DCM. The IR spectrum 
exhibited an ester carbonyl stretch at 1711 cm-i. The NMR contained the 
characteristic codeine N-Me and O-Me singlets at a 2.46 and 3.76 respectively, the 
5- and 6-H's were as usual shifted downfield to a 5.17 and 5.41, and as expected a 
singlet integrating for two protons was also observed at a 6.03 representing the 
methylene protons. The accurate mass was found to be 447.1679 consistent with the 
formula C26H25N06. 
Consideration was given to converting the esters (51) and (55) to the corresponding 
hydroxybenzoates of morphine. However it was decided that the conditions required 
for cleavage would probably cause the breakdown of the ester linkage. 
4.2 Morphine Esters 
The selective protection of the 3-position in morphine has been achieved with a 
variety of groups, benzyl and TBDMS giving the highest yields. It was decided to 
utilise morphine 3-0-TBDMS ether in further reactions, due to the fact that its 
removal with fluoride ions would leave the remainder of the morphine structure 
untouched. Benzyl groups are generally removed by hydrogenation which would 
also reduce the double bond in the C-ring of the morphine skeleton. 
It was decided to initially prepare a very simple ester, morphine 6-0-acetate (57), to 
defme a standard procedure for the preparation of all morphine esters. Morphine 
3-0-TBDMS ether was stirred with acetic anhydride in pyridine, at room temperature, 
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to give the protected acetate (56) in good yield. The IR spectrum showed an absence 
of hydroxyl, and the appearance of an ester carbonyl stretch at 1736 cm-I. The NMR 
spectrum showed the appearance of a singlet at S 2.14 corresponding to the acetate, 
with the morphine N-Me singlet apparent at S 2.45. The 5- and 6-H's were clearly 
distinguishable and shifted downfield to S 5.04 and 5.17, as observed in the codeine 
series for the introduction of an ester functionality at position-6. The remaining step 
was to remove the TBDMS protecting group, leaving the ester functionality 
unaffected. 
I 
+SiO 
I 
(45) 
acetic acid 
pyridine 
I 
+SiO I 
, 
(56) 
TBAF 
THF 
N-Me 
HO 
Me-CO"-
11 
o 
(57) 
Selective removal of the silyl ether was readily accomplished by treatment with 
tetrabutylammonium fluoride (TBAF), in THF,53 to give morphine 6-0-acetate (57). 
The TBDMS singlets at S 0-1 were absent from the NMR spectrum, signifying its 
removal. The acetate singlet remained at S 2.15. The 5- and 6-H's were again located 
at S 5.06 and 5.14, suggesting the ester still remains at the 6-position, and the 
morphine N-Me singlet at S 2.45 suggesting that the morphine skeleton also remains 
intact. The IR spectrum exhibited a carbonyl stretch at 1732 cm-!, but also the 
presence of a hydroxyl group was noted by a broad band at 3368 cm-I. Thus a viable 
route to the synthesis of morphine esters has been achieved. 
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Progressing In a parallel series to the codeine derivatives morphine 
6-0-succinate-3-0-TBDMS ether (58) was initially prepared by refluxing morphine 
3-0-TBDMS ether with succinic anhydride in pyridine. The IR spectrum showed 
two carbonyl stretches at 1735 and 1628 cm-I, consistent with the presence of both 
ester and acid functionalities. Three singlets were observed in the NMR spectrum at 
Ii 0.15, 0.20 and 0.98 representing respectively the two methyl groups and the t-butyl 
group of the TBDMS protecting group. The characteristic morphine N-Me singlet 
was observed at Ii 2.82. Four aliphatic protons were apparent, as expected, in the 
region Ii 2.52 - 2.72. The accurate mass was found to be 499.2388 consistent with 
the formula C27H37N06Si. Close examination of the spectra again reveals that our 
compound exists as a zwitterion. The carbonyl stretch of the carboxylic acid group in 
the IR spectrum is lower than expected, suggesting the presence of the carboxylate 
anion. The N-Me singlet in the NMR spectrum is shifted downfield, suggesting 
quatemisation. 
Morphine 6-0-phthalate-3-0-TBDMS ether (59) was prepared similarly ~sing 
phthalic anhydride in pyridine. The IR spectrum showed two carbonyl stretches at 
1714 and 1602 cm-I, consistent with the presence of both ester and acid 
functionalities. The NMR spectrum showed the characteristic pattern of three singlets 
for the TBDMS group at Ii 0.04, 0.06 and 0.88. The morphine N-Me singlet was 
observed at Ii 2.91. Two 1 H lriplets were observed at Ii 7.38 and 7.52 and two 1 H 
doublets at Ii 7.66 and 7.92, following the same pattern as the codeine 6-0-phthalic 
ester. Again we find that morphine 6-0-phthalate-3-0-TBDMS ether exists as a 
zwitterion. The carbonyl stretch of the carboxylic acid group in the IR spectrum is 
lower than expected, suggesting the presence of the carboxylate anion. The N-Me 
singlet in the NMR spectrum is shifted downfield, suggesting quatemisation. The 
elemental analysis obtained was consistent with the molecular formula C31H37N06Si. 
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Reagents: i, succinic anhydride, pyridine, reflux; ii, phthalic anhydride, pyridine, reflux; 
Hi, p-x-benzoyl chloride, pyridine; iv, TBAF, TIIF; v, HF in pyridine; vi, TBAF, TIIF. 
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The morphine 6-0-benzoate 3-0-TBDMS ethers were prepared in the same way as 
their codeine analogues, from morphine 3-0-TBDMS ether and the corresponding 
substituted benzoyl chloride in pyridine, using DMAP as a catalyst where required. 
Scheme 3. In all cases the IR spectra exhibited a carbonyl stretch at - 1715 cm-I. 
NMR spectra all contained the characteristic TBDMS singlets in the region 0 0 - I, 
and the N-Me singlet of the morphine skeleton at - 0 2.45. The same splitting 
patterns were observed for the substituted ester groups compared to the codeine 
compounds in the region 0 6.90 - 8.05. In all cases the 5- and 6-H's were shifted 
downfield as expected. Mass spectroscopy results gave the expected molecular ion 
for the benzoate, p-nitrobenzoate, p-methoxybenzoate, and p-fluorobenzoate 
derivatives. The p-chlorobenzoate spectrum showed two molecular ions in the ratio 
3: 1 and the p-bromobenzoate spectrum showed two molecular ions in the ratio 1: 1. 
See Table 1. 
Table 1. 
Compound IR TBDMS N-Me 5-H 6-H benzoate mass ion 
benzoate 1717 0.02,0.04, 2.53 5.21 5.40 7.42, 7.56, 503.2446 
(60) 0.84 8.09 
p-nitrobenzoate 1718 0.03, 0.06, 2.47 5.20 5.43 8.29 548.2331 
(61) 0.85 
p-methoxybenzoate 1710 0.04,0.06, 2.46 5.17 5.38 6.90,8.06 533.2602 
(62) 0.87 
p-fluorobenzoate 1717 0.01, 0.04, 2.58 5.19 5.39 7.07, 7.11, 521.2413 
(63) 0.84 8.08, 8.12 
p-chlorobenzoate 1719 0.01, 0.05, 2.45 5.16 5.39 7.41, 8.01 539.2070 
(64) 0.85 537.2123 
p-bromobenzoate 1719 0.01,0.04, 2.47 5.17 5.38 7.56, 7.95 583.1641 
(65) 0.84 581.1603 
TBDMS deprotection was easily effected in most cases using TBAF in THF, though 
isolation and purification of the morphine 6-0-benzoates proved extremely difficult, 
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due to their insolubility in virtually all common solvents. Recrystallisations were 
eventually accomplished from CHCI3/MeOH as solvent, though no compound was 
soluble in either of these solutions alone. In the case of morphine 
6-0-p-nitrobenzoate (69) recrystallisation was effected from a DMSO/water solution. 
All IR spectra were comparable to their morphine 3-0-TBDMS ether counterparts, 
with carbonyl stretches at - 1715 cm'!, but broad stretching was also apparent in the 
region 3400 cm'! due to the presence of the aromatic hydroxyl group. All NMR 
spectra were comparable with their morphine 3-0-TBDMS ether counterparts except 
that they lacked the TBDMS singlets in the region I) 0 - 1. Mass spectroscopy results 
were comparable with the morphine 3-0-TBDMS ether derivatives giving the 
expected molecular ion for the benzoate, p-nitrobenzoate, and p-fluorobenzoate 
derivatives. The p-chlorobenzoate spectrum showed two molecular ions in the ratio 
3: 1 and the p-bromobenzoate spectrum showed two molecular ions in the ratio 1: 1. 
See Table 2. 
Table 2 
Compound IR N-Me 5-H 6-H benzoate mass ion 
benzoate 1713 2.44 5.21 5.41 7.45, 7.59, 389.1623 
(68) 8.10 
p-nitrobenzoate 1719 2.31 5.12 5.43 8.22, 8.36 434.1479 
(69) 
p-fluorobenzoate 1713 2.45 5.18 5.40 7.11, 7.15, 407.1593 
(70) 8.09, 8.11 
p-chlorobenzoate 1719 2.46 5.22 5.41 7.39, 7.42, 425.1227 
(71) 7.98, 8.01 423.1268 
p-bromobenzoate 1718 2.46 5.18 5.40 7.60,7.95 469.0544 
(72) 467.0583 
Morphine 6-0-phthalate-3-0-TBDMS ether (59) was found to be resistant to 
TBAFfTHF deprotection. The use of acetic acid and water in THF also proved 
fruitless. It is obvious that quite vigorous conditions are required in this case in order 
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to remove the protecting group. The difficulty was to find conditions which would 
leave the ester and the morphine skeleton unaffected. It was decided to use hydrogen 
fluoride (HP) and pyridine. This reagent was used by Nicolaou54 for the removal of 
silyl protecting groups. The reaction proved extremely successful for our purposes. 
Again though, purification proved rather difficult, owing to the insolubility of 
morphine 6-0-phthalate (67). However recrystallisation was fmally effected from a 
CHChlMeOH solution. The IR spectrum contained two carbonyl stretches at 1716 
and 1601 cm-! corresponding to the ester and acid functionalities, and a broad OH 
band was observed at 3398 cm-I. The NMR spectrum lacked the TBDMS singlets, 
showing successful removal of the protecting group. The N-Me singlet was apparent 
at 0 3.01 and the 5- and 6-H's were as usual shifted downfield to 0 5.66 and 5.50 
respectively. The phthalate protons had similar chemical shifts and splitting patterns 
to the codeine and morphine 3-0-TBDMS ether derivatives, appearing at 07.40, 7.56 
and 7.92. A mass spectrum obtained by FAB showed the molecular ion (M+H+) at 
434.1604 consistent with the formula C2SH23N06. Close examination of the spectra 
again reveals that our compound exists as a zwitterion. The carbonyl stretch of the 
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carboxylic acid group in the IR spectrum is lower than expected, suggesting the 
presence of the carboxylate anion. The N-Me singlet in the NMR spectrum is shifted 
downfield, suggesting quaternisation. 
4.3 poHydroxy Esters 
The preparation of benzoate esters with hydroxy substituents has proved a rather 
difficult task. It was first decided to prepare a morphine 6-0-benzoate ester with the 
introduction of a single hydroxyl group in the para position. The obvious reagent to 
be utilised is 3-hydroxybenzoic acid (73). Studying the reaction pathway, however, 
it is noted that the carboxylate centre can react with not only the free hydroxyl group 
at position-6 on the morphine skeleton, but also with the free hydroxyl group on other 
molecules of the reagent. Thus the first priority is to protect the hydroxyl group to 
prevent this occurrence. 
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It was decided to protect the hydroxyl function of the reagent with the TBDMS group, 
so that later in the preparation of morphine 6-0-p-hydroxybenzoate from 
morphine 3-0-TBDMS ether, all deprotections could be effected together in one 
simple step. 
4.3.1 Transesterification 
It is known that carboxylic acids can be protected using silyl ethers,55 under similar 
conditions to those required for the protection of a phenol group, and it was feared 
that we would be unable to selectively protect the hydroxyl function in the presence of 
.the carboxylic acid. It was thought that this problem could be avoided by selectively 
modifying the carboxylic acid group making it insusceptible to reaction with 
TBDMS-Cl, but still able to react with the morphine 6-hydroxyl function. 
Thus the carboxylic acid group was initially converted to the methyl ester, which may 
be further utilised in a transesterification procedure, to introduce the required 
functionality. The methyl ester (74) was prepared, in high yield, from the free acid 
by refluxing with concentrated sulphuric acid in methanol.56 A carbonyl stretch was 
observed in the IR spectrum at 1724 cm·1 and the NMR spectrum showed the 
appearance of a methyl singlet at I) 3.90, indicating the presence of a methyl ester. 
Protection of the hydroxyl functionality with the TBDMS group proved a little more 
difficult. The use of NaH and TBDMS-Cl in THF was unsuccessful, rather the 
sodium salt of the methyl ester was isolated. Moving to a slightly more polar solvent, 
DMF, did not alleviate this problem. Reacting methyl 3-hydroxybenzoate with 
imidazole and TBDMS-Cl in DMF however, did allow the isolation of our reagent 
(75). The O-Me singlet was still apparent in the NMR spectrum at I) 3.87 with the 
appearance of the two TBDMS singlets in the region I) 0-1. 
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The transesterification procedure was attempted using codeine, with the hope of 
progressing to morphine if successful. Reacting codeine with methyl p-TBDMS-oxy 
benzoate, in the presence of PTSA, in refluxing toluene proved fruitless. Repeating 
the reaction using a DMAP catalyst in refluxing toluene was again unsuccessful, as 
was using NaH to produce the codeine anion before proceeding with the 
transesterification reaction. 
4.3.2 DCC Coupling 
Using DCC to couple the hydroxyl group of codeine with a carboxylic acid group has 
previously been successful in the preparation of codeine 6-0-benzoate It was decided 
to use the same procedure here, but using p-TBDMS-oxy benzoic acid (76), as the 
reagent. 
It was attempted to prepare the p-TBDMS-oxy benzoic acid by the demethylation of 
methyl p-TBDMS-oxy benzoate (75). Using potassium carbonate in a methanolic 
solution, followed by an acidic work up did not give the p-TBDMS-oxy benzoic acid, 
but rather methyl p-hydroxybenzoate. It is believed that the reaction itself is 
unsuccessful and that the silyl protecting group is lost during the work up. Using 
potassium hydroxide in ethanol was also unsuccessful, but in this case all protecting 
groups were removed to give p-hydroxybenzoic acid. 
The protection of p-hydroxybenzoic acid with TBDMS-Cl, in DMF with imidazole, 
as previously predicted, did protect both the acid and phenolic functions. Modifying 
this reaction by using NaH in THF, in an attempt to make the phenolic group more 
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reactive by forming the anion, did however have its benefits. The reaction was found 
to initially favour reaction at the phenolic position, so that if reaction times were kept 
to a minimum the hydroxy protected acid could be isolated, albeit in low yield. 
eOOH eOOH COOTBDMS Q TBDMS-CI • Q Q + NaH, DMF 
OH OTBDMS OTBDMS 
(73) (76) (77) 
The IR spectrum of (76) contained a carbonyl stretch at 1678 cm-I. The NMR 
spectrum contained two TBDMS singlets at 1) 0.22 and 0.98 and two aromatic 
doublets at 1) 6.87 and 6.98, each integrating for two protons. The IR of the 
disubstituted product (77) contained a carbonyl stretch at 1700 cm-I and the NMR 
spectrum contained five singlets at 1) 0.22, 0.24, 0.36, 0.98, and 1.02 indicating the 
presence of two silyl groups. 
DCC coupling with codeine in the presence of DMAP however was unsuccessful. It 
is thought the p-TBDMS-oxy group is having a strongly deactivating effect on the 
benzene ring and thus the carboxylate function. A more reactive form of the 
carboxylic acid is required. 
4.3.3 Acid Chloride Reaction 
The traditional way to prepare acid chlorides is from the free acid using thionyl 
chloride (SOCI2).57 Thus p-TBDMS-oxybenzoic acid was reacted with SOCI2 in 
pyridine as solvent, to mop up any HCI produced. The reaction appeared to proceed 
by TLC but the acid chloride could not be isolated. Thus it was decided to prepare the 
acid chloride and react it insitu. Reaction with codeine in pyridine did appear 
successful by TLC, but no codeine derivative could be isolated, rather a TBDMS 
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product, indicating that the acid chloride had not been formed and that the initial 
reaction had removed the protecting group. 
Another milder method to for the preparation of acid chlorides, is to use an excess of 
oxalyl chloride in DCM.S8 Thus p-TBDMS-oxybenzoic acid was reacted with oxalyl 
chloride in DCM, taking care only to use fresh oxalyl chloride, the reaction mixture 
effervesced indicating the formation of the acid chloride. Solvent and excess oxalyl 
chloride were easily removed on a rotor evaporator under reduced pressure, using a 
small amount of benzene to help remove the excess oxalyl chloride. The reagent was 
stored under nitrogen, without any further purification. 
~OH 
oxalyl chloride ~ 
DCM 
OTBDMS 
(76) 
Q' 
OTBDMS 
(78) 
4.3.4 Preparation of 6-0-p-hydroxybenzoates 
To prepare codeine 6-0-p-hydroxybenzoate a pyridine solution of codeine was added 
to the freshly prepared acid chloride at room temperature, but after 6 h TLC indicated 
that the reaction was unsuccessful. However, on the further addition of a catalytic 
amount of DMAP the reaction did progress to completion and codeine 
6-0-p-TBDMS-oxybenzoate was isolated (79). The IR spectrum exhibited a carbonyl 
stretch at 1709 cm-I. The NMR spectrum contained the characteristic codeine N-Me 
and O-Me singlets at 11 2.56 and 3.73 respectively, the 5- and 6-H's were as expected 
shifted downfield to II 5.20 and 5.41. The silyl protecting group was observed as 
two singlets at II 0.22 and 0.98. The accurate mass was found to be 533.2597 
consistent with the formula C3IH39NOsSi. 
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The TBDMS protecting group was easily removed using TBAFrrHF, to give the 
desired codeine 6-0-p-hydroxy benzoate (80). The loss of the silyl protecting group 
was noted by the appearance of an OH band in the IR spectrum at 3563 cm· l and by 
the loss of the two characteristic singlets in the region 8 0-1 in the NMR spectrum. 
The ester function remained present shown by the carbonyl stretch at 1712 cm· l in the 
IR spectrum and the downfield shift of the 5- and 6·H's to 8 5.19 and 5.39 in the 
NMR spectrum. The characteristic codeine N-Me and O-Me singlets were apparent at 
82.51 and 3.73. The accurate mass was found to be 419.1733 consistent with the 
formula C25H25N05' 
A similar route was followed in the preparation of morphine 6·0-p-hydroxybenzoate, 
but in this case morphine 3-0· TBDMS ether was used as the starting material. A 
pyridine solution of morphine 3-0-TBDMS ether was added to a solution of freshly 
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prepared p-TBDMS-oxybenzoyl chloride at room temperature, and the reaction 
proceeded without the use of a catalyst. Morphine 3-0-TBDMS-ether 
6-0-p-TBDMS-oxybenzoate (81) was isolated as a colourless powder. The ester 
preparation was successful, shown by the carbonyl stretch in the IR spectrum at 
1711 cm- i and the downfield shift of the 5- and 6-H's to li 5.13 and 5.31, in the 
NMR spectrum. The presence of two silyl protecting groups was indicated by the 
five upfield singlets at 0.02, 0.04, 0.17, 0.82 and 0.94. The characteristic morphine 
N-Me singlet was apparent at li 2.42. The remainder of the fine structure was 
comparable to that of the codeine derivative. 
Scheme 5 
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The two TBDMS protecting groups were easily removed in one step, using 
TBAFfTHF and morphine 6-0-p-hydroxybenzoate (82) was finally prepared. The 
loss of the protecting groups was noted by the appearance of two OH bands in the IR 
58 
spectrum at 3640 and 3475 cm-I, and by the loss of all singlets in the region 15 0-1 in 
the NMR spectrum. The ester carbonyl stretch was apparent at 1736 cm-I in the IR 
spectrum and the 5- and 6-H's were located, as expected for the presence of an ester, 
at 15 5.15 and 5.34 in the NMR spectrum. The characteristic morphine N-Me singlet 
was apparent at 15 2.43. The accurate mass was found to be 405.1569 consistent with 
the formula C24H23N05. 
Later a different approach to the synthesis of carboxylic acid chlorides was 
investigated. Acid chlorides can be prepared from t-butyldimethylsilyl esters using 
oxalyl chloride in the presence of a catalytic amount of DMF, under neutral 
conditions.59 Interestingly t-butyldimethylsilyl ethers are stable to oxalyl chloride 
under these conditions. Thus in the case of p-hydroxybenzoic acid both the hydroxyl 
and carboxylate moieties were silylated in a single step and then the silyl ester 
selectively converted to the acid chloride, giving the required p-TBDMS-oxybenzoyl 
chloride (78)_ 
It has been shown that acid chloride formation proceeds extremely slowly in the 
absence of DMF, implicating it as the reactive species. The suggested mechanism 
involves the addition of DMF to the carboxyl group of the siIyl ester to give an 
intermediate (83) which could undergo fragmentation to generate 
t-butyldimethyIchlorosiIane, DMF, and the carboxylic acid chloride. 
HCON(CH3h + ClCOCOCl --l.~[ :>-"(C"'), r cr + CO + Co, 
59 
4.3.4 Future Work 
This procedure could easily be extended to include the introduction of other hydroxy 
substituted benzoate esters, possibly culminating with gallic acid (84), allowing the 
• introduction of three neighbouring hydroxyl groups, as found in M-6-G. 
eOOH 
HO~OH 
OH 
(84) 
60 
BENZYL ETHERS 
The next series of compounds to be investigated were the 6-0-benzyl ethers. 
The Williamson synthesis is generally used for the preparation of ethers. It is important 
because of its versatility, being used to prepare both symmetrical and unsymmetrical 
ethers. During the synthesis an alkyl halide is allowed to react with an alkoxide ion, 
prepared from an alcohol or phenol. 
5.1 Benzylation using a Base and an Alkyl Halide 
Applying this to codeine, the function we hope to etherify is the secondary alcohol at 
position-6 on the codeine skeleton. It was hoped that using NaH to form the alkoxide 
ion and reacting with benzyl bromide (BnBr), in THF at room temperature, would lead 
to the isolation of codeine 6-0-benzyl ether (85). 
NaH,BnBr 
1HF 
(20) 
The reaction was successful and codeine 6-0-benzyl ether (85) was isolated as a pale 
yellow powder. The NMR spectrum of the crude product exhibited the characteristic 
codeine O-Me and N-Me singlets at Ii 3.85 and 2.67 respectively. A multiplet was 
observed at Ii 7.38 integrating for five protons and thus representing the benzyl aromatic 
protons, indicating that benzylation has been successful. Two ABq's were observed 
one at Ii 6.68 and 6.54 corresponding to the codeine aromatic protons, and one at Ii 4.85 
and 4.64 corresponding to the benzyl alkyl protons. The codeine double bond protons 
were identified, as expected, at Ii 5.81 and 5.28. The remainder of the fine structure 
was comparable with that of codeine. The COSY spectrum exhibited couplings between 
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the 5- and 6- protons, also between the 9- and 10- protons and the 9- and 14- protons 
signifying that the codeine skeleton is unaltered. Also as the N-Me singlet shows no 
quatemisation, benzylation must be at the 6-hydroxyl position. The accurate mass was 
found to be 389.1995 consistent with the formula C2SH27N03. 
The next codeine analogue to be prepared was the 6-0-p-nitrobenzyl ether (86). 
Codeine was reacted with NaH in THF to form the alkoxide ion, as previously. 
p-Nitrobenzyl bromide was added at room temperature to prepare codeine 
6-0-p-nitrobenzyl ether. The NMR spectrum of the crude product showed that codeine 
6-0-p-nitrobenzyl ether had been isolated but was stilI a little impure. The characteristic 
codeine O-Me and N-Me singlets were apparent at II 3.83 and 2.45 respectively. Two 
doublets were observed at II 8.21 and 7.62 each integrating for two protons and thus 
representing the benzyl aromatic protons, indicating that benzylation has been 
successful. Two ABq's were observed one at II 6.66 and 6.54 corresponding to the 
codeine aromatic protons, and one at 115.33 and 4.73 corresponding to the benzyl alkyl 
- protons. The codeine double bond protons were identified, as expected, at II 5.78 and 
5.38. The remainder of the fine structure was comparable with that of codeine. The 
accurate mass was found to be 434.1846 consistent with the formula C2SH26N20S. 
MeD 
NaH, p-NO?BnBr .. 
DMF N-Me 
(20) ~ \" O2 ~ CH2-0 (86) 
Purification of these codeine analogues proved to be impossible. Column 
chromatography on silica and alumina, both neutral and basic, lead to degradation of the 
product with an apparent quatemised compound being isolated. Indicated by the 
downfield shift of the N-Me singlet. Recrystallisation was also unsuccessful. It is not 
understood why the 6-0-benzylated products are unstable under such a wide variety of 
conditions. 
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The reaction was repeated using morphine 3-0-TBDMS ether as the starting material to 
ascertain whether a 6-0-benzylated product could be prepared. Unfortunately, 
however, the reaction was unsuccessful. The reaction progress was followed by 1LC 
but no clear product was identified, the plates being streaky. On work up a yellow / 
brown product was isolated. The NMR spectrum showed that the product was a 
morphine type compound, as much of the fine structure was apparent. Benzylation had 
occurred shown by a multiplet at 1) 7.2 - 7.4 and a doublet at 1) 7.7, possibly on the 
nitrogen as the characteristic N-Me singlet is shifted downfield to 1) 3.3. The TBDMS 
singlets were still observed at 1) 0-1, but the spectrum was gt:nerally impure with a 
considerable amount of background interference. Attempts at purification by column 
chromatography, on silica, failed to improve characterisation and it was decided that 
morphine 6-0-benzyl-3-0-TBDMS ether had not been obtained. Repeating the reaction 
in DMF as solvent gave the same results. 
Repeating the reactions again but heating to reflux, was also unsuccessful as was 
- attempting to use a different base, KOH, to form the alkoxide ion. 
It had been suggested that maybe the large bulky TBDMS protecting group could be 
folded in such a way that it could hinder electrophilic attack at the alcohol function. It 
was initially thought that this could be solved by using a slightly more reactive benzyl 
species, the benzyl iodide.60 3-0-TBDMS-morphine was initially stirred with NaH in 
DMF. Benzyl bromide was added followed by tetra-n-butyl ammonium iodide 
(BU4NI), to form the reactive benzyl iodide in situ.. The reaction progress was 
monitored by TLC, but this was inconclusive, again being very streaky. Unfortunately 
on work up the reaction was found to be unsuccessful as the product isolated was a 
morphine compound with some ill defined benzylation, the NMR spectrum being 
comparable to that obtained from the NaH / BoBr reaction previously. 
Maybe if the bulky TBDMS group was substituted for a smaller protecting group the 
problem of steric hindrance would not occur. It was hoped to investigate the use of the 
methoxy methyl ether protecting group. Morphine 3-0-MOM ether was successfully 
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prepared, but in a fairly low yield, See Chapter 3. It was then attempted to prepare 
morphine 3-0-MOM-6-0-benzyl ether. Morphine 3-0-MOM ether and NaH were 
reacted together in THF to form the alkoxide ion. Benzyl bromide was then added and 
the reaction left stirring at room temperature, overnight. Unfortunately on work up no 
satisfactory results were obtained. 
5.2 Benzylation using a Silver Oxide Catalyst 
Another common procedure for the preparation of ethers, under mild conditions, is to 
use silver oxide (Ag20) as a catalyst with an alkyl halide in DMF.61 Silver oxide was 
freshly prepared from an aqueous solution of silver nitrate treated with sodium 
hydroxide. The silver oxide precipitated immediately and was collected by filtration. 
The reaction of morphine 3-0-TBDMS ether and benzyl bromide in DMF, in the 
presence of Ag20 did allow the isolation of a colourless powder. The NMR spectrum 
- was well defined. A two proton doublet was apparent at Ii 7.76 and a three proton 
multiplet at Ii 7.31-7.44, these are assigned to the benzyl aromatic protons and show that 
benzylation has occurred. The morphine aromatic ABq was apparent at Ii 6.62 and 6.49 
and the TBDMS singlets were clearly seen in the region Ii 0-1. Another ABq was 
apparent at Ii 5.96 and 5.79 representing the benzyl alkyl protons. The morphine double 
bond protons were observed at Ii 5.53 and 4.92. The fine structure was all shifted 
downfield, the 5-H to Ii 5.28, the 6-H to Ii 4.81, the 9-H to Ii 4.55 and the 14-H to 
Ii 4.38. The COSY spectrum exhibited couplings between the 5- and 6- protons, also 
between the 9- and 10- protons and the 9- and 14- protons signifying that the morphine 
skeleton is unaltered. The characteristic N-Me singlet, however, was shifted downfield 
to Ii 3.26, suggesting quatemisation. The mass spectrum did not exhibit a molecular ion 
at 489 as would be expected for morphine 3-0-TBDMS-6-0-benzyl ether, rather the 
molecular ion was found at 399, representing morphine 3-0-TBDMS ether. However 
the major ion was observed at mlz 91 which corresponds to the benzyl ion, suggesting 
that the parent compound is broken down in the mass spectrometer. It is conduded that 
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benzylation had occurred at the nitrogen rather than at the 6-hydroxyl position and that 
the quaternary benzyl product (87) had been isolated. 
TBDMSO 
(45) 
TBDMSO 
BnBr,Agp JI 
DMF 
(87) 
Repeating the reaction in THF as solvent gave the same results. 
5.3 Benzylation using a Polar Aprotic Solvent 
It was thought that the use of a polar aprotic solvent may increase the rate of alkylation at 
the oxygen atom rather than at the nitrogen atom. The more electronegative end of the 
• nuc1eophiJe is thought to be freer from entanglement by both the solvent and the cation 
so that a change from aprotic to polar aprotic solvent increases the extent of attack by the 
more electronegative atom. Thus it was decided to incorporate 
N,N dimethylpropyleneurea62 (DMPU). Codeine and NaH were reacted together in 
THF, to form the alkoxide ion. DMPU was then added and the reaction stirred for a 
further 30 min before the addition of BnBr. After leaving ovemight the reaction was 
quenched with water and the product isolated. 1 H NMR data suggested the product was 
a mixture of O-benzylated and N-benzylated compounds. The benzyl protons were seen 
as a large multiplet at 1) 7.22-7.46 but with two doublets apparent at Il 7.79 and 7.63 
suggesting more than one benzyl substitution. Also two O-Me singlets were observed at 
I) 3.84 and 3.83 and two N-Me singlets were observed at 1) 3.61 and 3.33. Attempts to 
separate the components by column chromatography on basic alumina were 
unsuccessful. 
65 
It was thought that a stronger base may allow selective O-benzylation and the above 
reaction was repeated using lithium diisopropylamide (LDA). The LDA was prepared 
just prior to use. To a stirred solution of diisopropylamine under nitrogen at -20'C was 
added butyllithium (2.5 M solution), with the formation of a thick yellow gel of LDA. 
(The reaction is unsuccessful if a solution is formed or if the product turns white). A 
codeine solution in THF was added to the freshly prepared LDA at -20'C, followed by 
stirring for 30 min. The reaction temperature was then allowed to rise to O'C and 
stirring continued for a further hour. DMPU was then added and the reaction stirred 
overnight. Benzyl bromide was added and the reaction followed by TLC. Preliminary 
results were inconclusive with the TLC plates being very streaky. On work up, again an 
inseparable mixture of what seems to be N-benzylated and O-benzylated products was 
isolated. 
5.4 Quaternisation 
• Due to the problems arising from quaternisation of the nitrogen function it was decided 
to selectively prepare the methyl quaternary salt. Then having already protected the 
nitrogen function as the quaternary salt, it may then be possible to benzylate the 
hydroxyl function and then remove one of the methyl groups from the nitrogen to give 
the desired product. 
The methyl quaternary salt of morphine 3-0-TBDMS ether was prepared by reacting the 
parent compound with potassium hydrogen carbonate (KHC03) in methano1.63 Then 
adding methyl iodide and stirring overnight. 
Before perfonning a benzylation reaction upon the methyl quaternary salts it was 
decided to attempt to remove one of the methyl groups to assess the viability of the 
process. Quaternary methyl groups can be removed using the sodium salt of 
thiophenol.64 To prepare the reagent, sodium in dry, distilled toluene was treated with 
thiophenol. Gentle heating allowed the formation of the sodium salt as a white 
precipitate, which was collected by filtration in (85% )yield. 
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Then to a solution of morphine 3-0-TBDMS ether quaternary methyl salt dissolved in 
ethanol was added a solution of sodium thiophenoxide in ethanol. The reaction was 
stirred for 30 min at room temperature after which the solvent was removed under 
reduced pressure. The residue was dissolved in acetonitrile and heated to reflux. 
Unfortunately a black sludge was obtained from which morphine 3-0-TBDMS ether 
could not be isolated. 
Time did not allow the exploration of any other methods for the removal of the 
quaternary methyl group, so we do not know whether the process would have been 
successful. 
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GLUCURONIDE SYNTHESIS 
6.1 Introduction 
Pharmacological tests were to be performed on isolated morphine-6-derivatives, but 
in order to complete a comparative binding proftle a reference point was needed. 
Thus the preparation and isolation of morphine 6-0-glucuronide (M-6-G), the lead 
compound, was required. 
For selective glycosidic linkage in an oligosaccharide synthesis, three fundamental 
procedures have proved to be particularly suitable ... 
a) .. the neighbouring group assisted procedure. An active substituent is required 
at C-2, e.g. an O-acetyl group. There then results via a carboxonium ion, a stabilised 
- cyclic acyloxonium intermediate, that can be opened at the anomeric centre by a 
nucleophile approaching in a direction trans to the substituent at C-2. When a halide 
is present at C-I mercury salts, silver perchlorate and silver triflate are suitable 
catalysts. When an acetate group is present at C-I Lewis acids are used as catalysts. 
b) .. the in situ anomerization procedure. A neighbouring group non-active 
substituent must be present at C-2. Use is made here of the possibility of producing 
an eqUilibrium, via suitable catalysts, between the a and ~ forms of the glycoside, 
usually the glycoside halide. The glycosides are destabilised by the anomeric effect. 
Suitable catalysts are trialkylammonium halides, mercury salts, silver perchlorate and 
silver triflate. 
c) .. the heterogeneous catalysis procedure. Generally an insoluble catalyst applied 
in the heterogeneous phase, under neutral conditions. Silver catalysts, particularly 
silver silicate, are suitable. 
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Elce65 et aJ have extended the heterogeneous catalysis procedure to incorporate the 
catalyst cadmium carbonate, successfully used in preparing glucuronide derivatives of 
estradiol. More recently Sasaki66 et aJ have shown that elevated pressures accelerate 
the condensation reaction of 2,3,6-tri-O-benzyl-a-D-glucuopyranosyl bromide and 
various alcohols, in the presence of hindered arnines. This also avoids the use of any 
heavy metal salts. Danishefsky67 has studied the usefulness of using oxiranes as 
glycosyl donors. The relevant glycal is epoxidised using dimethyldioxirane to 
produce the 1,2-anhydro sugar. Conjugation is performed in the presence of ZnCb 
wi th stereospecific construction of the product glycoside. 
6.2 Protection of Glucose 
Firstly the required sugar moiety, glucose, needed to be manipulated into a form 
which could be utilised in further glycosylation reactions. Preparation of the tetra 
acetate derivative of glucuronic acid was effected from glucuronolactone (88), by the 
method of BoIlenback.68 Initially the lactone was dissolved in methanol with a base 
catalyst, which causes a rearrangement to occur with the formation of a six membered 
ring. 
(88) OH OH 
Subsequent treatment with acetic anhydride in pyridine, leads to the selective isolation 
of both the a and ~ forms of tetra-O-acetyl-D-glucopyranuronate, (89) and (90) 
respectively. 
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OH OAc 
(89) 
COOMe 
flQOAC 4 OAc 1 AcO J3-fonn 
OAc 
(90) 
The NMR spectra of tetra-O-acetyl-a-D-glucopyranuronate exhibited an O-Me singlet 
at 0 3.75 and acetyl groups at 0 2.00 - 2.20. The 1-H appeared as a doublet located 
the farthest downfield at 0 6.40. The 5-H appeared as a doublet located the farthest 
upfield. Two triplets were observed for the 3- and 4-H's at 0 5.27 and 5.52 
respectively, and a double doublet was observed for the 2-H at B 5.12. 
The NMR spectra of tetra-O-acetyl-~-D-glucopyranuronate exhibited an O-Me singlet 
at 0 3.75 and acetyl groups at 0 2.00 - 2.20, as in the a-case. The 1-H appeared as a 
doublet located the farthest downfield at 0 5.77. The remaining protons appeared as a 
multiplet at 0 5.11 - 5.35. 
Melting points and optical rotation values in both cases were consistent with literature 
values.68 
6.3 Glycosylation - Neighbouring Group Support 
In peptide synthesis the glycosidation of secondary alcohols is known to progress by 
the neighbouring group assisted procedure.69 Good results are usually obtained if a 
J3-D-1-0-acetate group is present. Thus in the case of glucuronide, the 2-0 acetate 
group functions as the nucleophile pushing out the 1-0 acetate leaving group to 
produce the cyclic acyloxonium intermediate (91). 
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COOMe COOMe COOMe 
fr -0". ~ fJR Ac 1 .. OAc + R-Q-H ~ AcO 2 AcO 0 AcO 
OAc (91) 04. Me OAc (89) 
The aim here was to utilise this procedure to glycosylate the secondary alcohol, at the 
6-position, on the morphine skeleton. The reaction was initially conducted using 
codeine, with the hope of extending it to morphine if successful. Thus a solution of 
codeine in DCM was cooled to O'C and boron trifluoride etherate added, the unusual 
formation of a precipitate was noted. Tetra-O-acetyl-~-D-glucopyranuronate was 
added in portions, keeping the reaction temperature below W'C. Unfortunately no 
reaction was observed. Using a more polar solvent, DMF, the reaction was again 
unsuccessful, and the formation of a precipitate on addition of boron trifluoride 
etherate was again observed. 
It was thought that the boron trifluoride could be forming an insoluble precipitate with 
codeine, preventing further reaction with the sugar. To overcome this problem it was 
decided to alter the sequence of addition for the reagents, such that codeine was added 
to the sugar. The sugar was dissolved in DMF and boron trifluoride etherate added, a 
homogeneous solution was noted. Codeine was slowly added in portions without the 
formation of a precipitate. Unfortunately the reaction was still unsuccessful, and it 
was decided to use a different approach. 
6.4 Glycosylation - Koenigs Knorr 
Casparis70 was the first to prepare a series of codeine glycosides, utilizing the 
Koenigs-Knorr procedure, but it was Yoshimura71 who extended this to condense 
codeine and morpine with the acetobromo derivative of glucuronic acid to produce 
the 6-0-g1ucuronides. It was decided to use this already successful procedure for the 
preparation of codeine-6-0-glucuronide (C-6-G) and M-6-G. 
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The acetobromo derivative of glucuronic acid (90) was prepared by reaction of the 
tetra-acetate derivative of glucuronic acid, with hydrobromic acid in acetic acid.68 
The NMR spectrum contained similar splitting patterns to that of the a-tetra-acetyl 
glucopyranuronate. Two distinct triplets for the 3- and 4-H's were observed at 
Ii 4.85 and 5.20 respectively, and a double doublet for the 2-H at Ii 4.51 but all are, 
shifted -0.4 ppm upfield. The 5-H and I-H doublets were also shifted slightly 
upfield to Ii 4.18 and 6.31 respectively. An O-Me singlet was observed at Ii 3.38 but 
there was a loss of an acetate singlet at Ii 2.02. Melting points and optical rotation 
values were consistent with literature values. 
Methyl(codein-6-yl-2,3,4-tri-O-acetyl-~-D-glucopyranosid)uronate (93) was next 
synthesised by the condensation of codeine with the acetobromo derivative of 
glucuronic acid in benzene, in the presence of silver carbonate. The reaction rate is 
very slow, requiring prolonged heating to complete the reaction. Slow concentration 
of the reaction solution, by the removal of benzene via distillation, also assisted in 
reactivity. 
~gMe OAc AeO Br MeO 
OAc q 
--be-nz-e-ne-, ....:A::::g:!!2C::...O-3---~~ COOMe ". 
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OAc 
(93) 
The NMR spectrum showed two methyl singlets at I) 3.76 and 3.78 corresponding to 
the methoxy group at C-3 and the carboxylic methyl ester. The acetate singlets were 
observed at I) 2.0 - 2.1, consistent with the original sugar. A carbonyl stretch was 
also observed in the IR spectrum at 1746 cm· l , consistent with an ester group. The 
mass spectrum showed a molecular ion at 615 which was consistent with the 
molecular formula C31H37N012. 
Removal of the protecting groups to yield C-6-G proved rather difficult. The 
procedure of Helfrich and Berger72 reported the conversion of the methyl acetate 
derivative of codeine glucuronide (93) to the methyl derivative (94) on solvolysis with 
a catalytic amount of sodium methoxide. The ester functionality was then hydrolysed 
by an equivalent amount of aqueous barium hydroxide and C-6-G (95) was isolated 
after neutralisation with oxalic acid. 
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Attempting to follow this procedure, the removal of the acetate groups with sodium 
methoxide appeared successful by TLC. The hydrolysis of the ester gave a white 
powder, which from TLC evidence was thought to be the required compound. 
However, spectra showed that this was not the case and the melting point was higher 
than expected. The NMR spectrum could not be clearly interpreted, although a 
morphine type structure was apparent, and mass spectroscopy showed a molecular 
ion at 551. 
It is believed the problem lies in the isolation and purification of the extremely polar 
C-6-G, though we can not be certain that the reaction was successful. It was decided 
to attempt a new approach. A mild de-protection process was required that would 
leave the glucuronide attached to the morphine skeleton, and it was decided to utilise 
enzyme catalysed hydrolysis. 
6.5 Esterases and Lipases 
There are a wide range of esterases commercially available, but few have been widely 
used in organic transformations. The most commonly used esterases are pig liver 
esterase (PLE), porcine pancreatic lipase (PPL) and ex-chymotrypsin. 
Three main properties make enzymes exceptional catalysts ... 
1) They are extremely versatile and catalyse a broad spectrum of reactions. Reactions 
take place under mild conditions, often at room temperature and close to neutral pH, 
minimising isomerisation, racemisation, epimerisation and rearrangement. 
2) They can be extremely efficient catalysts. The rates of enzyme promoted reactions 
can be faster than those of the corresponding uncatalysed reactions by factors of up 
to 1012• 
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3) They are generally very selective in tenns of the type of reaction catalysed and with 
respect to the structure and stereochemistry of the substrate and product. These 
properties collectively constitute the specificity of an enzyme and are its most 
important feature for selective and asymmetric synthetic exploitation. 
There are six main groups of enzymes: oxidoreductases, transferases, hydrolyases, 
lyases, isomerases and ligases. The most useful enzymes for organic synthesis 
applications are those which accept a broad structural range of substrates while 
retaining the ability to operate stereospecifically on each. 
Investigating hydrolytic enzymes 73 we find that their abilities to catalyse selective 
hydrolyses have been widely exploited. e.g . 
... the hydrolysis of nitriles to amides and subsequently carboxylic acids, under very 
mild conditions. 
nitrile hydralase. R- eONH _.::.am",:",id::as",e--J.~ R- eOOH 
H20 2 HP 
... using yeast of PPL to hydrolyse the methyl ester functions of highly sensitive 
prostaglandin precursors to the corresponding acids. 
o o 
••• ,~eooeH3 lipase ••• ,~eOOH 
OH OH 
9 
o 
"'\~eOOCH3 l ' 0 
'pase • ' 
o 
"'\~eOOH 
OH OH 
PLE is also a useful enzyme for prostaglandin methyl ester hydrolysis. 
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Examining further methyl ester hydrolysis reactions74 it was found that PLE and 
a-chymotrypsin have been used in the hydrolysis of C-3 substituted glutarate diesters 
and are generally pro-S ester group selective. 
MeOOC COOH 
PLE exhibits a broad tolerance of structural variations in its meso- diester substrates. 
(XCOOMe 
COOMe 
(XCOOH PLE ~ 
COO Me 
o:xCOOMe PLE.. O:''j(COOH Me COOMe --~~~ ~ Me COOMe MeO MeO 
In this instance it was decided to utilise PLE, a complex mixture of trimeric 
isoenzymes which can behave similarly or differently depending on reaction 
conditions. 
Thus to prepare C-6-G the methyl acetate derivative of codeine glucuronide (93) was 
treated with a catalytic amount of sodium methoxide. The hydrolysis of the methyl 
derivative (94) was then carried out in phosphate buffer at pH 7, incubation at 25'C, 
using PLE suspended in ammonium sulphate. The pH was monitored continuously 
using a pH meter and base was automatically added during the course of the reaction 
to maintain a pH 7, to compensate for the production of the glucuronic acid. 
Acidification is generally used to destroy the enzyme at the end of the reaction but care 
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was needed here not to destroy the glycosidic bond. Thus the reaction mixture was 
slowly acidified to pH 5 using acetic acid. Again isolation of C-6-G proved difficult 
due to its high polarity. The products of most enzymatic reactions are isolated from 
the enzyme by extraction into an organic solvent. Unfortunately in this case C-6-G is 
insoluble in organic solvents but highly soluble in water. Thus isolation and 
purification was effected using HPLC with a reverse phase silica column, using 
aqueous methanol as the mobile phase. A white powder was isolated whose melting 
point was consistent with literature values for C-6-G. The NMR spectrum exhibited 
the characteristic codeine methoxy singlet at 1) 3.81 and N-Me singlet at 1) 2.51. The 
aromatic ABq and double bond protons were comparable to codeine. The glycosidic 
protons were apparent in the region 1) 3.49 - 4.60. The 2', 3' and 4' protons 
appearing as a multiplet, and the l' and 5' protons as doublets with the 1'-H being 
farthest downfield. An El mass spectrum showed a molecular ion at 299, not at 475 
as expected. This corresponds to the codeine ion and obviously conditions are 
causing early fragmentation of the C-6-G molecule. A different procedure such as 
- fast atom bombardment (FAB) would be required to identify the molecular ion. 
6.6 Morphine 6-0-gIucuronide 
Yoshimura prepared M-6-G (29) using 3-0-acetylmorphine71 , for protection of the 
three position. This was condensed with the acetobromo derivative of glucuronic acid 
in benzene, in the presence of silver carbonate to give the protected sugar. 
Deprotection was reported using successively sodium methoxide and barium 
hydroxide solution, as in the codeine case. 
Repeating this procedure proved unsuccessful, with the failure to isolate 
methyl(3-acetylmorphin-6-yl-2,3,4-tri-O-acetyl-p-D-glucopyranosid)uronate. As 
outlined earlier in the preparation of morphine 3-G-acetate the problem is probably 
due to the instability of this compound. This was overcome by utilising the much 
more stable morphine 3-0-TBDMS ether. The same glycosylation procedure was 
used, condensing morphine 3-0-TBDMS ether with the acetobromo derivative of 
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glucuronic acid in benzene, in the presence of silver carbonate, and the reaction 
proved successful, allowing the isolation and purification of 
methyl (3-0-TBDMS-morphin-6-yl-2,3,4-tri-O-acetyl-p-D-glucopyranosid) uronate 
(96). The IR spectrum exhibited a carbonyl stretch at 1758 cm- i , suggesting an ester. 
The NMR spectrum showed TBDMS singlets at 11 0.14, 0.16 and 0.96 corresponding 
to 2xSiMe and SiCMe3 respectively. Three acetate singlets were observed in the 
region 11 2.07, defining the presence of the sugar moiety. A singlet was apparent at 
11 3.74, identifying the presence of a methyl ester. The remaining sugar protons were 
observed along with the morphine fine structure. The accurate mass was found to be 
687.3264, by El mass spectroscopy, which was consistent with the molecular 
formula C36H49N012. 
It was decided that due to the problems arising in isolating the highly polar 
glucuronides the next step would be to remove the TBDMS group, before 
deprotection of the glucuronide sugar. This was easily effected using TBAF in THF. 
The NMR spectrum showed the loss of all singlets in the region 11 0-1, indicating the 
successful removal of the TBDMS group. The remainder of the spectrum was 
comparable with that of the protected compound. The IR spectrum still showed a 
carbonyl stretch at 1746 cm-I, suggesting the remainder of the molecule is still intact 
and that methyl(morphin-6-yl-2,3.4-tri-O-acetyl-p-D-glucopyranosid)uronate (97) has 
been isolated. It also exhibited a carbonyl stretch at 1746cm-1 corresponding to an 
ester functionality. The NMR spectrum showed the characteristic N-Me singlet of 
morphine at 11 2.49 and the aromatic ABq at 11 6.47 - 6.64. The three acetate singlets 
were apparent at 11 2.01 - 2.18 and the methoxy singlet of the ester at 11 3.73. 
Elemental analysis was correct for C30H35N012. 
The initial attempt at de-protection was, as for codeine, using the method of Helferich 
and Berger. Again the methyl derivative of morphine glucuronide seemed to be 
produced by TLC, on reaction with a catalytic amount of sodium methoxide in 
methanol. However, after hydrolysis of the ester functionality with an equivalent 
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amount of aqueous barium hydroxide and neutralisation with oxalic acid, M-6-G (29) 
could not be isolated. 
Following the success of using PLE to hydrolyse the methyl ester, in the preparation 
of C-6-G, it was decided to repeat the procedure to isolate M-6-G. Thus treatment of 
the methyl acetate derivative of morphine glucuronide (97) with sodium methoxide in 
methanol and then incubation with PLE in phosphate buffer, at 25'C, afforded M-6-G 
(29). Isolation and purification was effected by HPLC using a reverse phase colunm 
and aqueous methanol as the mobile phase. The melting point was consistent with 
literature values. The NMR spectrum exhibited the characteristic N-Me singlet of 
morphine at 0 2.87. The aromatic ABq and the double bond protons were clearly 
identified. The methoxy and acetate singlets were no longer visible compared to the 
spectrum of the protected compound. The glycosidic protons were all shifted upfield, 
consistent with the removal of the acetate groups. A mass spectrum by FAB showed 
the molecular ion (M+H) at 462 consistent with the formula C23H27N09. 
The preparation and isolation of M-6-G though far more difficult than expected has 
been accomplished. It is thought the method could be further utilised to prepare a 
series of morphine glycosides. 
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EXPERIMENTAL 
7.1 General Procedures 
All solvents were distilled before use. Chloroform (CH Cb) and dichloromethane 
(DCM) were distilled from phosphorus pentoxide. Diethyl ether (EtzO), ethyl acetate 
(EtOAc) and petroleum ether (40-60'C) were distilled from calcium chloride. 
Dimethylformamide (DMF) and dimethylsulphoxide (DMSO) were dried over calcium 
hydride, distilled under reduced pressure and stored over 4A molecular sieves under 
nitrogen. Methanol (MeOH) was distilled from magnesium methoxide, and ethanol 
(EtOH) was distilled from magnesium ethoxide, both were stored over 4A molecular 
sieves. Pyridine was distilled from and stored over potassium hydroxide pellets. 
Tetrahydrofuran (THF) was stored over sodium wire and distilled from the 
sodium-benzophenone ketyl immediately prior to use. Toluene and benzene were 
distilled from sodium hydride and stored over sodium wire. Glassware used in the 
reactions was generally flame dried under nitrogen and reactions were conducted 
under an inert atmosphere of nitrogen or argon. 
Analytical TLC was carried out on aluminium backed plates coated with Merck 
Kieselgel 60 FZ54 and compounds were visualised by staining with iodine, or under 
uv light (at 254 and / or 360 nm). Preparative TLC was performed on 20 cm by 
20 cm glass plates coated with Merck Kieselgei 60 PFZ54+366 (0.75 mm thickness). 
Flash chromatography was performed on Matrex® Silica 60 (35-70 micron). 
Melting points were detennined on a Kofler hot - stage apparatus and are uncorrected. 
Infra red spectra were recorded in the range 4000 - 600 cm· l , as nujol mulls or 
chloroform solutions using a Nicolet 205 FT-IR spectrophotometer, with internal 
calibration. 
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NMR spectra were recorded on a Bruker AC-250 spectrometer operating at 250 MHz 
for lH NMR and at 62.9 MHz for 13C NMR. Chemical shifts are expressed in ppm 
relative to tetramethylsilane as internal standard. Coupling constants (J) are quoted in 
hertz (Hz). The following abbreviations are used in the presentation of spectra: 
s = singlet. d = doublet. dd = double doublet. dt = double triplet. t = triplet. 
q = quartet. m = multiplet. 
Electron impact mass spectra were recorded on a Kratos MS-80 spectrometer with an 
ionising potential of 70 e V. Chemical ionisation mass spectra were recorded on a 
Finnigan MAT-90 mass spectrometer. 
Elemental analyses were initially sent to Medac Ltd. Department of Chemistry. Brunei 
University. Uxbridge. Middlesex and later performed on a Perkin Elmer 2400 
Elemental Analyser. 
HPLC was performed on a Fisons Spherisorb ODS-2 column. 300 mm x 25 mm. 
The solvents used were degassed. HPLC grade methanol and water. 
7.2 Experimental 
Preparation of Morphine (1) 
To a well stirred solution of BBr3 (25 g. 0.1 mol) in CHCI3 (250 ml). was added 
dropwise a solution of codeine (5 g. 16.7 mmol) in CHCI3 (35 ml). maintaining the 
solution at 25·C. The addition funnel was flushed with 10 ml of CHCI3. and the 
resulting mixture stirred for 1 h. The reaction mixture was poured onto a well stirred 
mixture of ice (125 g) and concentrated ammonia (30 ml). and kept at -5-0·C for 
30 min. with continuous stirring. This mixture was filtered and the resulting 
crystalline material washed thoroughly with small portions of cold CHC!) and water. 
and dried. Morphine. a white solid was obtained (4.615g. 97%) m.p. 253-4·C 
(decomp) [lit 254-256·C40); umax(nujol)/cm-1 3476 (OH); OH (CD30D) 1.91 (1 H. 
d. J 11. lSe-H). 2.12 (1 H. dt. J 12.5. 5. 5. 15a-H). 2.37 (1 H. dd. J 18.5. 6. 
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lOa-H), 2.50 (4 H, m, NMe and 16a-H), 2.68 (1 H, dd, 1 12.5, 4, 16e-H), 2.75 
(1 H, t, 12.5, 14-H), 3.03 (1 H, d,1 18.5, lO~-H), 3.43 (1 H, q, 13.5, 9-H), 4.19 
(1 H, m, 6-H), 4.85 (1 H, d, 16.5, 5-H), 5.26 (1 H, d, 110, 8-H), 5.67 (1 H, d, 
110, 7-H), 6.49 and 6.63 (2 H, ABq, 1 and 2-H); HPLC: Solvent - MeOHlH20 
(80:20), Flow rate - 0.5 rnl/min, Elution time - 30 min. 
Preparation of Morphin-6-yl-~.D.glucopyranosiduronic Acid (29) 
To a solution of methyl(morphin-6-yl-2,3,4-tri-O-acetyl-~-D-glucopyranosid)uronate 
(150 mg, 0.21 mmol) in methanol (3 cm3), was added om M NaOMe solution 
(1 cm3) and the solution stirred overnight. On completion of the reaction, indicated by 
TLC, the reaction mixture was evaporated to dryness under reduced pressure. The 
residue was dissolved in phosphate buffer (10 cm3), at 25'C, and the pH adjusted to 7 
using 0.05 M NaOH. PLE (0.45 cm3, 1 mg, -200 units) as a suspension in 3.2 M 
(Nl4)S04 solution was added and the reaction left stirring overnight, maintaining the 
temperature at 25'C and the pH at 7, by using a pH-stat. The reaction mixture was 
adjusted to pH 6 using acetic acid, and evaporated under reduced pressure to give a 
concentrated solution. The crude solution was chromatographed on reverse phase 
silica (elution with 30% H20 in MeOH). Final purification was by semi-prep HPLC, 
using a silica reverse phase column, to give colourless needles of M-6-G 29 (42 mg, 
35%) m.p. 252-255'C (decomp) [lit 254-256'C71); 'llmax(nujol)/cm·1 (C=O); 
BH (D20) 1.98 (1 H, d, 111, 15e-H), 2.25 (1 H, dt, 1 12.5, 5, 5, 15a-H), 2.87 
(6 H, m, NMe, lOa, 14 and 16a-H), 3.17 (2 H, m, 10~ and 16e-H), 3.70 (1 H, d, 
19, 22-H), 4.02 (1 H, q, 1 4, 9-H), 4.51 (1 H, m, 6-H), 4.59 (1 H, d, 18, 18-H), 
5.17 (1 H, d, 17, 5-H), 5.30 (1 H, d, 110, 8-H), 5.66 (1 H, d, 110, 7-H), 6.61 and 
6.69 (2 H, ABq, 1 and 2-H); Bc 24.18, 34.50, 40.20, 43.24 (NMe), 44.34, 49.05, 
62.50,74.20,75.42,75.54,77.95,78.72,90.74, 103.92, 120.17, 122.79, 125.98, 
129.05, 131.77, 135.58, 140.88, 148.15, 178.07; HPLC: Solvent - MeOHlH20 
(70:30), Flow rate - 0.5 rnl/min, Elution time - 10.5 min. 
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Preparation of 6a-(2' -Carboxybenzyloxy)-7 ,8-didehydro-4,5a-epoxy-3-
methoxy-17 -methyl-morphinan (36) 
A mixture of codeine (1 g, 3.34 mmol) and phthalic anhydride (2 g, 13.5 mmol) in 
pyridine (5 cm3) was refluxed for 1 h. The hot reaction mixture was poured onto ice 
and the resulting white precipitate collected on a filter. The precipitate was washed with 
cold water. Crystallisation from DCM-light petroleum gave the ester 36 (2.67 g, 88%) 
m.p. 227-8'C (decomp); 'Ilmax(nujol)/cm'\ 3417 (OH), 1713 (C=O ester), 1608 (C=O 
acid); oH(CDCI) 1.98 (I H, d, J 13.5, 15e-H), 2.68-2.97 (7 H, m, NMe, lOa, 15a, 
16a-H and OH), 3.07 (I H, d, J 18.5, 1OJ3-H), 3.44 (I H, d, J 7, 16e-H), 3.59 (I H, 
t, J 2.5, 14-H), 3.85 (4 H, m, OMe and 9-H), 5.44 (3 H, m, 5, 6 and 8-H), 5.80 
(1 H, d, J 8.5, 7-H), 6.61 and 6.74 (2 H, ABq, 1 and 2-H), 7.37 (1 H, t, J 7.5, 
21-H), 7.51 (I H, t, 17.5, 22-H), 7.67 (I H, d, 17.5, 20-H), 8.04 (I H, d, 17.5, 
23-H); oc 21.40, 32.09, 36.84, 40.80 (NMe), 40.96, 47.31, 56.99 (OMe), 60.11, 
67.66, 87.38, 115.40, 119.88, 122.83, 126.79, 127.29, 127.90, 129.75, 129.98, 
130.22, 131.16, 131.39, 132.07, 143.26, 146.81, 166.68, 175.83; mlz 447 (M+) 
299(100), 282(10), 229(14), 148(7), 124(11), 104(33), 76(19). [FAB-MS, Found 
(M+H+): 448.1752. C26H26N06 requires 448.1760] 
Preparation of 3-Acetyloxy-7,8-didehydro-4,5a-epoxy-17-methyl-
morphinan-6-ol (38) 
To a stirred solution of sodium carbonate (10 g) in water (lOO cm3) was added 
morphine (1 g, 3.5 mmol). To this suspension was added acetic anhydride (5.4 g, 
5 cm3, 53 mmol) dropwise with constant stirring, at room temperature. After the 
mixture ceased to foam, it was poured onto ice / water and extracted into CHCI3. The 
organic layer was dried (Na2S04) and evaporated under reduced pressure to yield a 
white solid 38 (1.121 g, 97%); 'Ilmax(nujol)/cm'\ 3400 (OH), 1690 (C=O); 
OH (CDCI3) 1.96 (I H, d, J 11, 15e-H), 2.29 (4 H, m, 10a-H and Ac), 2.58 (5 H, 
m, NMe, lOa and 16a-H), 2.95 (2 H, m, 14 and 16e-H), 3.08 (1 H, d, J 18.5, 
1OJ3-H), 3.70 (I H, q, J 3.5, 9-H), 4.20 (I H, m, 6-H), 4.96 (I H, d, J 6.5, 5-H), 
5.26 (1 H, d, J 10, 8-H), 5.79 (I H, d, J 10, 7-H), 6.64 and 6.77 (2 H, ABq, 1 and 
2-H). 
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Preparation of 3·Benzyloxy~7 ,8·didehydro·4,Sa·epoxy.17 .methyl· 
morphinan.6.ol (43) 
A solution of morphine (100 mg, 0.35 mmol) in dry DMF (5 cm3), with fmely 
divided KOH (100 mg), was stirred, under nitrogen, at room temperature for 1 h. 
Benzyl bromide (0.05 cm3, 72 mg, 0.42 mmol) was added and the reaction stirred at 
room temperature overnight. The reaction mixture was dissolved in CHCh washed 
with water, dried (Na2S04) and evaporated under reduced pressure. A yellow 
solution was obtained which was purified by column chromatography (elution with 
15% MeOH in DCM) to give a cream powder 43 (40 mg, 30%) m.p. 122-5'C 
[lit 125-6'05]; 'Umax(nujol)/cm-I 3540 (OH); 8H (CDCI3) 1.89 (1 H, d, J 11, 
15e-H), 2.05 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.28 (1 H, dd, J 18.5, 6, lOa-H), 2.43 
(4 H, m, NMe and 16a-H), 2.56 (I H, dd, J 12.5, 4, 16e-H), 2.65 (1 H, t, J 2.5, 
14-H), 3.03 (1 H, d, J 18.5, IO~-H), 3.34 (1 H, q, J 3.5, 9-H), 4.15 (1 H, m, 6-H), 
4.87 (1 H, d, J 6.5, 5-H), 5.13 (2 H, ABq, Qh-Ph), 5.27 (1 H, d, J 10, 8-H), 5.66 
(l H, d, J 10, 7-H), 6.53 and 6.71 (2 H, ABq, 1 and 2-H), 7.36-7.44 (5 H, m, 
CH2-Eh). 
Preparation of 3,6.Di·t· butyldimethylsilyloxy. 7,8·didehydro.4,Sa· 
epoxy.17.methyl·morphinan (44) 
Morphine (200 mg, 0.7 mmol), imidazole (120 mg, 1.75 mmol) and 
t-butyldimethylsilyl chloride (315 mg, 2.1 mmol) were shaken together in dry DMF 
(0.5 cm3), under nitrogen for 5 min. The reaction mixture was left stirring at room 
temperature overnight. The product was taken up in CHCI3, washed with 
aq. NaHC03 and water, dried (Na2S04) and evaporated to yield a cream solid. 
Crystallisation from DCM-light petroleum gave colourless crystals of 44 (133 mg, 
37%) m.p. 116-8°C; 'Umax(nujol)/cm- I 1628; 8H (CDCI3) 0.13 (12 H, m, 2xSiMe2), 
0.92 (9 H, S, SiCMe3), 0.98 (9 H, s, SiCMe3), 1.86 (l H, d, J 11.5, 15e-H), 2.03 
(l H, dt, J 12.5, 5, 5, 15a-H), 2.31 (I H, dd, J 18.5, 6, lOa-H), 2.49 (4 H, m, 
NMe and 16a-H), 2.60 (2 H, m, 14 and 16e-H), 3.02 (1 H, d, J 18.5, lO~-H), 3.35 
(l H, q, J 3.5, 9-H), 4.21 (1 H, m, 6-H), 4.66 (I H, d, J 6.5, 5-H), 5.22 (1 H, d, 
J 10, 8-H), 5.60 (1 H, d, J 10, 7-H), 6.41 and 6.56 (2 H, ABq, 1 and 2-H); mlz 513 
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(M+, 15%) 456(54), 413(48), 335(12), 278(17), 238(9), 146(10), 73(100), 59(14), 
41(17). 
Preparation of 3·t·B utyldimethylsilyloxy· 7 ,8·didehydro·4,5a·epoxy· 
17·methyl·morphinan·6·ol (45) 
To a solution of morphine (2 g, 7 mmol) in THF, under nitrogen, was added 
NaH-60% dispersion in mineral oil (310 mg, 7.75 mmol) and the reaction stirred for 
1 hr. t-Butyldimethylsilyl chloride (1.27 g, 8.45 mmol) was added and the reaction 
stirred overnight. The mixture was fIltered and THF removed under reduced 
pressure. The residue was purified by column chromatography (elution with 15% 
MeOH in CHCh). A cream powder was obtained 45 (1.445 g, 52%) m.p. 121-22'C 
[lit. 122-123'C76]; llmax(nujol)/cm-1 3552 (OH), 1629; IlH (CDCI3) 0.16 (3 H, s, 
SiMe), 0.20 (3 H, s, SiMe), 0.98 (9 H, s, SiCMe3), 1.89 (1 H, d, J 12, lSe-H), 
2.21 (1 H, dt, J 12.5, 5,5, 15a-H), 2.43 (2 H, m, lOa and 16a-H), 2.55 (3 H, s, 
NMe), 2.75 (1 H, dd, J 12.5, 4, 16e-H), 2.89 (1 H, t, J 2.5, 14-H), 3.04 (1 H, d, 
J 18.5, 1013-H), 3.50 (I H, q, J 3.5, 9-H), 4.19 (I H, m, 6-H), 4.87 (1 H, d, J 6.5, 
5-H), 5.26 (1 H, d, J 10, 8-H), 5.70 (1 H, d, J 10, 7-H), 6.50 and 6.60 (2 H, ABq, 
1 and 2-H). 
Preparation of 3·Methoxymethyloxy-7,8·didehydro-4,5a.epoxy·17. 
methyl·morphinan·6·ol (46) 
To a solution of morphine (500 mg, 1.75 mmol) in THF (50 cm3), under nitrogen, 
was added NaH-60% dispersion in mineral oil (77 mg, 1.92 mmol) and the reaction 
stirred for 1 h. Chloromethyl methyl ether (182 mg, 0.17 cm3, 2.27 mmol) in THF 
(10 cm3) was added dropwise and the reaction stirred overnight. TLC showed 
complete reaction of morphine. THF was removed under reduced pressure and the 
residue dissolved in DCM. The solution was washed with water, dried (Na2S04), 
and evaporated under reduced pressure. A brown residue was obtained which was 
purified by column chromatography (elution with 5% MeOH in DCM) to give a beige 
powder 46 (118 mg, 20 %) m.p. 92-95'C. [lit. 91-93'C77]; llmax(CHCI3)/Cm-l 3536 
(OH); IlH (CDCI3) 2.07 (1 H, d, J 12, 15e-H), 2.56 - 2.90 (6 H, m, NMe, lOa-, 
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15a- and 16a-H ), 2.95 (2 H, m, 1O~- and 16e-H), 3.46 (4 H, m, OMe and 14-H), 
3.87 (1 H, q, J 3.5, 9-H), 4.22 (1 H, m, 6-H), 4.97 (2 H, d, J 6.5, OCH20), 5.21 
(l H, d, J 10, 8-H), 5.56 (1 H, d, J 6.5, 5-H), 5.79 (1 H, d, J 10, 7-H), 6.63 and 
6.84 (2 H, ABq, 1 and 2-H); oe 21.87,32.62, 37.57, 41.22, 41.68, 47.11, 56.31, 
60.35, 65.34, 90.20, 95.23, 119.94, 120.70, 124.47, 124.59, 130.34, 135.65, 
139.02, 146.52. 
Preparation of 7,8-Didehydro-4,Sa-epoxy-3-methoxy-17 -methyl-6a-
succinyloxy-morphinan (48) 
A mixture of codeine (1 g, 3.34 mmol) and succinic anhydride (2 g, 20 mmol) in 
pyridine (5 cm3) was refluxed for 1 h. The hot reaction mixture was poured onto ice 
and the resulting white precipitate collected on a filter. The precipitate was washed with 
cold water. Crystallisation from DCM-petroleum ether gave the ester 48 (240 mg, 
18%) m.p. 154-6·C; umax.<nujol)/cm·1 3432 (OH), 1720 (C=O ester), 1632 (C=O 
acid); OH(CDCI3) 1.89 (1 H, d, J 13.5, 15e-H), 2.39-2.79 (11 H, m, NMe, 16-H2, 
19-H2,20-H2' lOa and 15a-H), 3.01 (1 H, d, J 19, lO~-H), 3.11 (1 H, t, J 2.5, 
14-H), 3.76 (1 H, q, J 3, 9-H), 3.86 (3 H, s, OMe), 5.15 (1 H, d, J 6.5, 5-H), 5.28 
(2 H, m, 6 and 8-H), 5.60 (1 H, d, J 10, 7-H), 6.55 and 6.68 (2 H, ABq, 1 and 2-H); 
miz 399 (M+ 13%) 299(100), 282(22), 229(29), 188(14), 162(31), 124(27),70(17), 
56(56), 42(49). 
Preparation of 6a-Benzoy)oxy-7,8-didehydro-4,Sa-epoxy-3-methoxy-
17-methyl-morphinan (49) 
To a solution of codeine (300 mg, 1 mmol) in pyridine (3 cm3), under nitrogen, was 
added benzoyl chloride (0.35 mI, 1 mmol) and the reaction stirred at room temperature 
for 4 h. DCM (10 mI) was added and the solution washed with a 5% CUS04 solution 
and water, dried (Na2S04) and evaporated under reduced pressure. The crude product 
was purified by column chromatography (elution with 5% MeOH in DCM) to give the 
ester 49 (295 mg, 73%). 
A mixture of codeine (300 mg, 1 mmol), benzoic acid (122 mg, 1 mrnol) and DMAP 
022 mg, 1 mmol) in DCM was stirred for 1 h at O·C, the flask being fitted with a 
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calcium chloride guard tube. DCC (230 mg, 1.1 mmol) was added and the solution 
was stirred at O'C for 5 min before being allowed to warm up to room temperature. 
After stirring for a further 3 h the reaction mixture was washed successively with dilute 
HCl / water / bicarbonate / water, dried (MgS04) and evaporated under reduced 
pressure. The crude product was purified by column chromatography (elution with 5% 
MeOH in DCM) to give the ester 49 (275 mg, 68%). Recrystallisation in each case 
from DCM-petroleum ether gave colourless crystals m.p. 130-32'C; llmax(nujol)/cm'! 
1717 (C=O ester); IiH(CDCI3) 1.91 (1 H, d, J 12.5, 15e-H), 2.12 (1 H, dt, J 12.5, 5, 
5, 15a-H), 2.37 (2 H, m, lOa and 16a-H), 2.48 (3 H, s, NMe), 2.65 (1 H, dd, J 12.5, 
4, 16e-H), 2.86 (1 H, t, J 2.5, 14-H), 3.06 (1 H, d, J 18.5, IO~-H), 3.42 (1 H, q, J 3, 
9-H), 3.72 (3 H, s, OMe), 5.20 (1 H, d, J 6.5, 5-H), 5.47 (2 H, m, 6 and 8-H), 5.78 
(1 H, d, J 10, 7-H), 6.55 and 6.67 (2 H, ABq, 1 and 2-H), 7.43 (2 H, t, J 8, 21 and 
23-H), 7.55 (1 H, t, J 8, 22-H), 8.09 (2 H, d, J 8, 20 and 24-H); lie 21.36, 35.09, 
40.39, 42.50, 42.85 (NMe) , 46.63, 56.79 (OMe) , 59.08, 68.40, 87.95, 114.59, 
119.13, 126.66, 128.13, 128.57, 129.31, 129.80, 130.63, 132.91, 142.10, 146.70, 
165.92; mlz 403 (M+, 53%) 282(28), 266(23), 229(14),155(15), 122(31), 105(100), 
77(51). (Found M+, 403.1795. C2SH2SN04 requires 403.1783). 
Preparation of 7,8-Didehydro-4,5cx-epoxy-3-methoxy-17 -methyl-6cx-( 4'-
nitrobenzoyloxy)-morphinan (50) 
To a solution of codeine (300 mg, 1 mmol) in pyridine (3 cm3), under nitrogen, was 
added p-nitrobenzoyl chloride (560 mg, 3 mmol) and the reaction stirred at room 
temperature for 4 h. EtOAc was added and the solution washed with 5% CUS04 
solution / water, dried (MgS04), and evaporated under reduced pressure. The crude 
product was purified by column chromatography (elution with 15% MeOH in CHCI3) 
and TLC plates (run in CHCI3IMeOHIN~OH) to give the ester 50 (283 mg, 63%). 
Recrystallisation from DCM-petroleum ether gave yellow crystals m.p. 186-87'C; 
umax(CHCI3)/cm'! 1722 (C=O ester); IiH(CDCI3) 1.90 (1 H, d, J 12.5, 15e-H), 2.08 
(1 H, dt, J 12.5, 5, 5, 15a-H), 2.34 (2 H, m, lOa and 16a-H), 2.46 (3 H, s, NMe), 
2.61 (1 H, dd, J 12, 4, 16e-H), 2.83 (1 H, t, J 2.5, 14-H), 3.07 (I H, d, J 18.5, 
10~-H), 3.40 (1 H, q, J 3, 9-H), 3.71 (3 H, s, OMe), 5.20 (1 H, d, J 6.5, 5-H), 5.47 
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(l H, m, 6-H), 5.55 (1 H, d, J 10, 8-H), 5.76 (1 H, d, J 10, 7-H), 6.58 and 6.67 
(2 H, ABq, 1 and 2-H), 8.27 (4 H, m, 20, 21, 23 and 24-H); lie 20.30, 35.35, 
40.66, 42.59, 43.09 (NMe), 46.74, 56.49 (OMe), 59.13, 69.17, 87.57, 113.86, 
119.46, 123.40, 127.03, 127.80, 130.20, 130.60, 131.07, 142.18, 146.44, 150.59, 
164.22; mlz 448 (M+, 84%), 311(20), 282(82), 229(25), 152(16), 104(44), 92(20), 
76(42), 59(39), 50(100), 44(58). (Found M+, 448.1607 C25H24N206 requires 
448.1634). 
Preparation of 7,8-Didehydro-4,5a-epoxy-3-methoxy-6a-(4'-methoxy 
benzoyloxy)-17 -methyl-morphinan (51) 
To a solution of codeine (300 mg, 1 mrnol) in pyridine (3 cm3), under nitrogen, was 
added p-anisoyl chloride (0.45 ml, 513 mg, 3 mrno1) and the reaction stirred at room 
temperature for 10 min. EtOAc was added and the solution washed successively with 
dilute HCI/ water / bicarbonate / water, dried (MgS04), and evaporated under reduced 
pressure. The crude product was purified by column chromatography (elution with 5% 
MeOH in DCM) to give the ester 51 (426 mg, 98%). Recrystallisation from DCM-
petroleum ether gave colourless crystals m.p. 174-76·C; umax(CHCI3)/cm-l 1711 
(C=O ester); IiH(CDCI]) 1.90 (1 H, d, J 12.5, 15e-H), 2.09 (1 H, dt, J 12, 5, 5, 
15a-H), 2.36 (2 H, m, lOa and 16a-H), 2.48 (3 H, s, NMe), 2.62 (1 H, dd, J 12, 4, 
16e-H), 2.83 (1 H, t, J 2.5, 14-H), 3.06 (1 H, d, J 18.5, 1O~-H), 3.42 (1 H, q, J 3, 
9-H), 3.44 (3 H, s, OMe), 3.74 (3 H, s, OMe), 5.18 (1 H, d, J 6.5, 5-H), 5.41 (1 H, 
m, 6-H), 5.48 (1 H, d, J 10, 8-H), 5.76 (1 H, d, J 10, 7-H), 6.55 and 6.66 (2 H, 
ABq, 1 and 2-H), 6.92 (2 H, d, J 9, 21 and 23-H), 8.04 (2 H, d, J 9, 20 and 24-H); 
lie 20.49, 35.28, 40.54, 42.69, 42.94 (NMe), 46.63, 55.42 (OMe), 57.02 (OMe), 
59.05, 68.34, 88.32, 114.82, 119.19, 122.41, 126.97, 128.85, 129.42, 130.90, 
131.98, 142.16, 146.78, 163.47, 165.77; mlz 433 (M+, 43%), 282(20), 229(12), 
152(14), 135(100), 77(16), 44(11). (Found M+, 433.1915 C26H27N05 requires 
433.1889). 
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Preparation of 7 ,8-Didehydro-4,5a-e poxy-6a-( 4'-f1uoro benzo yloxy)-3-
methoxy-17-methyl-morphinan (52) 
To a solution of codeine (300 mg, 1 mmol) in pyridine (3 cm3), under nitrogen, was 
addedp-fluorobenzoyl chloride (0.35 cm3, 477 mg, 3 mmol) and the reaction stirred at 
room temperature for 10 min. CHCI3 was added and the solution washed successively 
with dilute HCII water I bicarbonate I water, dried (MgS04), and evaporated under 
reduced pressure. The crude product was purified by column chromatography (elution 
with 5% MeOH in CHCb) to give the ester 52 (403 mg, 95%). Recrystallisation from 
DCM-petroleum ether gave colourless crystals m.p. 136-39'C; llmax(nujol)/cm·1 1717 
(C=O ester); liH(CDCI3) 1.92 (1 H, d, J 12.5, 15e-H), 2.16 (1 H, dt, J 12.5, 5, 5, 
15a-H), 2.42 (2 H, m, lOa and 16a-H), 2.52 (3 H, s, NMe), 2.75 (1 H, dd, J 12.5, 4, 
16e-H), 2.92 (1 H, t, J 2.5, 14-H), 3.08 (1 H, d, J 18.5, 10~-H), 3.53 (1 H, q, J 3, 
9-H), 3.72 (3 H, s, OMe), 5.20 (1 H, d, J 6.5, 5-H), 5.43 (1 H, m, 6-H), 5.51 (1 H, 
d, J 10; 8-H), 5.77 (1 H, d, J 10, 7-H), 6.58 and 6.68 (2 H, ABq, 1 and 2-H), 7.11 
(2 H, m, 21 and 23-H), 8.10 (2 H, m, 20 and 24-H); lie 20.63, 34.82, 39.98, 42.41, 
42.60 (NMe), 46.60, 56.74 (OMe), 59.04, 68.41, 87.85, 114.49, 115.24, 115.59, 
119.37, 126.36, 128.69, 129.26, 130.49, 132.43, 132.58, 142.30, 146.76, 165.05, 
.167.88; mlz 421 (M+, 53%) 282(28), 266(23), 229(14),155(15), 122(31), 105(100), 
77(51). (Found M+, 421.1689. C2SH24NF04 requires 421.1725). 
Preparation of 6cx-( 4'-Chlorobenzoyloxy)-7 ,8-didehydro-4,5a-epoxy-3-
methoxy-17-methyl-morphinan (53) 
To a solution of codeine (300 mg, 1 mmol) in pyridine (3 cm3), under nitrogen, was 
added p-chlorobenzoyl chloride (0.38 rnI, 527 mg, 3 mmol). The reaction mixture was 
stirred at room temperature for 10 min. EtOAc was added and the solution washed 
successively with dilute HCI I water I bicarbonate I water, dried (MgS04), and 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (elution with 10% MeOH in CHCI3) to give the ester 53 (315 mg, 
72%). Recrystallisation from DCM-petroleum ether gave colourless crystals m. p. 
165-67'C; llmax(CHCI3)/cm·l 1719 (C=O ester); liH(CDCb) 1.91 (1 H, d, J 12.5, 
15e-H), 2.11 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.38 (2 H, m, lOa and 16a-H), 2.49 
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(3 H, s, NMe), 2.65 (1 H, dd, J 12.5, 4, 16e-H), 2.87 (1 H, t, J 2.5, 14-H), 3.07 
(1 H, d, J 18.5, 1O~-H), 3.46 (1 H, q, J 3, 9-H), 3.72 (3 H, s, OMe), 5.19 (1 H, d, 
J 6.5, 5-H), 5.43 (1 H, m, 6-H), 5.50 (1 H, d, J 10, 8-H), 5.76 (1 H, d, J 10, 7-H), 
6.57 and 6.67 (2 H, ABq, 1 and 2-H), 7.41 (2 H, d, J 8, 21 and 23-H), 8.02 (2 H, d, 
J 8, 20 and 24-H); /le 20.63, 35.30, 40.59, 42.62, 43.01 (NMe), 46.70, 56.74 
(OMe), 59.12, 68.68, 87.93, 114.35, 119.31, 126.95, 128.49, 128.60, 128.81, 
129.75, 130.73, 131.33, 139.47, 142.18, 146.52, 165.20; miz 439 and 437 (M+, 23 
and 63%) 302(8), 300(24), 282(58), 229(26), 155(12), 141(33), 139(100), 111(38), 
94(9),59(44),42(54). (Found M+, 439.1364 and 437.1394. C2SH24NCI04 requires 
439.1383 and 437.1397). 
Preparation of 6a.( 4' ·Bromobenzoyloxy)· 7,S·didehydro·4,5a·epoxy·3· 
methoxy·17·methyl.morphinan (54) 
To a solution of codeine (300 mg, 1 nunol) in pyridine (3 cm3), under nitrogen, was 
addedp-bromobenzoyl chloride (1.1 g, 5 nuno!) and a catalytic amount ofDMAP. The 
reaction mixture was stirred at room temperature for 10 min. CHCl3 was added and the 
solution washed successively with dilute HCI / water / bicarbonate / water, dried 
(MgS04), and evaporated under reduced pressure. The crude product was purified by 
column chromatography (elution with 5% MeOH in CHCI3) to give the ester 54 
(441 mg,92%). Recrystallisation from DCM-petroleum ether gave colourless crystals 
m.p. 177-80'C; 'Umax(CHCI3)/Cm-l 1719 (C=O ester); /lH(CDCI}) 1.90 (1 H, d, 
J 12.5, 15e-H), 2.11 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.37 (2 H, m, lOa and 16a-H), 
2.48 (3 H, s, NMe), 2.65 (1 H, dd, J 12.5, 4, 16e-H), 2.S5 (1 H, t, J 2.5, 14-H), 
3.07 (1 H, d, J 18.5, 10~-H), 3.44 (1 H, q, J 3, 9-H), 3.72 (3 H, s, OMe), 5.19 (l H, 
d, J 6.5, 5-H), 5.42 (1 H, m, 6-H), 5.51 (1 H, d, J 10, 8-H), 5.76 (1 H, d, J 10, 
7-H), 6.57 and 6.67 (2 H, ABq, 1 and 2-H), 7.58 (2 H, d, J 8, 21 and 23-H), 7.94 
(2 H, d, J 8, 20 and 24-H); /le 20.46, 35.14, 40.38, 42.54, 42.88 (NMe), 46.68, 
56.74 (OMe), 59.10, 68.62, 87.84, 114.38, 119.34, 126.72, 128.16, 128.42, 
128.92, 129.60, 130.63, 131.46, 131.60, 142.23, 146.66, 165.31; mlz 483 and 481 
(M+, 80 and 90%), 282(100), 346 and 344(25 and 27), 229(42), 185 and 183(76 and 
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83), 157(27), 105(34), 81(38), 59(52). (Found M+, 483.0887 and 481.0716. 
C25H2~Br04 requires 483.0869 and 481.0889). 
Preparation of 7,8-Didehydro-4,5a-epoxy-3-methoxy-6a-(3' ,4'-
methylene dioxybenzoyloxy)-17-methyl-morphinan (SS) 
To a solution of codeine (200 mg, 0.67 mmol) in DCM (2 cm3) at O·C, under 
nitrogen, was added piperonylic acid (333 mg, 2 mmol) and DMAP (82 mg, 
0.67 mmol) and the solution was stirred for 30 min. DCC (152 mg, 0.74 mmol) was 
added and the reaction flask fitted with a calcium chloride guard tube. After stirring 
for 5 min at O·C, the reaction mixture was allowed to warm up to room temperature 
and stirred ovemight. The reaction mixture was filtered, washed with water I 
bicarbonate, dried (MgS04) and evaporated under reduced pressure. The crude 
product was purified by column chromatography (elution with 10% MeOH in CHCI3) 
to give the ester SS (195 mg, 65%). Recrystallisation from DCM petroleum ether 
gave colourless crystals m.p. 63-5·C; '\)max(CHCl)/cm'\ 1711 (C=O ester); 
IiH(CDCI3) 1.90 (1 H, d, J 12.5, 15e-H), 2.11 (1 H, dt, J 12, 5, 5, 15a-H), 2.37 
(2 H, m, lOa and 16a-H), 2.46 (3 H, s, NMe), 2.64 (1 H, dd, J 12, 4, 16e-H), 2.84 
(1 H, t, J 2.5, 14-H), 3.06 (1 H, d, J 18.5, 10/3-H), 3.44 (1 H, q, J 3, 9-H), 3.76 
(3 H, s, OMe), 5.17 (1 H, d, J 6.5, 5-H), 5.41 (1 H, m, 6-H), 5.50 (1 H, d, J 10, 
8-H), 5.75 (1 H, d, J 10, 7-H), 6.03 (2 H, s, CH2), 6.56 and 6.67 (2 H, ABq, 1 and 
2-H), 6.84 (l H, d, J 8, 23-H), 7.52 (1 H, d, J 1.5, 20-H), 7.70 (1 H, dd, J 8, 1.5, 
24-H); lie 20.54, 35.08, 40.30, 42.57, 42.82 (NMe), 46.64, 56.86 (OMe), 59.07, 
68.34, 88.12, 101.75, 107.90, 109.86, 114.57, 119.26, 124.00, 124.91, 125.79, 
126.68, 128.80, 129.32, 130.72, 142.24, 147.64, 151.70, 165.38; mlz 447 (M+, 
40%) 310(17), 282(25), 229(13), 165(29), 149(100), 121(20), 91(8), 65(25), 
42(21). (Found M+, 447.1679. C26H2SN06 requires 447.1682). 
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Preparation of 6a-Acetyloxy-3-t-butyldimethylsilyloxy-7,8-didehydro-
4,5a-epoxy-17-methyl-morphinan (56) 
To a solution of morphine 3-0-TBDMS ether 45 (200 mg, 0.5 mmol), in pyridine 
(2 cm3), was added acetic anhydride (1 cm3, 1.1 g, 10 mmol), and the reaction stirred 
overnight. The reaction mixture was dissolved in DCM and washed three times with a 
5% CUS04 solution. The organic layer was dried (Na2S04), and evaporated under 
reduced pressure to give a white solid. Re-crystallisation from DCM-petroleum ether 
afforded the ester 56 (195 mg, 85%) m.p. 145-8'C (decomp); (Found: C, 66.2; H, 
7.75; N, 2.95. C2SH3SN04Si requires C, 66.6; H, 8.0; N, 3.1 %);. tlmax(nujol)/cm-1 
1736 (C=O ester); oH(CDCI3) 0.16 (3 H, s, SiMe), 0.19 (3 H, s, SiMe), 0.98 (9 H, s, 
SiCMe3), 1.83 (1 H, d, J 12.5, lSe-H), 2.05 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.14 
(3 H, s, Ac), 2.30 (1 H, dd, J 12.5,6, lOa-H), 2.44 (4 H, m, NMe and 16a-H), 2.59 
(l H, dd, J 12.5,4, 16e-H), 2.72 (1 H, t, J 2.5, 14-H), 3.02 (IH, d, J 18.5, 10~-H), 
3.36 (1 H, q,J3, 9-H), 5.04 (l H, d, J6, 5-H), 5.17 (1 H, m, 6-H), 5.41 (l H, d, 
J 8.5, 8-H), 5.58 (l H, d, J 8.5, 7-H), 6.45 and 6.58 (2 H, ABq, 1 and 2-H); 
oe -4.18, -4.66, 18.26,20.54,20.94,25.68,35.52,40.87,43.04 (N-Me), 43.17, 
46.52, 58.94, 68.91, 88.08, 119.03, 121.27, 127.36, 128.26, 129.83, 130.68, 
137.12, 148.96, 170.48 (C=O). 
Preparation of 6a-Acetyloxy-7,8-didehydro-4,5a-epoxy-17-methyl-
morphinan-3-o1 (57) 
To a stirred solution of morphine 3-0-TBDMS ether 6-0-acetate 56 (165 mg, 
0.37 mmol) in THF, at O'C, under an inert atmosphere, was added TBAF (0.33 cm3, 
300 mg, 1.15 mmol). The reaction mixture was stirred at O'C for 5 min, then allowed 
to warm up to room temperature and left stirring for a further 6 h. EtOAc was added 
and the solution washed with water, dried (Na2S04), and evaporated under reduced 
pressure. The crude product was purified by preparative TLC to give the ester 57 
(77 mg, 63%) m.p. 106-9'C (decomp); 'Umax(nujol)/cm-1 3368 (OH), 1732 (C=O 
ester); oH(CDCI]) 1.84 (1 H, d, J 12.5, lSe-H), 2.06 (l H, dt, J 12.5, 5, 5, 15a-H), 
2.15 (3 H, s, Ac), 2.31 (1 H, dd, J 12.5, 6, lOa-H), 2.44 (4 H, m, NMe and 
16a-H), 2.62 (l H, dd, J 12.5,4, 16e-H), 2.75 (1 H, t, J 2.5, 14-H), 3.03 (1 H, d, 
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J 18.5, lO[3-H), 3.39 (1 H, q, J 3, 9-H), 5.06 (1 H, d, J 6, 5-H), 5.14 (1 H, m, 
6-H), 5.42 (1 H, d, J 8.5, 8-H), 5.59 (1 H, d, J 8.5, 7-H), 6.50 and 6.63 (2 H, 
ABq, 1 and 2-H). 
Preparation of 3-t-B u ty Idimethy Isily loxy -7 ,8-didehydro.4,5a· epoxy· 
17 ·methy 1.6a·succinyloxy.morphinan (58) 
A mixture of morphine 3-0-TBDMS ether 45 (300 mg, 0.75 mmol) and succinic 
anhydride (375 mg, 3.75 mmol) in pyridine (5 cm3), under nitrogen, was refluxed for 
I h. The hot reaction mixture was poured onto ice and the resulting white precipitate 
collected on a filter. The precipitate was washed with cold water. Crystallisation from 
DCM-petroleum ether gave the ester 58 (225 mg, 60%) m.p. 144-7'C; 
'\)max(CHC13)/cm-i 1735 (C=O ester), 1628 (C=O acid); liH (CDCI3) 0.15 (3 H, s, 
SiMe), 0.20 (3 H, s, SiMe), 0.98 (9 H, s, SiCMe3), 1.86 (1 H, d, J 12, 15e-H), 
2.41-2.82 (10 H, m, NMe, 2xCH2, lOa, 15a, and 16-H), 3.00 (I H, d, J 18.5, 
lOi3-H), 3.10 (2 H, m, 14 and 16-H), 3.79 (1 H, q, J 3.5, 9-H), 5.09 (1 H, d, J 6, 
5-H), 5.28 (2 H, m, 6 and 8-H), 5.56 (1 H, d, J 10, 7-H), 6.47 and 6.61 (2 H, ABq, 
1 and 2-H); lie -4.78, -4.55, 18.15, 21.19, 25.66, 30.18, 30.95, 33.20, 37.63, 
40.92 (NMe), 42.01, 46.16, 58.66, 68.08, 88.18, 119.19, 122.01, 124.45, 127.71, 
129.60, 129.94,137.80, 148.62, 172.70, 172.85; mlz 499 (M+, 3%) 456(5), 382(9), 
324(11), 267(12), 215(29), 105(24), 73(100), 41(94) (Found M+, 499.2388. 
C27H37N06Si requires 499.2390). 
Preparation of 3·t·Butyldimethylsilyloxy.6a·(2' ·carboxybenzoyloxy). 
7 ,8·didehydro.4,5 a·epoxy·17 .methyl.morphinan (59) 
A mixture of morphine 3-0-TBDMS ether 45 (250 mg, 0.63 mmol) and phthalic 
anhydride (500 mg, 3.38 mmol) in pyridine (2 cm3), under nitrogen, was refluxed for 
I h. The hot reaction mixture was poured onto ice and the resulting white precipitate 
collected on a filter. The precipitate was washed with cold water. Crystallisation from 
DCM-petroleum ether gave the ester 59 (237 mg, 69%) m.p. 193-5'C (decomp); 
'\)max(CHCI3)/cm-i 1714 (C=O ester), 1602 (C=O acid); liH (CDCI3) 0.04 (3 H, s, 
SiMe), 0.06 (3 H, s, SiMe), 0.88 (9 H, s, SiCMe3), 1.97 (1 H, d, J 11, 15e-H), 
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2.78-2.88 (3 H, m, IOn, 15a and 16-H), 2.91 (3 H, s, NMe), 3.08 (1 H, d, 1 18.5, 
lO~-H), 3.45 (1 H, dd, 112,4, 16-H), 3.59 (1 H, t, 12.5, 14-H), 4.03 (1 H, q, 
13.5, 9-H), 5.32 (1 H, d, 1 6.5, 5-H), 5.40 (1 H, d, 1 10, 8-H), 5.55 (1 H, m, 6-H), 
5.80 (1 H, d, 1 10, 7-H), 6.54 and 6.66 (2 H, ABq, 1 and 2-H), 7.38 (1 H, t, 17.5, 
22-H), 7.52 (1 H, t, 17.5, 23-H), 7.66 (1 H, d, 17.5, 2I-H), 7.92 (1 H, d, 17.5, 
24-H). 
Preparation of 6n-Benzoyloxy-3-t-butyldimethylsilyloxy-7,S-didehydro-
4,5n-epoxy-17 -methyl-morphinan (60) 
To a solution of morphine 3-0-TBDMS ether 45 (300 mg, 0.75 mmol) in pyridine 
(3 cm3) with a catalytic amount of DMAP, under nitrogen, was added benzoyl chloride 
(0.5 cm3, 317 mg, 2.25 mmol) and the reaction stirred at room temperature for 10 min. 
CHCI3 was added and the solution washed successively with 5% CUS04 solution I 
water, dried (MgS04), and evaporated under reduced pressure. The crude product was 
purified by column chromatography (elution with 3% MeOH in DCM) to give the ester 
60 (336 mg, 89%) m.p. 133-5'C; 'Ilmax(CHCI3)1cm-l 1717 (C=O); liH (CDCb) 0.02 
(3 H, s, SiMe), 0.04 (3 H, s, SiMe), 0.82 (9 H, s, SiCMe3), 1.88 (1 H, d, 1 11, 
15e-H), 2.16 (1 H, dt, 1 12.5, 5, 5, 15a-H), 2.44 (2 H, m, IOn and 16-H), 2.53 (3 H, 
s, NMe), 2.72 (1 H, dd, 1 12.5, 4, 16-H), 2.88 (1 H, t, 12.5, 14-H), 3.07 (1 H, d, 
1 18.5, lO~-H), 3.51 (1 H, q, 13.5, 9-H), 5.21 (1 H, d, 16, 5-H), 5.40 (1 H, m, 
6-H), 5.48 (1 H, d, 1 10, 8-H), 5.76 (1 H, d, 1 10, 7-H), 6.49 and 6.60 (2 H, ABq, 
1 and 2-H), 7.42 (2 H, t, 17.5,21 and 23-H), 7.56 (1 H, t, 17.5, 22-H), 8.09 (2 H, 
d, 17, 20 and 24-H); lie -4.93, -4.90, 18.05, 20.71, 25.47, 35.11, 40.33, 42.62 
(NMe), 43.03, 46.36, 58.80, 69.34, 88.10, 119.04, 121.35, 126.81, 128.16, 
128.52, 129.57, 130.03, 130.47, 131.40, 133.01, 137.25, 149.07, 166.02; m/z 503 
(M+, 15%) 446(10), 324(6), 266(9), 122(8), 105(100), 77(27), 57(16), 41(35). 
(Found M+, 503.2446. C30H37N04Si requires 503.2492). 
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Preparation of 3·t·Butyldimethylsilyloxy·7,8·didehydro·4,5a·epoxy· 
17 ·methyl·6a.( 4'·nitrobenzoyloxy).morphinan (61) 
To a solution of morphine 3-0-TBDMS ether 45 (150 mg, 0.37 mmol) in pyridine 
(5 cm3) with a catalytic amount of DMAP, under nitrogen, was added p-nitrobenzoyl 
chloride (210 mg, 1.13 mmol) and the reaction stirred overnight. EtOAc was added 
and the solution washed with 5% CUS04 solution / water, dried (Na2S04) and 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (elution with 10% MeOH in CHCI3) to give the ester 61 (162 mg, 
78%) m.p. 129-3I'C; "Umax(nujol)/cm·1 1718 (C=O ester); /lH (CDCI3) 0.03 (3 H, s, 
SiMe), 0.06 (3 H, s, SiMe), 0.85 (9 H, s, SiCMe3), 1.89 (I H, d, J 11, lSe-H), 2.13 
(1 H, dt, J 12.5, 5, 5, 15a-H), 2.40 (2 H, m, lOa and 16-H), 2.47 (3 H, s, NMe), 
2.65 (I H, dd, J 12.5, 4, 16-H), 2.85 (I H, t, J 2.5, 14-H), 3.10 (I H, d, J 18.5, 
lOP-H), 3.44 (I H, q, J 3, 9-H), 5.20 (I H, d, J 6.5, 5-H), 5.43 (I H, m, 6-H), 5.54 
(1 H, d, J 10, 8-H), 5.75 (I H, d, J 10, 7-H), 6.49 and 6.59 (2 H, ABq, I and 2-H), 
8.29 (4 H, s, 20, 21, 23 and 24-H); /le -4.92, 17.96, 20.36, 25.35, 35.43, 40.71, 
42.87,42.95 (NMe), 46.51, 58.91, 69.85, 87.37, 119.19, 121.23, 123.29, 127.27, 
127.49, 130.27, 130.43, 131.01, 135.29, 137.06, 148.42, 150.48, 163.98; mlz 548 
(M+, 52%) 491(38), 382(25), 266(21), 137(18), 122(14), 104(40), 92(20), 77(45), 
50(79),41(100). (Found M+, 548.2331. C30H36N206Si requires 548.2342). 
Preparation of 3·t.Butyldimethylsilyloxy.7,8·didehydro·4,5a·epoxy. 
6a·( 4'.methoxybenzoyloxy)·17·methyl·morphinan (62) 
To a solution of morphine 3-0-TBDMS ether 45 (lOO mg, 0.25 mmol) in pyridine 
(3 cm3), under nitrogen, was addedp-anisoyl chloride (0.1 cm3, 128 mg, 0.75 mmol) 
and the reaction stirred at room temperature for 30 min. EtOAc was added and the 
solution washed successively with dilute HCl / water / bicarbonate / water, dried 
(MgS04), and evaporated under reduced pressure. The crude product was purified by 
column chromatography (elution with 5% MeOH in CHCI3) to give the ester 62 
(82 mg, 61%) m.p.173-5'C; "Umax(CHCI3)/cm·1 1710 (C=O ester); /lH (CDCI3) 0.04 
(3 H, s, SiMe), 0.06 (3 H, s, SiMe), 0.87 (9 H, s, SiCMe3), 1.88 (I H, d, J 11, 
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15e-H), 2.10 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.38 (2 H, m, lOa and 16-H), 2.46 (3 H, 
s, NMe), 2.61 (1 H, dd, J 12.5, 4, 16-H), 2.80 (1 H, t, J 2.5, 14-H), 3.05 (1 H, d, 
J 18.5, lOll-H), 3.40 (1 H, q, J 3, 9-H), 3.87 (1H, s, OMe), 5.17 (1 H, d, J 6.5, 
5-H), 5.38 (1 H, m, 6-H), 5.45 (1 H, d, J 10, 8-H), 5.73 (1 H, d, J 10, 7-H), 6.47 
and 6.59 (2 H, ABq, 1 and 2-H), 6.90 (2 H, d, J 9,21 and 23-H), 8.06 (2 H, d, J 9, 
20 and 24-H); lie -4.85, -4.77, 18.14, 20.68, 25.59, 35.51, 40.85, 42.98 (NMe), 
43.30, 46.53, 55.43 (OMe), 58.96, 69.26, 88.50, 113.48, 119.00, 121.30, 122.38, 
127.25, 128.65, 129.69, 130.75, 132.07, 137.20, 149.19, 163.48, 165.82; mlz 533 
(M+, 8%) 476(4),382(3),324(4),296(4), 152(5), 135(100),92(4), 73(11), 51(9), 
41(10). (Found M+, 533.2602. C31H39NOsSi requires 533.2598). 
Preparation of 3-t-Butyldimethylsilyloxy-7,8-didehydro-4,5a-epoxy-6a-
(4' -fluorobenzoyloxy)-17-methyl-morphinan (63) 
To a solution of morphine 3-0-TBDMS ether 45 (300 mg, 0.75 mmol) in pyridine 
(3 cm3), under nitrogen, was added p-fluorobenzoyl chloride (0.3 cm3, 360 mg, 
2.25 mmol) and the reaction stirred at room temperature for 20 min. CHCI3 was added 
and the solution washed successively with 5% CUS04 solution and water, dried 
(MgS04), and evaporated under reduced pressure. The crude product was purified by 
column chromatography (elution with 3% MeOH in DCM) to give the ester 63 
(342 mg, 87%) m.p. 134-6'C; umax(CHCI3)!cm-l 1717 (C=O ester); liH (CDCI3) 
0,0] (3 H, s, SiMe), 0.04 (3 H, s, SiMe), 0.84 (9 H, s, SiCMe3), 1.90 (1 H, d, J 11, 
15e-H), 2.24 (I H, dt, J 12.5, 5, 5, 15a-H), 2.52 (2 H, m, lOa and 16-H), 2.58 (3 H, 
s, NMe), 2.85 (1 H, dd, J 12.5, 4, 16-H), 3.01 (1 H, t, J 2.5, 14-H), 3.08 (1 H, d, 
J 18.5, lOll-H), 3.66 (I H, q, J 3, 9-H), 5.19 (1 H, d, J 6.5, 5-H), 5.39 (1 H, m, 
6-H), 5.48 (1 H, d, J 10, 8-H), 5.76 (1 H, d, J 10, 7-H), 6.50 and 6.61 (2 H, ABq, 
1 and 2-H), 7.07 and 7.11 (2 xl H, d, J 8.5,21 and 23-H), 8.08 and 8.12 (2 x 1 H, 
d, J 8.5,20 and 24-H); lie -4.85, -4.81, 18.06,21.11,25.51,34.56, 39.55,42.16 
(NMe), 42.71, 46.39, 58.90, 69.16, 87.79, 115.24, 115.59, 119.31, 121.71, 
126.11, 128.80, 129.04, 130.11, 131.96, 132.52, 132.67, 137.76, 149.03, 163.86, 
168.12; mlz 521 (M+, 14%) 464(9), 382(5), 324(4), 284(5), 140(20), 123(100), 
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95(28), 73(21), 59(9), 42(11). (Found M+, 521.2413. C30H36NF04Si requires 
521.2398). 
Preparation of 3-t-Butyldimethylsilyloxy-6a-(4'-chloro benzoyloxy)-7 ,S-
didehydro-4,5a-epoxy-17-methyl-morphinan (64) 
To a solution of morphine 3-0-TBDMS ether 45 (300 mg, 0.75 mmol) in pyridine 
(3 cm3), under nitrogen, was added p-chlorobenzoyl chloride (0.3 cm3, 396 mg, 
2.25 mmol) and the reaction stirred at room temperature for 5 min. CHCI3 was added 
and the solution washed successively with 5% CUS04 solution and water, dried 
(MgS04), and evaporated under reduced pressure. The crude product was purified by 
column chromatography (elution with 3% MeOH in DCM) to give the ester 64 
(381 mg, 94%) m.p. 119-21'C; 'Ilmax(CHCI3)/cm-l 1719 (C=O ester); liH (CDCI3) 
0.05 (6 H, s, SiMe2), 0.85 (9 H, s, SiCMe3), 1.84 (1 H, d, J 11, 15e-H), 2.05 (1 H, 
dt, J 12.5, 5, 5, 15a-H), 2.34 (2 H, m, lOa and 16-H), 2.45 (3 H, s, NMe), 2.57 
(1 H, dd, J 12.5,4, 16-H), 2.77 (l H, t, J 2.5, 14-H), 3.04 (l H, d, J 18.5, lOP-H), 
3.38 (1 H, q, J 3.5, 9-H), 5.16 (1 H, d, J 6.5, 5-H), 5.39 (l H, m, 6-H), 5.48 (l H, 
d, J 10, 8-H), 5.72 (1 H, d, J 10, 7-H), 6.47 and 6.58 (2 H, ABq, 1 and 2-H), 7.41 
(2 H, d, J 8.5, 21 and 23-H), 8.01 (2 H, d, J 8.5, 20 and 24-H); lie -4.84, -4.78, 
18.10, 21.26, 25.49, 34.23, 39.17, 41.92 (NMe), 42.52, 46.40, 58.95, 69.08, 
87.57, 119.39, 121.86, 125.67, 128.22, 128.63, 128.91, 129.95, 131.10, 131.43, 
137.70, 139.60, 149.03, 165.12; mlz 539 and 537 (M+, 23 and 55%) 482(13), 
480(34), 456(15), 413(13), 382(25), 324(18), 300(14), 266(14), 141(35), 139(91), 
123(7), 94(10), 73(100), 59(36), 42(48). (Found M+, 539.2070 and 537.2123. 
C30H36NCI04Si requires 539.2072 and 537.2102). 
Preparation of 6a-( 4'-Bromobenzoyloxy)-3-t-butyldimethy Isilyloxy-7 ,S-
didehydro-4,5a-epoxy-17 -methyl-morphinan (65) 
To a solution of morphine 3-0-TBDMS ether 45 (300 mg, 0.75 mmol) in pyridine 
(3 cm3) with a catalytic amount of DMAP, under nitrogen, was added p-bromobenzoyl 
chloride (825 mg, 3.75 mmol) and the reaction stirred at room temperature for 20 min. 
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CHCI3 was added and the solution washed successively with 5% CUS04 solution and 
water, dried (MgS04), and evaporated under reduced pressure. The crude product was 
purified by column chromatography (elution with 3% MeOH in DCM) to give the ester 
6S (315 mg, 72%) m.p. 137-8'C; "llmax(CHCI3)/Cm·l 1719 (C=O ester); IiH (CDCI3) 
0.01 (3 H, s, SiMe), 0.04 (3 H, s, SiMe), 0.84 (9 H, s, SiCMe3), 1.87 (1 H, d, J 11, 
15e-H), 2.15 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.40 (2 H, m, lOa and 16-H), 2.47 (3 H, 
s, NMe), 2.72 (1 H, dd, J 12, 4, 16-H), 2.88 (1 H, t, J 2.5, 14-H), 3.06 (1 H, d, 
J 18.5, 10j3-H), 3.50 (I H, q, J 3, 9-H), 5.17 (1 H, d, J 6.5, 5-H), 5.38 (1 H, m, 
6-H), 5.48 (1 H, d, J 10, 8-H), 5.73 (1 H, d, J 10, 7-H), 6.49 and 6.59 (2 H, ABq, 
1 and 2-H), 7.56 (2 H, d, J 8.5, 21 and 23-H), 7.95 (2 H, d, J 8.5, 20 and 24-H); 
lie -4.84, -4.79, 18.09, 21.26, 25.48, 34.20, 39.16, 41.98 (NMe), 42.48, 46.50, 
59.09, 69.05, 87.52, 119.40, 121.89, 125.56, 128.28, 128.65, 128.95, 129.91, 
131.24, 131.34, 131.63, 137.73, 149.01, 165.25; m/z 583 and 581 (M+, 22 and 
22%) 527(15), 525(14), 382(19), 266(15), 202(29), 200(30), 185(96), 183(100), 
155(31), 123(41), 105(33), 75(50), 73(62), 51(56), 41(58). (Found M+, 583.1641 
and 581.1603. C30H36NBr04Si requires 583.1578 and 581.1597). 
Preparation of 7 ,8·didehydro·4,5a·epoxy·17 .methyl·6a·succinyloxy· 
morphinan·3·o1 (66) 
To a solution of the ester 58 (150 mg, 0.3 mmol) in THF (2 cm3), under nitrogen, 
at O'C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was stirred 
at O'C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction mixture was quenched with water. The 
resulting precipitate was collected on a filter giving the ester 66 (62 mg, 54%). 
Crystallisation was from CHCI3/MeOH. rn.p. 275-9'C (decomp); Found C, 60.9; 
H, 6.05; N, 3.20. C21H23N06 requires C, 61.2; H, 6.31; N, 3.39%); 
"llmax(nujol)/cm-1 3382 (OH), 1736 (C=O ester), 1605 (C=O acid); 
IiH (CD30D/CDCI3) 1.96 (1 H, d, J 12, 15e-H), 2.43-2.86 (10 H, m, NMe, 
2xCH2, lOa, 15a, and 16-H), 3.04 (1 H, d, J 18.5, 10j3-H), 3.15 (2 H, rn, 14 and 
16-H), 3.83 (1 H, q, 13.5, 9-H), 5.11 (1 H, d, J 6, 5-H), 5.30 (2 H, m, 6 and 
8-H), 5.58 (1 H, d, J 10, 7-H), 6.57 and 6.61 (2 H, ABq, I and 2-H). 
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Preparation of 6a.(2' ·Carboxybenzoyloxy)· 7 ,8·didehydro·4,5a· 
epoxy·17·methyl.morphinan·3·ol (67) 
To a solution of the ester 59 (300 mg, 0.7 mmol) in pyridine (5 cm3), under nitrogen, 
at O'C, was added HF-pyridine (I cm3). The reaction was stirred at O'C for 5 min and 
then allowed to warm up to room temperature, with stirring continuing overnight. The 
reaction mixture was quenched with water. The resulting precipitate was collected on a 
filter giving the ester 67 (135 mg, 57%). Crystallisation from CHCI3 I MeOH yielded 
colourless prisms. m.p. 259-64'C (decomp); (Found: C, 65.5; H, 5.35; N, 2.85. 
C2SH23N06 requires C, 65.2; H, 5.65; N, 3.05%); umax(nujol)/cm-1 3398 (OH), 
1716 (C=O ester), 1601 (C=O acid); 3H (CD30D/CDCIJ) 2.03 (1 H, d, J 10, 15e-H), 
2.90 (3 H, rn, lOa, 15a and 16-H), 3.01 (3 H, s, NMe), 3.21 (1 H, d, J 18.5, 10~-H), 
3.48 (1 H, d, J 8, 16-H), 3.86 (1 H, t, J 2.5, 14-H), 4.12 (1 H, q, J 3, 9-H), 5.53 
(2 H, m, 6 and 8-H), 5.66 (lH, d, J 6.5, 5-H), 5.91 (1 H, d, J 10, 7-H), 6.59 and 
6.63 (2 H, ABq, 1 and 2-H), 7.40 (1 H, m, 22-H), 7.56 (2 H, m, 21 and 23-H), 7.92 
(1 H, d, J 7.5, 23-H); mlz (M+, 433) 285(100), 268(11), 215(21), 162(29), 124(17), 
104(96),76(79),42(31). 
Preparation of 6a·Benzoy!oxy·7,8·didehydro·4,5a·epoxy·17·methy!. 
morphinan.3·ol (68) 
To a solution of the ester 60 (150 mg, 0.27 mmol) in dry THF (3 cm3), under 
nitrogen, at O'C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was 
stirred at O'C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction mixture was dissolved in EtOAc and washed with 
water, dried (Na2S04) and evaporated under reduced pressure. The crude product was 
purified by TLC to give the ester 68, a white powder, (102 mg, 88%). Crystallisation 
was from CHCl31 MeOH yielding colourless crystals m.p. 264-8'C (decomp); (Found: 
C, 73.25; H, 5.85; N, 3.65. C24H23N04 requires C, 73.2; H, 5.95; N, 3.55%); 
umax(nujol)/cm-1 1713 (C=O ester); 3H(CD30D/CDCI3) 1.88 (1 H, d, J 12.5, 
15e-H), 2.08 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.37 (2 H, m, lOa and 16-H), 2.44 (3 H, 
s, NMe), 2.61 (1 H, dd, J 12.5, 4, 16-H), 2.80 (1 H, t, J 2.5, 14-H), 3.04 (1 H, d, 
J 18.5, IO~-H), 3.38 (1 H, q, J 3, 9-H), 5.21 (1 H, d, J 6.5, 5-H), 5.41 (1 H, m, 
100 
6-H), 5.49 (1 H, d, J 10, 8-H), 5.76 (1 H, d, J 10, 7-H), 6.52 and 6.63 (2 H, ABq, 
1 and 2-H), 7.45 (2 H, t, J 8,21 and 23-H), 7.59 (1 H, t, J 7.5, 22-H), 8.10 (2 H, d, 
J 7, 20 and 24-H); Bc 20.30, 34.92, 40.23, 42.71 (NMe), 46.58, 58.98, 68.74, 
88.07, 116.69, 119.63, 125.34, 128.16, 128.35, 129.46, 129.58, 129.71, 129.71, 
129.92, 133.20, 138.27, 144.94, 166.24; mlz 389 (M+, 38%) 268(33), 215(13), 
146(12), 122(11), 105(100), 94(6), 77(34). (Found M+, 389.1623. C24H23N04 
requires 389.1627). 
Preparation of 7,8-Didehydro-4,5a-epoxy-17-rnethyl-6a-(4' -nitro 
benzoyloxy)-rnorphinan-3-ol (69) 
To a solution of the ester 61 (300 mg, 0.18 mmol) in dry THF (5 cm3), under 
nitrogen, at C'C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was 
stirred at O'C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction mixture was evaporated under reduced pressure. 
The crude product was purified by TLC to give the ester 69, a yellow powder, 
(206 mg, 87%). Crystallisation was from DMSO / water yielding yellow prisms. 
m.p. 253-8'C (decomp); (Found: C, 64.0; H, 5.4; N, 5.95. C24H22N206 requires 
C, 63.7; H, 5.35; N, 6.2%); '\)max(nujol)/cm- l 1719 (C=O ester); BH(DMSO-~) 1.62 
(1 H, d, J 11, 15e-H), 2.06 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.21 (2 H, rn, lOa and 
16-H), 2.31 (3 H, s, NMe), 2.48 (1 H, m, 16-H), 2.76 (1 H, t, J 2.5, 14-H), 2.89 
(1 H, d, J 18.5, lOP-H), 3.31 (1 H, q, J 3, 9-H), 5.12 (1 H, d, J 6.5, 5-H), 5.43 
(1 H, m, 6-H), 5.55 (1 H, d, J 10, 8-H), 5.72 (1 H, d, J 10, 7-H), 6.41 and 6.47 
(2 H, ABq, 1 and 2-H), 8.22 (2 H, d, J 9, 20 and 24-H), 8.36 (2 H, d, J 9, 21 and 
23-H); Bc 19.90, 34.85, 39.94, 42.12, 42.78 (NMe), 46.32, 58.27, 69.38, 86.84, 
116.48, 119.16, 123.87, 125.18, 127.64, 130.46, 130.53, 130.98, 135.32, 138.88, 
145.14, 150.36, 163.90; mlz 434 (M+, 14%) 268(15), 248(16), 136(11), 104(17), 
91(21),88(19),44(100). (Found M+, 434.1479. C24H22N206 requires 434.1478). 
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Preparation of 7 ,8.Didehydro.4,Sa·epoxy-6a·( 4' .f1uorobenzoyloxy)-17-
methyl·morphinan-3-ol (70) 
To a solution of the ester 63 (150 mg, 0.29 mmol) in dry THF (3 cm3), under 
nitrogen, at O'C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was 
stirred at O'C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction mixture was dissolved in EtOAc and washed with 
water, dried (Na2S04) and evaporated under reduced pressure. The crude product was 
purified by TLC to give the ester 70, a white powder, (96 mg, 82%). Crystallisation 
was from CHCI3 I MeOH. m.p. 279-83'C (decomp); (Found: C, 70.45; H, 5.4; 
N, 3.3. C24H22NF04 requires C, 70.75; H, 5.45; N, 3.45%); umax(nujol)/cm-1 1713 
(C=O ester); oH(CD30D/CDCI3) 1.88 (1 H, d, J 11, lSe-H), 2.06 (1 H, dt, J 12.5, 5, 
5, 15a-H), 2.37 (2 H, m, lOa. and 16-H), 2.45 (3 H, s, NMe), 2.62 (1 H, dd, J 12.5, 
4, 16-H), 2.80 (1 H, t, J 2.5, 14-H), 3.04 (1 H, d, J 18.5, 10!3-H), 3.38 (1 H, q, 
J 3.5, 9-H), 5.18 (1 H, d, J 6.5, 5-H), 5.40 (I H, m, 6-H), 5.50 (1 H, d, J 10, 8-H), 
5.74 (1 H, d, J 10, 7-H), 6.51 and 6.62 (2 H, ABq, I and 2-H), 7.11 and 7.15 
(2 x 1 H, d, J 8.5, 21 and 23-H), 8.09 and 8.11 (2 x I H, d, J 8.5, 20 and 24-H); 
Oc 21.28, 34.77, 40.06, 42.59 (NMe), 46.56, 58.95, 68.66, 87.84, 115.21, 115.56, 
116.64, 119.53, 125.15, 128.10, 129.39, 129.86, 132.26, 132.41, 138.36, 145.03, 
163.80, 165.32, 167.84; mlz 407 (M+, 30%) 284(17), 268(33), 215(14), 146(13), 
123(100),95(31),84(21). (Found M+, 407.1593. C24H22NF04 requires 407.1533). 
Preparation of 6a·( 4' ·Chlorobenzoyloxy)· 7 ,8-didehydro-4,Sa·epoxy. 
17 ·methyl.morphinan-3-ol (71) 
To a solution of the ester 64 (150 mg, 0.28 mmol) in dry THF (3 cm3), under 
nitrogen, at O°C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was 
stirred at O'C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction mixture was dissolved in EtOAc and washed with 
water, dried (Na2S04) and evaporated under reduced pressure. The crude product was 
purified by TLC to give the ester 71 (105 mg, 89%). Crystallisation was from CHCb I 
MeOH. m.p. 269-72'C (decomp); (Found: C, 67.7; H, 5.2; N, 3.25. C24H22NCI04 
requires C, 68.0; H, 5.25; N, 3.3%); umax(nujol)/cm-1 1719 (C=O ester); 
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0H(CD30D/CDCI3) 1.95 (1 H, d, J 12, 15e-H), 2.29 (1 H, dt, J 12.5, 5, 5, 15a-H), 
2.57 (2 H, m, lOa and 16-H), 2.66 (3 H, s, NMe), 3.04 (3 H, m, lOp, 14 and 16-H), 
3.75 (1 H, q, J 3, 9-H), 5.22 (1 H, d, J 6.5, 5-H), 5.41 (1 H, m, 6-H), 5.51 (I H, d, 
J 10, 8-H), 5.79 (1 H, d, J 10, 7-H), 6.55 and 6.65 (2 H, ABq, I and 2-H), 7.39 and 
7.42 (2 x I H, d, J 8.5, 21 and 23-H), 7.98 and 8.01 (2 x I H, d, J 8.5,20 and 24-H); 
miz 423 and 425 (M+, 36 and 12%) 300(8), 268(54), 215(21), 141(34), 139(100). 
111(32), 94(10). 81(17). (Found M+, 425.1207 and 423.1237. C24H22NCI04 
requires 425.1227 and 423.1268). 
Preparation of 6a-( 4' -Bromobenzoyloxy)-7 ,8-didehydro-4,5a-epoxy-
17-methyl-morphinan-3-o! (72) 
To a solution of the ester 65 (150 mg, 0.26 mmol) in dry THF (3 cm3), under 
nitrogen, at O'C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was 
stirred at O'C for 5 rnin and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction rnixture was dissolved in EtOAc and washed with 
water, dried (Na2S04) and evaporated under reduced pressure. The crude product was 
purified by TLC to give the ester 72, a white powder, (97 mg, 80%). Crystallisation 
was from CHCI3 I MeOH. m.p. 279-84'C (decomp); (Found: C, 61.25; H, 4.7; 
N, 3.05. C24H22NBr04 requires C, 61.5; H, 4.7; N, 3.0%); umax(nujol)/cm-\ 1718 
(C=O ester); oH(CD30D/CDCI3) 1.88 (1 H, d, J 12.5, 15e-H), 2.08 (1 H, dt, J 12.5, 
5, 5, 15a-H), 2.37 (2 H, m, lOa and 16-H), 2.46 (3 H, s, NMe), 2.62 (1 H, dd, 
J 12.5, 4, 16-H), 2.81 (I H, t, J2.5, 14-H), 3.04 (1 H, d, J 18.5, lOP-H), 3.40 (1 H, 
q, J 3, 9-H), 5.18 (1 H, d, J 6.5, 5-H), 5.40 (1 H, m, 6-H), 5.51 (I H, d, J 10, 8-H), 
5.74 (1 H, d, J 10, 7-H), 6.51 and 6.63 (2 H, ABq, 1 and 2-H), 7.60 (2 H, d, J 8.5, 
21 and 23-H), 7.95 (2 H, d, J 8.5, 20 and 24-H); miz 469 and 467 (M+, 39 and 
42%) 268(95), 215(36), 185(92), 183(100), 155(42), 141(23), 94(17), 81(32). 
(Found M+, 469.0544 and 467.0583. C24H22NBr04 requires 469.0713 and 
467.0733). 
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Preparation of Methyl p.hydroxybenzoate (74) 
p-Hydroxybenzoic acid 73 (8 g, 0.058 mol) was mixed with absolute methanol 
(25 ml). Concentrated H2S04 was cautiously added with shaking to give a slightly 
yellow solution, which was refluxed for 6 h. Excess MeOH was evaporated under 
reduced pressure and the residue dissolved in EtOAc. The organic solution was 
washed with water and saturated NaHC03 solution, dried (Na2S04), and evaporated 
under reduced pressure. The resulting white product was recrystallised from DCM to 
give colourless crystals of 74, (7.79 g, 88%) m.p. 125·127·C [Lit. 126-128'C56]; 
'Umax(CHCI))/cm-1 2800 (OH), 1724 (C=O ester); ()H(CDCI3) 3.90 (3 H, s, OMe), 
6.88 (2 H, d, J 8.8,4 and 6-H), 7.92 (2 H, d, J 8.8,3 and 7-H). 
Silylation of Methyl p.hydroxybenzoate 
To a mixture of methyl p-hydroxybenzoate 74 (5 g, 0.032 mol) and imidazole (5.6 g, 
0.082 mol) in DMF was added t-butyldimethylsilylchloride (5.45 g, 0.036 mol) and the 
reaction stirred at 25' C overnight. The reaction mixture was dissolved in ether, 
washed with water, dried (Na2S04) and evaporated under reduced pressure. The crude 
product was purified by column chromatography (elution with 25% EtOAc in petroleum 
ether) to give a colourless solution 75 (7.713 g, 88%); 'Umax(CHCI3)/Cm-l 1723 (C=O 
ester); ()H(CDCI3) 0.22 (6H, s, 2xSiMe2), 0.98 (9H, s, SiCMe3), 3.87 (3 H, s, 
OMe), 6.85 (2 H, d, J 8.8,4 and 6-H), 7.93 (2 H, d, J 8.8,3 and 7-H). 
Preparation of p-TBDMS-oxybenzoic acid (76) 
To a solution of p-hydroxybenzoic acid (5 g, 0.036 mol) and N aH (1.6 g, 0.040 mol) 
in THF was added t-butyldimethylsilylchloride (7 g, 0.046 mol) and the reaction stirred 
for 2 h. The reaction was then quenched with water and the product extracted into ethyl 
acetate. The organic layer was dried (MgS04) and evaporated under reduced pressure. 
The crude product contained two components by TLC and these were separated by 
column chromatography (elution with 25% EtOAc in petroleum ether) to give colourless 
powders. The first fraction collected was the disubstituted product 77 (7.61 g, 58%) 
m.p. 57-59'C; 'Umax(CHCI)/cm-1 1700 (C=O ester); ()H(CDCI3) 0.22 (3H, s, 
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SiMe2), 0.24 (3H, s, SiMe~, 0.36 (6H, s, 2xSiMe~, 0.98 (9H, s, SiCMe3), 1.02 
(9H, s, SiCMe3), 6.86 (2 H, d, J 8.8,4 and 6-H), 7.93 (2 H, d, J 8.8, 3 and 7-H). 
The second fraction collected was the hydroxy protected product 76 (2.06 g, 23%) 
m.p. 108-110'C; umax(CHCI3)!Cm-l 1678 (C=O ester); BH(CDCI3) 0.22 (6H, s, 
2xSiMe2), 0.98 (9H, s, SiCMe3), 6.87 (2 H, d, J 8.8, 4- and 6-H), 7.98 (2 H, d, 
J 8.8,3- and 7-H); Bc -4.74, -4.37, 18.25, 25.57, 119.81, 119.94, 122.27, 132.13, 
132.32, 160.87, 172.22. 
Preparation of 6a-( 4'-t-Butyldimethylsilyloxybenzoyloxy)-7 ,8-
didehydro-4,5a-epoxy-3-methoxy-17-methyl-morphinan (79) 
Freshly prepared p-TBDMS-oxybenzoic acid (500 mg, 1.98 mmol) in DCM (5 cm3), 
under nitrogen, was treated with oxalyl chloride (630 mg, 0.43 cm3, 5 mmol). 
Effervescence implied formation of the acid chloride. On completion of the reaction, 
after 20 min, benzene (5 cm3) was added and all solvents removed under reduced 
pressure. To the acid chloride residue, under nitrogen, was added a solution of codeine 
(200 mg, mmol) in pyridine (3 ml). The reaction mixture turned yellow and was stirred 
for 2 h. EtOAc was added and the solution washed with dilute HCI ! water ! 
bicarbonate! water, dried (MgS04) and evaporated under reduced pressure. The crude 
product was purified by column chromatography (elution with 5% MeOH in DCM) to 
give the ester 79 (293 mg, 82 %) m.p. 102-5'C; umax(CHCI3)!Cm-l 1709 (C=O ester); 
BH (CDCI3) 0.22 (6 H, s, SiMe2), 0.98 (9 H, s, SiCMe3), 1.93 (1 H, d, J 12.5, 
15e-H), 2.21 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.47 (2 H, m, lOa and 16a-H), 2.56 
(3 H, s, NMe), 2.83 (1 H, dd, J 12, 4, 16e-H), 2.99 (1 H, t, J 2.5, 14-H), 3.08 (1 H, 
d, J 18.5, lOJ3-H), 3.60 (1 H, q, J 3, 9-H), 3.73 (3H, s, OMe), 5.20 (1 H, d, J 6, 
5-H), 5.41 (1 H, m, 6-H), 5.48 (1 H, d, J 10, 8-H), 5.78 (1 H, d, J 10, 7-H), 6.57 
and 6.68 (2 H, ABq, 1 and 2-H), 6.86 (2 H, d, J 9, 21 and 23-H), 7.98 (2 H, d, J 9, 
20 and 24-H); Bc -4.36, -3.75, 18.16, 21.11, 25.67, 34.20, 39.28, 42.07, 42.21 
(NMe), 46.83, 57.11 (OMe), 59.43,67.98, 88.08, 115.09, 115.35, 119.60, 119.80, 
125.74, 128.30, 129.60, 131.21, 132.26, 142.51, 146.96, 161.87, 166.33; mlz 533 
(M+, 77%) 396(25), 282(57), 266(23), 235(100), 229(25), 195(52), 121(43), 73(59), 
42(34). (Found M+, 533.2597. C31H39NOsSi requires 533.2597). 
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Preparation of 7 ,8-didehydro-4,5 a-epoxy-6a-( 4'-hydroxybenzoyloxy)-
3-methoxy-17 -methyl-morphinan (80) 
To a solution of the ester 79 (100 mg, 0.187 mmol) in dry THF (3 cm3), under 
nitrogen, at O°C, was added TBAF (1 M solution in THF) (1 cm3). The reaction was 
stirred at 0' C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing for 2 h. The reaction mixture was dissolved in EtOAc and washed with 
water, dried (Na2S04) and evaporated under reduced pressure. The crude product was 
purified by column chromatography (elution with 5% MeOH in DCM) to give the ester 
80. Crystallisation was from CHCI] I MeOH (48 mg, 61%), m.p. 132-5'C; 
llmax(CHCI3)/cm·l 3563 (OH), 1712 (C=O ester); liH (CDCI3) 1.91 (1 H, d, J 12.5, 
15e-H), 2.15 (I H, dt, J 12.5, 5,5, 15a-H), 2.41 (2 H, m, lOa and 16a-H), 2.51 
(3 H, s, NMe), 2.68 (1 H, dd, J 12, 4, 16e-H), 2.89 (1 H, t, J 2.5, 14-H), 3.06 (1 H, 
d, J 18.5, 10~-H), 3.47 (I H, q, J 3, 9-H), 3.73 (3H, s, OMe), 5.19 (1 H, d, J 6, 
5-H), 5.39 (1 H, m, 6-H), 5.47 (1 H, d, J 10, 8-H), 5.78 (1 H, d, J 10, 7-H), 6.56 
and 6.67 (2 H, ABq, 1 and 2-H), 6.83 (2 H, d, J9, 21 and 23-H), 7.95 (2 H, d, J 9, 
20 and 24-H); lie 20.85, 34.57, 39.73, 42.39, 42.54 (NMe), 46.80, 57.10 (OMe), 
59.32, 68.08, 88.18, 114.99, 115.16, 119.42, 121.19, 126.18, 128.64, 129.35, 
130.52, 132.23, 142.35, 146.90, 161.65, 166.18; m/z 419 (M+, 20%) 282(19), 
162(40), 138(32), 121(80), 94(36), 73(21), 44(100). (Found M+, 419.1733. 
C2SH2sNOs requires 419.1749). 
Preparation of 3-t-Bu tyldimethylsily loxy -6a-( 4'- t-buty Idimethylsily loxy 
benzoyloxy)-7 ,8-didehydro-4,5a-epoxy-17 -methyl-morphinan (81) 
Freshly prepared p-t-BDMS-oxy benzoic acid (500 mg, 1.98 mmol) in DCM (5 cm3), 
under nitrogen, was treated with oxalyl chloride (630 mg, 0.43 cm3, 5 mmol). On 
completion of the reaction, after 20 min, benzene (5 cm3) was added and all solvents 
removed under reduced pressure. To the acid chloride residue, under nitrogen, was 
added a solution of morphine 3-0-TBDMS ether 45 (250 mg, 0.63 mmol) in pyridine 
(3 cm3) and the reaction stirred at room temperature overnight. EtOAc was added and 
the solution washed with dilute HCII water I bicarbonate I water, dried (Na2S04) and 
evaporated under reduced pressure. The crude product was purified by column 
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chromatography (elution with 5% MeOH in DCM) to give the ester 81 (276 mg, 70 %) 
m.p. 122-4'C; umax(nujol)/cm-! 1711 (C=O ester); OH (CDCI3) 0,02 (3 H, s, SiMe), 
0.04 (3 H, s, SiMe), 0.17 (6 H, s, SiMe2) 0.82 (9 H, s, SiCMe3), 0.94 (9 H, s, 
SiCMe3), 1.83 (I H, d, 1 11, lSe-H), 2.07 (1 H, dt, 1 12.5, 5, 5, 15a-H), 2.34 (2 H, 
m, IOn and 16-H), 2.42 (3 H, s, NMe), 2.58 (1 H, dd, 1 12, 4, 16-H), 2.78 (1 H, t, 
12.5, 14-H), 3.00 (1 H, d, 1 18.5, IO~-H), 3.39 (1 H, q, ]3, 9-H), 5.13 (1 H, d, 
16.5, 5-H), 5.31 (1 H, m, 6-H), 5.40 (1 H, d,1 10, 8-H), 5.68 (1 H, d, 110, 7-H), 
6.42 and 6.53 (2 H, ABq, I and 2-H), 6.80 (2 H, d, 19,21 and 23-H), 7.94 (2 H, d, 
19,20 and 24-H). 
Preparation of 7,8-Didehydro-4,Sn-epoxy-6n-( 4' -hydroxy-
benzoyloxy)-17 -methyl-morphinan-3-ol (82) 
To a solution of the ester 81 (500 mg, 0.79 mmol) in dry THF (5 cm3), under 
nitrogen, at O'C, was added TBAF (1 M solution in THF) (2 cm3). The reaction was 
stirred at O'C for 5 min and then allowed to warm up to room temperature, with stirring 
continuing overnight. The reaction mixture was dissolved in EtOAc and washed with 
water, dried (Na2S04) and evaporated under reduced pressure. The crude product was 
purified by TLC to give the ester 82. Crystallisation was from CHCb I MeOH 
(268 mg, 84%), m.p. 178-82'C (decomp); (Found: C, 68.1; H, 5.65; N, 3.2. 
C24H23NOS requires C, 68.1; H, 5.9; N, 3.3%); umax(nujol)/cm-! 3640, 3475, 1736 
(C=O ester); OH (CD30D/CDCI3) 1.81 (1 H, d, 1 11.5, 15e-H), 2.05 (1 H, dt, 1 12.5, 
5, 5, 15a-H), 2.34 (2 H, m, IOn and 16-H), 2.43 (3 H, s, NMe), 2.61 (1 H, dd, 
112.5,4, 16-H), 2.79 (1 H, t, 12.5, 14-H), 3.02 (I H, d, 1 18.5, 10[3-H), 3.38 (1 H, 
q, 1 3, 9-H), 5.15 (1 H, d, 16, 5-H), 5.34 (1 H, m, 6-H), 5.46 (1 H, d, 1 10, 8-H), 
5.73 (1 H, d, 110, 7-H), 6.50 and 6.63 (2 H, ABq, I and 2-H), 6.85 (2 H, d, 19, 21 
and 23-H), 7.95 (2 H, d, 19,20 and 24-H); oe 20.38, 34.68, 39.94, 42.48 (NMe), 
42.62, 46.56, 58.94, 68.27, 88.15, 115.30, 116.78, 119.58, 120.47, 125.27, 
128.48, 129.19, 129.97, 132.04, 138.28, 145.02, 162.06, 166.27; mlz 405 (M+, 
11 %) 285(14), 210(14), 155(15), 138(23), 121(84),94(100),65(42), 51(28),44(49). 
(Found M+, 405.1569. C24H23NOS requires 405.1576). 
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Preparation of 6a-Benzyloxy-7,8-didehydro-4,5a-epoxy-3-methoxy-
17-methyl-morphinan (85) 
To a solution of codeine (300 mg, 1 mmol) in THF, under nitrogen, was added 
NaH-60% dispersion in mineral oil (4.4 mg, 1.1 mmol) and the reaction stirred for 2 h. 
Benzyl bromide (0.14 cm3, 205 mg, 1.2 mmol) was added and the reaction stirred 
overnight. The reaction was quenched with water and extracted into EtOAc. The 
organic layer was washed with water dried (Na2S04) and evaporated under reduced 
pressure to yield a light yellow product 85 (372 mg, 95 %); liH (CDCI3) 2.00 (I H, d, 
J 11.5, lSe-H), 2.44 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.67 (5 H, m, NMe, lOa and 
16-H), 3.03 (3 H, m, lO~, 14 and 16-H), 3.68 (1 H, q, J 3, 9-H), 3.84 (3H, s, OMe) 
4.01 (1 H, m, 6-H), 4.64 and 4.85 (2 H, ABq, CH2-Ph), 5.03 (I H, d, J 6, 5-H), 
5.28 (1 H, d, J 10, 8-H), 5.81 (I H, d, J 10, 7-H), 6.55 and 6.68 (2 H, ABq, 1 and 
2-H), 7.36 (5 H, m, CH2-£h); mlz 389 (M+, 34%) 298(21), 282(13), 229(11), 
178(9), 146(14), 91(100), 81(24), 65(15), 42(26). (Found M+, 389.1995. 
C25H27N03 requires 389.1991). 
Preparation of 7,S-Didehydro-4,5a-epoxy-3-methoxy-6a-
(4' -nitrobenzyloxy)-17 -methyl-morphinan (86) 
To a solution of codeine (300 mg, 1 mmol) in THF, under nitrogen, was added 
NaH-60% dispersion in mineral oil (4.4 mg, 1.1 mmol) and the reaction stirred for 2 h. 
p-Nitrobenzyl bromide (260 mg, 1.2 mmol) was added and the reaction stirred 
overnight. The reaction was quenched with water and extracted into EtOAc. The 
organic layer was washed with water, dried (Na2S04) and evaporated under reduced 
pressure to yield a yellow product 86 (391 mg, 90 %); liH (CDCh) 1.91 (I H, d, 
J 12.5, lSe-H), 2.02 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.37 (5 H, m, NMe, lOa and 
16-H), 2.61 (lH, dd, J 12.5, 4, 16-H), 2.68 (1 H, t, J 2.5, 14-H), 3.05 (1 H, d, 
J 18.5, 10~-H), 3.37 (1 H, q, J 3, 9-H), 3.83 (3 H, s, OMe), 4.03 (I H, m, 6-H), 
4.72 and 4.97 (2 H, ABq, QU-Ph), 5.04 (1 H, d, J 6, 5-H), 5.38 (1 H, d, J 10, 
8-H), 5.77 (1 H, d, J 10, 7-H), 6.54 and 6.66 (2 H, ABq, 1 and 2-H), 7.62 (2 H, d, 
J 8.5,20 and 24-H), 8.17 (2 H, d, J 8.5,21 and 23-H); mlz 434 (M+, 33%) 298(21), 
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282(29), 146(14), 136(25), 104(19), 91(38), 77(42), 63(24),44(100). (Found M+, 
434.1842. C2SH26N20S requires 434.1846). 
Preparation of Methyl Tetra·O·acetyl·(ex+~)·D.glucopyranuronate 
NaOH (0.05 g) was dissolved in MeOH (115 ml) and to this was added 
glucuronolactone 88 (15 g, 0.085 mol) in small increments, making sure the pH did 
not fall below 8. The reaction mixture was stirred at room temperature for 2 h and the 
MeOH evaporated to yield ~·D·glucopyranuronate, a yellow syrup. To this was added 
pyridine (38 ml) and acetic anhydride (60 ml, 65 g, 0.64 mol) dropwise, keeping the 
reaction temperature below 30·C. The solution was refrigerated overnight. The 
crystals that formed were separated from the mother liquor and washed with cold 
EtOH, to give clear white crystals. Recrystallisation was affected from hot EtOH 
yielding white needles of methyl tetra-O-acetyl-~-D-glucopyranuronate 89 (12.493 g, 
43%). The mother liquor and EtOH washings were condensed and refrigerated 
ovemight to give another crop of crystals 0.8 g. Total product (13.293g, 45%) m.p. 
174-8°C [lit 178·C68]; 23[a]D +7.80 (cl in CHCb); OH (CDCb) 2.03 - 2.12 (12 H, 
m, 4xAc), 3.75 (3 H, s, OMe), 4.18 (1 H, d, J 9, 5-H), 5.11 - 5.35 (3 H, m, 2,3 and 
4-H), 5.77 (1 H, d, J 8, I-H). 
The mother liquor from the reaction was poured onto crushed ice and neutralised with 
aq. NaHC03. The rnixture was filtered to remove excess NaHC03. The cake and 
fIltrate were extracted thoroughly with CHC13, and the combined extracts dried 
(N a2S04) and concentrated to a syrup. The syrup was taken up in hot isopropyl 
alcohol and refrigerated overnight. The white crystals that separated were collected and 
recrystallised from isopropyl alcohol yielding methyl tetra-O-acetyl-ex-D-
glucopyranuronate 90 (1.419g, 5%). 23[a]D +98· (cl in CHCb); OH (CDCI3) 
2.02-2.19 (12 H, m, 4xAc), 3.75 (3 H, s, OMe), 4.41 (1 H, d, J 10, 5-H), 5.12 (1 H, 
dd, J 10, 3.5, 2-H), 5.27 (1 H, t, J 10, 3-H), 5.52 (1 H, t, J 10, 4-H), 6.40 (1 H, d, 
J 3.5, I-H). 
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Preparation of Methyl-2,3,4-tri-O-acetyl-la-bromo-l-deoxy-D-
glucopyranuronate (92) 
Methyl tetra-O-acetyl-p-D-glucopyranuronate (5 g, 0.015 mol) was dissolved in 45% 
hydrobromic acid in acetic acid (20 rnl, 20 g, 0.15 mol), and the mixture refrigerated 
overnight. The solvent was evaporated to give a brown syrup residue, which was 
dissolved in CHCI3 (10 rnl), washed with cold aq. NaHC03 and water, and dried 
(NaZS04). The resulting pale yellow solution was evaporated under reduced pressure 
and the residual syrup dissolved in EtOH (15 rnl). Crystals formed immediately but 
were dissolved on heating. The solvent was evaporated to give a white product which 
was recrystallised from EtOAc using petroleum ether, to yield white needles of the 
bromo acetate sugar 92 (3.384g, 64%). m.p. 80-2°C [lit 104-105'C68]; 23[Cl.lo +199' 
(cl in CHCI3); OH (CDCI3) 1.71 (9 H, m, 3xAc), 3.38 (3 H, s, OMe), 4.18 (1 H, d, 
J 10, 5-H), 4.51 (1 H, dd, J 10, 4, 2-H), 4.85 (1 H, t, J 10, 3-H), 5.20 (1 H, t, J 10, 
4-H), 6.31 (1 H, d, J 4, I-H). 
Preparation of Methyl (codein-6-yl-2,3,4-tri-O-acetyl-p-D-
glucopyranosid) uronate (93) 
Codeine (0.5 g, 1.67 mrnol) was dissolved in sodium dried benzene (30 cm3), under 
nitrogen. Dry AgC03 (lA g, 804 mmol) was added, tuming the clear solution grey. 
Methyl-2,3,4-tri-0-acetyl-la-bromo-l-deoxy-D-glucopyranuronate (0.9 g, 2.27 
mrnol) was added in several portions, with constant stirring. The reaction mixture 
was heated to reflux, and benzene was gradually distilled off using a Dean Stark 
apparatus. Heating was continued for 13 h, with reaction progress being monitored 
by TLC. On completion the reaction mixture was fIltered and washed with benzene. 
The fIltrate was evaporated under reduced pressure to yield a brown residue 
(1.275 g). The crude product was purified by column chromatography (elution with 
50% benzene in CHCb and 5% MeOH in CHCI3). A cream powder was obtained 93 
(347 mg, 33%) m.p. 111-4'C (decomp) [lit. 112-4'C71]; '\lmax(nujol)/cm-1 1746 
(C=O); OH (CDCI3) 1.90 (1 H, d, J 12, lSe-H), 2.03 (6 H, s, 2xAc), 2.15 (4 H, m, 
Ac and 15a-H) 2.39 (1 H, dd, J 18.5, 6, lOa-H), 2.51 (4 H, m, NMe and 16a-H), 
2.71 (1 H, d, J 18.5, 16e-H), 2.81 (1 H, s, 14-H), 3.04 (1 H, d, J 18.5, lOP-H), 
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3.47 (1 H, m, 9-H), 3.76 (3 H, s, OMe), 3.78 (3 H, s, OMe), 4.11 (1 H, d, J 9, 
22-H), 4.39 (1 H, m, 6-H), 4.95 (2 H, m, 5 and 20-H), 5.09 (1 H, t, J 8, 21-H), 
5.29 (3 H, m, 8, 18 and 19-H), 5.70 (1 H, d, J 9, 7-H), 6.52 and 6.64 (2 H, ABq, 
1 and 2-H); m/z 615 (W, 8%) 555(7),298(18),282(83),229(13), 197(8), 155(32), 
127(21),43(100). 
Preparation of Codein.6.yl.J3.D.glucopyranosiduronic Acid (95) 
To a solution of methyl(codein-6·yl-2,3,4-tri-O-acetyl-J3-D-glucopyranosid)uronate 
(150 mg, 0.24 mrnol) in methanol (3 cm3), was added 0.01 M NaOMe solution 
(1 cm3) and the solution stirred overnight. On completion of the reaction indicated by 
TLC, the reaction mixture was evaporated to dryness under reduced pressure. The 
residue was dissolved in phosphate buffer (10 cm3), at 25·C, and the pH adjusted to 7 
using 0.05 M NaOH. PLE (0.45 cm3, 1 mg, -200 units) as a suspension in 3.2 M 
(N14)S04 solution was added and the reaction left stirring overnight, maintaining the 
temperature at 25·C and the pH at 7, by using a pH-stat. 2.6 cm3 of base were 
consumed. The reaction mixture was adjusted to pH 6 using acetic acid, and 
evaporated under reduced pressure to give a concentrated solution. The crude solution 
was chromatographed on reverse phase silica (elution with 30% H20 in MeOH). 
Final purification was by semi-prep HPLC, using a silica reverse phase column, to 
give colourless needles of C-6-G 95 (48 mg, 41%) m.p. 272-276·C (decomp) 
[lit 276-27S·C71]; 'Umax(nujol)/cm-1 (C=O); (5H (CD30D) 1.89 (1 H, m, lSe-H), 
1.98 (1 H, dt, J 12.5, 5, 5, 15a-H), 2.51 (5 H, m, NMe, lOa and 16a-H), 2.74 
(2 H, m, 14 and 16e-H), 3.10 (1 H, d, J 18.5, 10J3-H), 3.49 (3 H, m, 19, 20 and 
21-H), 3.61 (1 H, d, J 9, 22-H), 3.81 (3 H, s, OMe), 4.53 Cl H, m, 9-H), 4.60 
(l H, d, J 8, 18-H) 4.88 (1 H, m, 6-H), 5.11 (1 H, d, 17, 5-H), 5.32 (l H, d, J 10, 
8-H), 5.80 (1 H, d, J 10, 7-H), 6.58 and 6.72 (2 H, ABq, 1 and 2-H); HPLC: 
Solvent - MeOHlH20 (70:30), Flow rate - 0.7 mlImin, Elution time - 4.5 rnin. 
III 
Preparation of Methyl (3·t·Butyldimethylsilyloxy.morphin.6.yl.2,3,4. 
tri·O·acetyl.~.D.glucopyranosid) uronate (96) 
Morphine 3·0-TBDMS ether 45 (0.4 g, 1 mmol) was dissolved in sodium dried 
benzene (20 cm3), under nitrogen. Dry AgC03 (1.12 g, 6.7 mmol) was added, 
turning the clear solution grey. Methyl-2,3,4-tri·0-acetyl-la-bromo-l-deoxy-D-
glucopyranuronate (0.75 g, 1.9 mmol) was added in several portions, with constant 
stirring. The reaction mixture was heated to reflux, and benzene was gradually 
distilled off using a Dean Stark apparatus. Heating was continued for 14 h, with 
reaction progress being monitored by TLC. On completion the reaction mixture was 
filtered and washed with benzene. The filtrate was evaporated under reduced pressure 
to yield a brown residue (0.93 g). The crude product was purified by column 
chromatography (elution with 15% MeOH in CHCI3 and 5% MeOH in DCM). A 
cream powder was obtained 96 (240 mg, 33%) m.p. 81-83'C (decomp); 
'\)max(nujol)/cm-I 1758 (C=O); ()H (CDCI3) 0.14 (3 H, s, SiMe), 0.16 (3 H, s, 
SiMe), 0.96 (9 H, s, SiCMe3), 1.83 (1 H, d, J 11, lSe-H), 2.07 (10 H, m, 3xAc and 
15a-H), 2.36 (5 H, m, NMe, lOa and 16a-H), 2.60 (2 H, m, 14 and 16e-H), 3.02 
(1 H, d, J 18.5, IO~-H), 3.37 (1 H, q, J 3, 9-H), 3.74 (3 H, s, OMe), 4.11 (1 H, d, 
J 9, 22-H), 4.28 (1 H, m, 6-H), 4.84 (1 H, d, J 6, 5-H), 5.01 (2 H, m, 19 and 
21-H), 5.28 (3 H, m, 8, 18 and 20-H), 5.71 (1 H, d, J 10, 7-H), 6.42 and 6.56 
(2 H, ABq, 1 and 2-H); ()e -4.73, -4.48, 18.37, 20.53, 20.65, 20.72, 20.84, 25.75, 
35.83, 41.10, 43.02 (NMe), 43.73, 46.38, 52.87 (OMe), 69.26, 71.62, 72.21, 
72.59, 74.15, 89.00, 99.36, 118.88, 121.45, 127.28, 128.77, 130.49, 130.63, 
137.16, 149.45, 167.44, 169.43, 169.52, 170.15. (Found M+, 687.3264. 
C36H49NOl2 requires 687.3255). 
Preparation of Methyl (morphin.6·yl.2,3,4·tri·0·acetyl·~·D. 
glucopyranosid) uronate (97) 
Methyl(3-0-TBDMS-morphin-6-yl-2,3,4-tri-0-acetyl+D-glucopyranosid)uronate 
(0.2 g, 2.8 mmol) was dissolved in THF (10 cm3), under an inert atmosphere, and 
the solution cooled to O'C. TBAF (1M solution in THF) (1 cm3) was added and the 
reaction mixture stirred at O'C for 30 min, before being allowed to warm up to room 
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temperature. The reaction was stirred for a further 3 h, quenched with water and 
extracted into CHCI). The organic layer was dried (Na2S04), and evaporated under 
reduced pressure. The residue was purified by column chromatography (elution with 
5% MeOH in CHCI3), to give a cream solid (139 mg, 83%) m.p. 106-9'C (decomp); 
(Found: C, 55.24; H, 6.2; N, 1.9. C30H3SN012 requires C, 54.96; H, 6.3; N, 
2.1 %); 'Umax(nujol)/cm-1 1746 (C=O); OH (CDCI3IDMSO-dt;) 1.69 (1 H, d, J 11, 
15e-H), 2.04 (7 H, m, 2xAc and 15a-H), 2.17(1 H, s, Ac), 2.44 (5 H, m, NMe, lOa 
and 16a-H), 2.69 (2 H, m, 14 and l6e-H), 3.00 (l H, d, J 18.5, 1O~-H), 3.41 Cl H, 
q, J 3, 9-H), 3.73 (3 H, s, OMe), 4.15 (1 H, d, J 9, 22-H), 4.32 Cl H, m, 6-H), 
4.87 (2 H, m, 5 and 19-H), 5.11 Cl H, t, J 8, 21-H), 5.33 (3 H, m, 8, 18 and 20-H), 
5.64 (1 H, d, J 10, 7-H), 6.49 and 6.65 (2 H, ABq, 1 and 2-H); Oc 20.47, 20.57, 
20.85, 21.55, 32.59, 37.69, 41.30 (NMe), 41.68, 47.30, 52.78 (OMe), 60.58, 
69.32,71.20, 71.79,71.84,77.69, 86.93, 98.74, 118.21, 119.64, 120.63, 125.24, 
128.33, 131.91, 140.10, 146.42, 167.27, 169.37, 169.82, 170.26. 
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